data_2my5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2my5 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.42 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' ASN . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.443 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.645 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.473 ' O ' ' N ' ' A' ' 48' ' ' LEU . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.45 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.473 ' N ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.44 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.403 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 16' ' ' LEU . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.415 ' O ' ' N ' ' A' ' 34' ' ' GLY . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.9 m-80 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.639 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.518 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.518 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.533 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.533 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.458 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.458 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.571 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.0 m-80 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.527 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.403 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.409 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.403 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.409 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.678 ' CE1' ' HG1' ' A' ' 81' ' ' THR . 25.7 m80 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' C ' ' CD ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.415 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.415 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.415 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.452 ' O ' ' CG2' ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.452 ' CG2' ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.678 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 1.1 t . . . . . 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.488 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.543 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.605 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.551 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 19' ' ' VAL . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.461 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 17' ' ' PRO . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.497 ' O ' ' N ' ' A' ' 34' ' ' GLY . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 34' ' ' GLY . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.695 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.446 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.601 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.601 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.435 ' O ' ' CG ' ' A' ' 29' ' ' ASP . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.7 t . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.63 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.538 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.454 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.595 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.5 ' CG2' ' O ' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.595 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.457 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.457 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.584 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.414 HG23 HD12 ' A' ' 69' ' ' ILE . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.63 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.424 ' CG2' ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.542 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.421 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.542 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.559 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.438 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.44 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 17' ' ' PRO . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.596 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.596 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.611 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.611 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.424 ' OD1' ' CG2' ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.531 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.5 tp60 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.531 ' CD2' HE21 ' A' ' 2' ' ' GLN . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.402 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.598 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.598 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' A' ' 48' ' ' LEU . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.509 ' N ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.492 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.51 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.7 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 10' ' ' PHE . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.599 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 31' ' ' VAL . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.429 ' H ' ' C ' ' A' ' 29' ' ' ASP . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.514 ' CD ' ' HG1' ' A' ' 81' ' ' THR . 26.1 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.428 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.0 pp0? -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.55 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.454 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.595 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.595 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.731 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.731 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.408 HG21 HD11 ' A' ' 54' ' ' ILE . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.428 ' CG2' ' NE2' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.514 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.421 ' O ' ' N ' ' A' ' 10' ' ' PHE . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.498 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.421 ' N ' ' O ' ' A' ' 6' ' ' VAL . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.605 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.424 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.424 ' H ' ' C ' ' A' ' 29' ' ' ASP . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.407 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.558 ' CG2' ' O ' ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.441 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.567 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.567 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.668 ' HD1' ' CG2' ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.668 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.706 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.706 ' N ' HE21 ' A' ' 9' ' ' GLN . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.481 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.571 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.467 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.467 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.3 m-80 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.414 HG22 HD11 ' A' ' 45' ' ' ILE . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.686 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.434 ' HG ' ' H ' ' A' ' 71' ' ' SER . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.434 ' H ' ' HG ' ' A' ' 68' ' ' SER . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.449 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.686 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.487 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 1.8 t . . . . . 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.433 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.1 pp0? -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.414 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.44 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.601 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.601 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.497 ' O ' ' N ' ' A' ' 33' ' ' ASN . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.421 ' H ' ' C ' ' A' ' 29' ' ' ASP . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.7 m80 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.423 ' O ' ' N ' ' A' ' 10' ' ' PHE . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.423 ' N ' ' O ' ' A' ' 6' ' ' VAL . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.604 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.477 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.465 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.555 ' CD1' HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.555 HH21 ' CD1' ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.425 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.425 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 t . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.509 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.444 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.548 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.548 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.554 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.432 ' C ' ' H ' ' A' ' 19' ' ' VAL . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.432 ' H ' ' C ' ' A' ' 17' ' ' PRO . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.62 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.456 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.62 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.579 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.579 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.413 HD13 HG21 ' A' ' 69' ' ' ILE . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.462 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.446 ' C ' ' H ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.446 ' H ' ' C ' ' A' ' 2' ' ' GLN . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.55 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.4 pp0? -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.55 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.682 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.551 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.455 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.413 ' H ' ' C ' ' A' ' 17' ' ' PRO . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.682 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 77.6 m-20 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.583 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.583 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.627 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.57 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.57 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.544 ' OG1' ' CE1' ' A' ' 3' ' ' HIS . 4.3 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.572 ' HD1' ' CG2' ' A' ' 77' ' ' VAL . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.434 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.434 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.519 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.519 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.442 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.572 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.482 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.532 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.571 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.425 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.425 ' H ' ' C ' ' A' ' 17' ' ' PRO . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.509 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.509 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.437 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.482 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 1.2 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.447 ' O ' ' C ' ' A' ' 3' ' ' HIS . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.447 ' C ' ' O ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.509 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.509 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.569 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.456 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.456 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.602 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.602 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.586 ' H ' ' CD1' ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.466 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.416 ' O ' ' CG2' ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.627 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.404 ' C ' ' CD1' ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.604 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.424 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.547 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.547 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.578 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.445 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.445 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.626 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.51 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.626 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 65.9 m-80 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.598 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.424 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.515 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.58 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 1.7 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.421 HG12 ' H ' ' A' ' 84' ' ' VAL . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.42 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' ASN . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.443 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.645 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.473 ' O ' ' N ' ' A' ' 48' ' ' LEU . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.464 ' CH2' ' O ' ' A' ' 88' ' ' LEU . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.473 ' N ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.0 t -124.2 88.0 53.17 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -91.19 109.89 0.32 Allowed 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 123.09 2.527 . . . . 0.0 112.919 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.22 133.95 10.07 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.135 1.89 . . . . 0.0 111.845 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.421 ' H ' HG12 ' A' ' 6' ' ' VAL . 11.2 p -133.13 140.85 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 54.8 mp0 -64.41 -35.62 81.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.176 -0.952 . . . . 0.0 109.921 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.405 ' H ' HG21 ' A' ' 84' ' ' VAL . . . -148.55 158.06 43.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.143 -0.973 . . . . 0.0 109.76 -179.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -72.65 133.9 44.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.447 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.464 ' O ' ' CH2' ' A' ' 47' ' ' TRP . 35.5 tp -100.27 130.58 46.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.506 179.976 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.454 ' N5 ' ' CE2' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.44 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.403 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 16' ' ' LEU . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.415 ' O ' ' N ' ' A' ' 34' ' ' GLY . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.9 m-80 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.639 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.518 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.518 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.533 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.533 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.6 t -138.48 88.0 14.91 Favored Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -94.33 107.52 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 123.359 2.706 . . . . 0.0 113.025 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.81 130.72 6.82 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.137 1.891 . . . . 0.0 111.732 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.412 HG21 ' H ' ' A' ' 86' ' ' ALA . 11.3 p -134.31 140.61 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.244 -0.91 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -65.55 -34.97 79.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.304 -0.873 . . . . 0.0 109.88 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.412 ' H ' HG21 ' A' ' 84' ' ' VAL . . . -145.06 159.02 43.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.116 -0.99 . . . . 0.0 109.615 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -68.39 137.52 54.61 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.254 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.9 mt -88.09 141.31 28.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.152 -0.967 . . . . 0.0 109.37 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 -179.902 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.58 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' O ' ' A' ' 83' ' ' PRO . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.458 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.458 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.571 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.615 ' CG1' ' HZ2' ' A' ' 87' ' ' LYS . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.0 m-80 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.527 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.403 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.409 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.403 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.409 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.2 t -130.04 88.39 48.64 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.4 Cg_exo -62.89 -175.17 0.2 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.637 2.225 . . . . 0.0 111.976 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 2' ' ' GLN . 21.0 Cg_exo -62.28 150.94 85.18 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.578 2.185 . . . . 0.0 111.574 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 45.4 t -99.03 127.91 51.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.093 -1.005 . . . . 0.0 109.854 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -146.58 164.41 32.7 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.31 137.92 51.59 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.948 -1.095 . . . . 0.0 108.908 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.615 ' HZ2' ' CG1' ' A' ' 26' ' ' VAL . 61.1 tttm -59.41 -36.37 75.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.502 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.8 mt -59.03 -35.69 73.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.915 . . . . 0.0 109.412 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.484 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.678 ' CE1' ' HG1' ' A' ' 81' ' ' THR . 25.7 m80 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.415 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.415 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.415 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.452 ' O ' ' CG2' ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.452 ' CG2' ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.503 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.678 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 1.1 t -137.26 89.24 16.46 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.52 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 66.6 Cg_endo -81.93 157.22 18.07 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.585 2.19 . . . . 0.0 112.227 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -63.67 147.63 92.6 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.593 2.195 . . . . 0.0 111.639 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.402 HG21 ' H ' ' A' ' 86' ' ' ALA . 7.6 p -130.81 136.02 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.294 -0.879 . . . . 0.0 109.897 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -70.8 -32.22 69.23 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.373 -0.829 . . . . 0.0 109.866 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.402 ' H ' HG21 ' A' ' 84' ' ' VAL . . . -130.15 169.61 15.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.295 -0.878 . . . . 0.0 109.859 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 27.1 mttm 59.13 43.73 16.9 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.482 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.2 tp -58.38 -37.34 75.06 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.374 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.483 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.553 ' N9 ' ' O4 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.488 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.543 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.605 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.551 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 19' ' ' VAL . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.461 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 17' ' ' PRO . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.497 ' O ' ' N ' ' A' ' 34' ' ' GLY . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 34' ' ' GLY . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.695 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.446 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.601 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.581 ' NH2' ' O ' ' A' ' 89' ' ' GLN . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.601 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HB3' ' H12' ' A' ' 101' ' ' PN7 . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.598 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.435 ' O ' ' CG ' ' A' ' 29' ' ' ASP . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.7 t -122.98 87.78 50.84 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -93.2 110.16 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 123.287 2.658 . . . . 0.0 112.804 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -78.62 132.75 11.15 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 121.982 1.788 . . . . 0.0 111.733 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.572 ' CG1' HH22 ' A' ' 51' ' ' ARG . 41.0 t -124.33 133.13 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.317 -0.864 . . . . 0.0 109.601 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.03 -35.87 82.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.407 ' H ' HG13 ' A' ' 84' ' ' VAL . . . -149.44 149.69 31.2 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.596 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 13.2 tttm -60.51 -39.43 87.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 72.8 mt -60.82 -34.8 75.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.442 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.581 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 95.0 mt-30 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.42 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.598 ' N9 ' ' CB ' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.45 ' O ' ' CG1' ' A' ' 84' ' ' VAL . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.63 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.538 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.454 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.595 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.5 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.595 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.457 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.457 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.476 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.584 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.414 ' H ' ' H18' ' A' ' 101' ' ' PN7 . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.414 HG23 HD12 ' A' ' 69' ' ' ILE . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.63 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.8 OUTLIER -128.97 87.73 53.73 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.517 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 17.3 Cg_exo -63.86 -174.92 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.759 2.306 . . . . 0.0 111.958 179.546 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 20.1 Cg_exo -62.52 148.96 92.55 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.44 2.093 . . . . 0.0 111.747 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' CG1' ' O ' ' A' ' 2' ' ' GLN . 48.3 t -109.19 132.57 56.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.345 -0.847 . . . . 0.0 109.732 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -121.95 152.42 39.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -88.1 127.11 35.41 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 0.0 109.491 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 21.4 mttp -59.55 -35.45 74.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.6 tp -57.89 -37.31 73.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.477 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.932 -1.032 . . . . 0.0 109.477 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.424 ' CG2' ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.542 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.676 ' CD2' ' NZ ' ' A' ' 87' ' ' LYS . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.542 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.559 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.438 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.44 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 17' ' ' PRO . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.596 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.596 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.464 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.611 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.41 ' H ' ' H18' ' A' ' 101' ' ' PN7 . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.611 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.424 ' OD1' ' CG2' ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.8 t -131.03 87.97 46.95 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -94.26 107.93 0.15 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.321 2.681 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -78.85 131.05 9.9 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 122.022 1.814 . . . . 0.0 112.071 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.1 t -127.53 132.23 69.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.412 -0.805 . . . . 0.0 109.438 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.68 -35.67 81.44 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 109.743 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -153.91 160.93 42.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.676 ' NZ ' ' CD2' ' A' ' 10' ' ' PHE . 29.3 mttm -78.79 144.66 34.91 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.176 -0.953 . . . . 0.0 109.358 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -57.25 -37.44 72.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.46 -179.91 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.559 ' S12' ' O8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.531 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.5 tp60 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.531 ' CD2' HE21 ' A' ' 2' ' ' GLN . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.402 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.429 ' CD ' ' HZ1' ' A' ' 87' ' ' LYS . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.598 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.598 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' A' ' 48' ' ' LEU . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.509 ' N ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.589 ' NH2' ' O ' ' A' ' 89' ' ' GLN . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.492 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.51 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.7 t -129.33 88.86 49.42 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -89.83 109.94 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.24 2.627 . . . . 0.0 113.16 -179.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.01 137.59 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.216 1.944 . . . . 0.0 111.586 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.16 141.42 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.144 -0.973 . . . . 0.0 109.705 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -63.12 -35.2 79.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.847 . . . . 0.0 109.477 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -145.97 155.2 42.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.568 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.429 ' HZ1' ' CD ' ' A' ' 14' ' ' GLU . 17.9 tttt -58.75 -38.73 79.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.328 -0.858 . . . . 0.0 109.367 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.0 tp -58.28 -37.57 75.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.589 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.5 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.579 ' NE2' ' O ' ' A' ' 83' ' ' PRO . 1.5 t-80 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 10' ' ' PHE . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.582 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.413 ' CG1' ' HZ1' ' A' ' 87' ' ' LYS . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.599 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 31' ' ' VAL . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.429 ' H ' ' C ' ' A' ' 29' ' ' ASP . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' O4 ' ' A' ' 101' ' ' PN7 . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.406 ' H ' ' H13' ' A' ' 101' ' ' PN7 . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.4 88.77 53.08 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -80.05 162.06 23.42 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.601 2.201 . . . . 0.0 112.655 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.579 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.8 Cg_endo -62.42 151.26 83.86 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.787 2.324 . . . . 0.0 111.435 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.5 p -116.55 137.19 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.383 -0.823 . . . . 0.0 110.237 -179.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.06 172.91 12.01 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.05 140.43 7.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.939 -1.101 . . . . 0.0 108.86 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.582 ' NZ ' ' O ' ' A' ' 21' ' ' PRO . 61.7 tttt -58.3 -36.0 72.68 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.225 -0.922 . . . . 0.0 109.332 -179.572 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 61.2 mt -95.08 142.1 27.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.388 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.472 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.586 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' CD ' ' HG1' ' A' ' 81' ' ' THR . 26.1 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.463 ' CD2' ' O ' ' A' ' 83' ' ' PRO . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.428 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.0 pp0? -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.55 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.454 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.595 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.595 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.453 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.401 ' H ' ' H18' ' A' ' 101' ' ' PN7 . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.731 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.731 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.408 HG21 HD11 ' A' ' 54' ' ' ILE . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.428 ' CG2' ' NE2' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.514 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t -130.37 88.09 48.57 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.454 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.9 Cg_exo -65.34 -175.68 0.44 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.657 2.238 . . . . 0.0 111.836 179.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.463 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 21.7 Cg_exo -62.01 150.67 85.5 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.533 2.156 . . . . 0.0 111.752 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.7 m -89.96 128.45 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.11 -0.994 . . . . 0.0 109.991 -179.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -141.44 157.63 44.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.498 -0.751 . . . . 0.0 109.08 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -60.2 139.75 57.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.067 -1.02 . . . . 0.0 109.111 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.6 tttm -59.57 -38.16 80.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.477 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.9 mt -60.24 -35.16 74.84 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.539 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.485 ' O ' ' O ' ' A' ' 86' ' ' ALA . 63.6 tt0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' N9 ' ' O4 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.421 ' O ' ' N ' ' A' ' 10' ' ' PHE . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.498 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.421 ' N ' ' O ' ' A' ' 6' ' ' VAL . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.605 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.424 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.424 ' H ' ' C ' ' A' ' 29' ' ' ASP . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.407 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.558 ' CG2' ' O ' ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.441 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.567 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.567 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.4 t -129.16 88.84 49.98 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -91.18 109.16 0.31 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.239 2.626 . . . . 0.0 112.972 -179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -82.02 133.84 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.303 2.002 . . . . 0.0 111.97 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.414 HG21 ' H ' ' A' ' 86' ' ' ALA . 13.9 p -134.26 141.09 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.25 -0.906 . . . . 0.0 109.498 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.15 -36.34 83.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.965 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.414 ' H ' HG21 ' A' ' 84' ' ' VAL . . . -148.2 155.32 41.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.185 -0.947 . . . . 0.0 109.698 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.8 tttm -58.49 -38.24 77.23 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.299 -0.875 . . . . 0.0 109.402 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.8 tp -58.09 -37.45 74.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.374 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 . . . . . 0 N--CA 1.49 1.525 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.487 -179.985 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.538 ' O4 ' ' C7 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.668 ' HD1' ' CG2' ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.668 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.706 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.706 ' N ' HE21 ' A' ' 9' ' ' GLN . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.481 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.571 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.467 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.467 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.3 m-80 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.55 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.414 HG22 HD11 ' A' ' 45' ' ' ILE . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.686 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.434 ' HG ' ' H ' ' A' ' 71' ' ' SER . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.434 ' H ' ' HG ' ' A' ' 68' ' ' SER . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.449 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.686 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.487 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 1.8 t -140.74 88.03 10.95 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -86.3 151.36 9.28 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.705 2.27 . . . . 0.0 111.878 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 32.7 Cg_endo -67.44 137.43 43.01 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.444 2.096 . . . . 0.0 112.224 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.418 HG13 ' H ' ' A' ' 3' ' ' HIS . 10.6 p -134.23 139.4 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.236 -0.915 . . . . 0.0 109.525 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 86' ' ' ALA . 97.1 mt-10 -66.27 -35.83 81.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.158 -0.964 . . . . 0.0 109.344 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.491 ' CB ' ' O ' ' A' ' 85' ' ' GLU . . . 164.03 153.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.345 -0.847 . . . . 0.0 109.251 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.4 tttm -75.12 133.7 41.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.095 -1.003 . . . . 0.0 109.424 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.2 mt -94.28 142.08 27.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.443 179.952 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.624 ' H17' ' C4 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.4 HG13 ' H ' ' A' ' 84' ' ' VAL . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.548 HE22 ' N ' ' A' ' 87' ' ' LYS . 1.1 pp0? -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.458 ' CE2' ' NZ ' ' A' ' 87' ' ' LYS . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.601 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.601 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.497 ' O ' ' N ' ' A' ' 33' ' ' ASN . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.421 ' H ' ' C ' ' A' ' 29' ' ' ASP . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.459 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 t -119.03 88.19 36.04 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -91.56 113.19 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 123.229 2.619 . . . . 0.0 113.186 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -80.17 130.66 8.36 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 122.037 1.825 . . . . 0.0 111.496 178.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.4 ' H ' HG13 ' A' ' 6' ' ' VAL . 25.0 t -128.95 133.42 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 109.751 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.43 -36.35 83.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.848 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -147.52 157.67 43.67 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.124 -0.985 . . . . 0.0 109.739 -179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.548 ' N ' HE22 ' A' ' 9' ' ' GLN . 20.6 tttm -57.06 -37.84 72.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.228 -0.92 . . . . 0.0 109.419 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 36.8 tp -100.84 131.39 46.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.504 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.487 ' O3 ' ' OD1' ' A' ' 37' ' ' ASP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.7 m80 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.423 ' O ' ' N ' ' A' ' 10' ' ' PHE . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.423 ' N ' ' O ' ' A' ' 6' ' ' VAL . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.604 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.477 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.477 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.465 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.446 ' OG ' ' N9 ' ' A' ' 101' ' ' PN7 . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.555 ' CD1' HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.555 HH21 ' CD1' ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.425 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.425 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 t -118.97 88.28 36.0 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -89.25 113.97 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.085 2.524 . . . . 0.0 112.99 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -80.3 132.71 9.34 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.094 1.862 . . . . 0.0 111.697 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.409 ' H ' HG13 ' A' ' 6' ' ' VAL . 34.3 t -125.25 132.15 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.395 -0.815 . . . . 0.0 109.621 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.87 -35.69 81.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.489 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -151.75 153.48 34.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.914 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 15.4 tttm -59.19 -34.85 72.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.542 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.9 mt -57.02 -35.65 69.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.556 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.468 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.616 ' CE1' ' N5 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.509 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.581 ' CB ' ' NE2' ' A' ' 89' ' ' GLN . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.444 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.548 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.548 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.554 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.432 ' C ' ' H ' ' A' ' 19' ' ' VAL . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.432 ' H ' ' C ' ' A' ' 17' ' ' PRO . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.62 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.456 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.62 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.579 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.579 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.413 HD13 HG21 ' A' ' 69' ' ' ILE . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.462 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 0.7 OUTLIER -140.04 87.97 12.09 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.48 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.5 Cg_exo -63.43 -173.58 0.18 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.81 2.34 . . . . 0.0 111.594 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.48 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.4 Cg_exo -61.73 150.78 84.34 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.389 2.06 . . . . 0.0 111.438 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.428 ' O ' ' CG2' ' A' ' 84' ' ' VAL . 4.1 m -89.53 127.31 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.075 -1.016 . . . . 0.0 110.092 -179.117 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.25 156.68 48.0 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.477 -0.764 . . . . 0.0 108.985 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -73.28 126.17 29.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.054 -1.029 . . . . 0.0 109.347 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -59.92 -38.34 82.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.455 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 66.8 mt -60.56 -34.97 74.94 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.581 ' NE2' ' CB ' ' A' ' 5' ' ' SER . 95.3 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.432 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.594 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.446 ' C ' ' H ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.446 ' H ' ' C ' ' A' ' 2' ' ' GLN . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.55 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.4 pp0? -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.55 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.682 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.551 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.455 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.413 ' H ' ' C ' ' A' ' 17' ' ' PRO . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.526 ' C ' ' HZ2' ' A' ' 87' ' ' LYS . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.682 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 77.6 m-20 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.416 ' OG ' ' S12' ' A' ' 101' ' ' PN7 . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.583 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.583 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.627 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.57 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.443 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.57 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.544 ' OG1' ' CE1' ' A' ' 3' ' ' HIS . 4.3 t -140.66 89.27 10.36 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -83.8 129.6 4.83 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.598 2.199 . . . . 0.0 112.371 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.54 149.14 34.14 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.22 1.946 . . . . 0.0 112.223 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.5 p -131.87 138.25 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 109.491 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.35 -39.39 92.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -0.932 . . . . 0.0 109.517 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -159.81 153.66 23.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.253 -0.904 . . . . 0.0 109.511 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.526 ' HZ2' ' C ' ' A' ' 21' ' ' PRO . 32.0 tttt -59.11 -37.97 78.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.5 tp -101.67 132.02 47.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.287 -0.883 . . . . 0.0 109.494 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.562 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.532 ' O4 ' ' S12' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.434 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.434 ' N ' ' CG2' ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.519 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.519 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.442 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.572 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.92 88.39 51.89 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 64.8 Cg_endo -81.89 161.26 18.57 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.69 2.26 . . . . 0.0 112.506 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -63.4 150.57 88.2 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.703 2.269 . . . . 0.0 111.761 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 47.0 t -105.94 130.44 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.219 -0.926 . . . . 0.0 109.691 -179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -145.77 12.82 1.31 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.346 -0.846 . . . . 0.0 109.114 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.88 151.5 23.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.317 -0.864 . . . . 0.0 109.632 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 15.1 mttm 58.85 45.14 15.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.526 -0.734 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' O ' ' O ' ' A' ' 89' ' ' GLN . 71.0 mt -59.31 -35.1 73.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.377 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.413 ' O ' ' O ' ' A' ' 88' ' ' LEU . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.462 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.482 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.532 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.571 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.425 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.425 ' H ' ' C ' ' A' ' 17' ' ' PRO . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.509 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.509 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.437 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.482 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 1.2 t -140.29 88.01 11.68 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 19.0 Cg_exo -63.71 -173.95 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 122.782 2.321 . . . . 0.0 111.741 179.22 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.473 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.2 Cg_exo -61.9 151.15 82.92 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.479 2.119 . . . . 0.0 111.481 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.5 t -92.12 128.42 43.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.092 -1.005 . . . . 0.0 110.016 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -141.32 156.12 45.89 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.37 134.31 52.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.06 -1.025 . . . . 0.0 109.357 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.49 ' O ' ' OG ' ' A' ' 5' ' ' SER . 16.5 tttm -60.41 -36.27 77.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 109.354 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 87' ' ' LYS . 36.7 tp 43.92 76.85 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.493 179.926 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.451 ' O3 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.447 ' O ' ' C ' ' A' ' 3' ' ' HIS . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.447 ' C ' ' O ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.509 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.509 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.569 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.456 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.456 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.602 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.616 ' CG1' ' HZ1' ' A' ' 87' ' ' LYS . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.602 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.586 ' H ' ' CD1' ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.466 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.416 ' O ' ' CG2' ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.627 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.404 ' C ' ' CD1' ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.8 88.64 53.53 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.477 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.1 Cg_exo -61.49 -174.55 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.615 2.21 . . . . 0.0 111.829 179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.3 Cg_exo -62.36 151.11 84.56 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.593 2.195 . . . . 0.0 111.595 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.4 t -93.34 125.33 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.079 -1.013 . . . . 0.0 109.705 -179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -147.98 154.89 40.9 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.387 -0.821 . . . . 0.0 109.079 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.76 136.14 55.02 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.061 -1.024 . . . . 0.0 109.187 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.616 ' HZ1' ' CG1' ' A' ' 26' ' ' VAL . 33.6 tttm -60.05 -38.79 83.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.143 -0.973 . . . . 0.0 109.455 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.455 ' O ' ' O ' ' A' ' 89' ' ' GLN . 53.7 mt -98.89 141.51 31.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.294 -0.879 . . . . 0.0 109.427 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' A' ' 88' ' ' LEU . 7.2 tt0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.468 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.486 ' N9 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.604 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.424 ' CD1' ' OD1' ' A' ' 73' ' ' ASP . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.547 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.547 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.578 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.445 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.445 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.626 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.51 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.626 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 65.9 m-80 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.598 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.424 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.515 ' O ' ' O ' ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.58 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 1.7 t -131.08 88.33 45.58 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -92.32 111.64 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.259 2.64 . . . . 0.0 112.91 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -79.42 137.03 12.89 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 122.111 1.874 . . . . 0.0 111.845 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.409 HG21 ' H ' ' A' ' 86' ' ' ALA . 12.6 p -134.19 141.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.205 -0.934 . . . . 0.0 109.523 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.39 -34.69 78.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 110.02 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.409 ' H ' HG21 ' A' ' 84' ' ' VAL . . . -142.23 155.28 45.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.136 -0.977 . . . . 0.0 109.705 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.401 ' NZ ' ' CE2' ' A' ' 10' ' ' PHE . 18.3 tttm -58.65 -37.34 75.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.274 -0.891 . . . . 0.0 109.533 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 53.7 mt -94.07 142.13 27.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.494 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.456 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.931 HG21 ' OD1' ' A' ' 73' ' ' ASP . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.406 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.597 HG23 ' N ' ' A' ' 12' ' ' VAL . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.597 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 19' ' ' VAL . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 16' ' ' LEU . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.406 HG12 ' HB1' ' A' ' 8' ' ' ALA . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.701 HD11 HG12 ' A' ' 69' ' ' ILE . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.444 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.444 ' N ' HG13 ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.516 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.691 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.45 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.464 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.443 HD13 HD21 ' A' ' 41' ' ' LEU . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.701 HG12 HD11 ' A' ' 30' ' ' LEU . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.931 ' OD1' HG21 ' A' ' 7' ' ' ILE . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 81' ' ' THR . 2.0 t . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.586 ' NE2' HG21 ' A' ' 81' ' ' THR . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.633 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.501 HG22 ' HE1' ' A' ' 15' ' ' PHE . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' ALA . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.501 ' HE1' HG22 ' A' ' 11' ' ' VAL . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.512 ' O ' HG12 ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.897 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.897 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.767 ' O ' HD12 ' A' ' 69' ' ' ILE . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.686 HD11 HG12 ' A' ' 69' ' ' ILE . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 31.7 m120 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.411 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.455 HG21 ' HB2' ' A' ' 56' ' ' ALA . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.435 ' HE1' ' HD2' ' A' ' 51' ' ' ARG . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.435 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HB2' HG21 ' A' ' 45' ' ' ILE . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.518 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.918 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE1' HG23 ' A' ' 72' ' ' ILE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' HD11 ' A' ' 72' ' ' ILE . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.767 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 77' ' ' VAL . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 73' ' ' ASP . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.598 ' O ' HG12 ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.586 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.6 t . . . . . 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.569 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.569 HG21 ' NE2' ' A' ' 3' ' ' HIS . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.534 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' HG23 ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.946 HD22 HG23 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.946 HG23 HD22 ' A' ' 16' ' ' LEU . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.511 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.511 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.532 ' O ' HD12 ' A' ' 69' ' ' ILE . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.471 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.7 m120 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.586 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.532 HD12 ' O ' ' A' ' 26' ' ' VAL . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.525 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.522 ' CD2' HG22 ' A' ' 77' ' ' VAL . 69.4 m-70 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.42 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.41 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.773 HG23 HD12 ' A' ' 36' ' ' ILE . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.745 HG21 HG11 ' A' ' 24' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' LEU . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.433 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.807 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.807 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.511 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.511 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.773 HD12 HG23 ' A' ' 11' ' ' VAL . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.454 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.535 ' CE1' HG21 ' A' ' 80' ' ' THR . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.722 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.722 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.517 HG21 ' HZ ' ' A' ' 75' ' ' PHE . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.517 ' HZ ' HG21 ' A' ' 59' ' ' VAL . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.522 HG22 ' CD2' ' A' ' 3' ' ' HIS . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.535 HG21 ' CE1' ' A' ' 52' ' ' PHE . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 81' ' ' THR . 1.1 t . . . . . 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.768 ' OE1' HG21 ' A' ' 81' ' ' THR . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.604 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.604 HD12 ' HA ' ' A' ' 4' ' ' ALA . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.775 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.609 HG11 ' CD1' ' A' ' 30' ' ' LEU . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.775 HG23 ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE1' HD12 ' A' ' 36' ' ' ILE . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.741 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.549 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG23 ' OD1' ' A' ' 18' ' ' ASP . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' HG11 ' A' ' 11' ' ' VAL . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.462 HG21 ' HD3' ' A' ' 67' ' ' ARG . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.741 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 3.2 m-20 -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.573 HD21 HD13 ' A' ' 61' ' ' LEU . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.464 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.596 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.596 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HB2' ' CG2' ' A' ' 45' ' ' ILE . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.573 HD13 HD21 ' A' ' 41' ' ' LEU . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.462 ' HD3' HG21 ' A' ' 31' ' ' VAL . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.463 HG12 HD11 ' A' ' 30' ' ' LEU . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.536 ' O ' HG12 ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.768 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.7 t . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.502 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.505 ' CE1' ' HG1' ' A' ' 81' ' ' THR . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.595 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 4' ' ' ALA . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.455 ' HE2' HG22 ' A' ' 44' ' ' VAL . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.712 ' CG2' HD12 ' A' ' 36' ' ' ILE . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 24' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.589 ' O ' HD12 ' A' ' 16' ' ' LEU . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 15' ' ' PHE . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.471 ' O ' HG23 ' A' ' 24' ' ' VAL . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 12' ' ' VAL . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.684 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.712 HD12 ' CG2' ' A' ' 11' ' ' VAL . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 40' ' ' GLY . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.505 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.619 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.619 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.91 HG21 ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.77 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 7' ' ' ILE . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.77 HG23 ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.55 ' OE1' HD11 ' A' ' 36' ' ' ILE . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.823 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.529 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.529 HG23 ' OD1' ' A' ' 18' ' ' ASP . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.517 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 20' ' ' ALA . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.555 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.555 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.412 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.419 HD13 ' HG ' ' A' ' 41' ' ' LEU . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.91 ' OD1' HG21 ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.555 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t . . . . . 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.55 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.578 HG13 ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.578 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.435 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.73 HD11 HG12 ' A' ' 69' ' ' ILE . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.519 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 40' ' ' GLY . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.454 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.471 ' O ' HD21 ' A' ' 61' ' ' LEU . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 57' ' ' ASP . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.73 HG12 HD11 ' A' ' 30' ' ' LEU . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.514 ' OD1' HG23 ' A' ' 77' ' ' VAL . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.514 HG23 ' OD1' ' A' ' 73' ' ' ASP . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 81' ' ' THR . 1.7 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.576 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 4.0 t60 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.576 ' HB ' ' CD2' ' A' ' 3' ' ' HIS . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.633 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.687 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.68 HG22 ' CD1' ' A' ' 36' ' ' ILE . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.564 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.564 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.68 ' CD1' HG22 ' A' ' 11' ' ' VAL . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.634 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 61' ' ' LEU . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.419 HD12 ' O ' ' A' ' 59' ' ' VAL . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.687 HD13 ' HB2' ' A' ' 8' ' ' ALA . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 77' ' ' VAL . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.496 HG23 ' OD1' ' A' ' 73' ' ' ASP . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.731 ' OE1' HG22 ' A' ' 77' ' ' VAL . 83.4 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.61 ' O ' HG23 ' A' ' 11' ' ' VAL . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.754 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.428 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 7' ' ' ILE . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.513 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.513 HG23 ' OD1' ' A' ' 18' ' ' ASP . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.409 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 26.7 m120 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.435 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.763 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.763 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.407 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.592 HD12 HD21 ' A' ' 41' ' ' LEU . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 77' ' ' VAL . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.731 HG22 ' OE1' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.655 ' OE1' HG21 ' A' ' 81' ' ' THR . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.408 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.74 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.815 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.438 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.4 ' H ' HG13 ' A' ' 26' ' ' VAL . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.744 HD11 HG12 ' A' ' 69' ' ' ILE . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.446 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG22 ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.679 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.404 ' CE1' HD13 ' A' ' 41' ' ' LEU . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.744 HG12 HD11 ' A' ' 30' ' ' LEU . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.628 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.487 HG23 ' OD1' ' A' ' 73' ' ' ASP . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.691 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.655 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.4 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.471 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.673 ' ND1' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.673 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.506 ' CE2' ' CZ2' ' A' ' 47' ' ' TRP . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.657 HG22 ' O ' ' A' ' 8' ' ' ALA . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.426 ' N ' HG23 ' A' ' 12' ' ' VAL . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.576 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.576 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.549 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.549 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.426 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.4 m120 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.57 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.476 ' O ' ' ND1' ' A' ' 65' ' ' HIS . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.458 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.434 HG23 ' HE1' ' A' ' 65' ' ' HIS . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.799 ' O ' HG23 ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.429 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t . . . . . 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 34.2 m80 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.433 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.1 pp0? -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.405 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.884 ' OD1' HG23 ' A' ' 19' ' ' VAL . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.884 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.429 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.55 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.717 ' O ' HD12 ' A' ' 69' ' ' ILE . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.55 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.564 HD11 HG12 ' A' ' 69' ' ' ILE . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.7 m-20 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.472 HD21 HD12 ' A' ' 54' ' ' ILE . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 48' ' ' LEU . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.419 HG13 HD21 ' A' ' 61' ' ' LEU . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.419 HD21 HG13 ' A' ' 59' ' ' VAL . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.414 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.509 ' OD1' HG23 ' A' ' 77' ' ' VAL . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.509 HG23 ' OD1' ' A' ' 73' ' ' ASP . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.7 m80 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.44 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.475 ' N ' HG13 ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 61' ' ' LEU . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.433 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.41 ' HE1' ' HD3' ' A' ' 51' ' ' ARG . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.904 HD12 HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.904 HH21 HD12 ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.503 ' CE1' HD13 ' A' ' 41' ' ' LEU . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.506 HG23 ' OD1' ' A' ' 73' ' ' ASP . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.496 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.509 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.428 HG21 ' CE1' ' A' ' 3' ' ' HIS . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.763 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 7' ' ' ILE . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.763 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.821 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.429 ' O ' HG12 ' A' ' 24' ' ' VAL . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.598 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.429 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.407 ' CE1' HD13 ' A' ' 41' ' ' LEU . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.598 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.535 HD12 HG23 ' A' ' 26' ' ' VAL . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.489 ' HA ' HD13 ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.528 ' HB3' ' HB3' ' A' ' 4' ' ' ALA . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.415 ' C ' ' N ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.646 ' HB2' ' OD2' ' A' ' 73' ' ' ASP . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 11' ' ' VAL . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.539 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.539 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.554 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.554 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 26.1 m120 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.473 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.567 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.526 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.886 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.708 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.708 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.619 HG23 ' O ' ' A' ' 81' ' ' THR . 4.3 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.559 ' ND1' HG22 ' A' ' 77' ' ' VAL . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.588 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 3' ' ' HIS . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.588 HD12 ' HA ' ' A' ' 4' ' ' ALA . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.547 ' O ' HD12 ' A' ' 16' ' ' LEU . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.547 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.544 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.544 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.445 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.681 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.402 ' CE1' HG21 ' A' ' 80' ' ' THR . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.597 HG12 ' HG3' ' A' ' 60' ' ' GLU . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.597 ' HG3' HG12 ' A' ' 59' ' ' VAL . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.509 HD23 ' C ' ' A' ' 60' ' ' GLU . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.486 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.559 HG22 ' ND1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.5 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.436 ' O ' ' C ' ' A' ' 3' ' ' HIS . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.735 ' O ' HG22 ' A' ' 11' ' ' VAL . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.759 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.735 HG22 ' O ' ' A' ' 7' ' ' ILE . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.818 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.583 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.583 HG23 ' OD1' ' A' ' 18' ' ' ASP . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.511 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 21' ' ' PRO . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.459 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 39' ' ' LEU . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.565 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.786 ' O ' HG23 ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.436 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.447 ' O ' ' C ' ' A' ' 3' ' ' HIS . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.447 ' C ' ' O ' ' A' ' 2' ' ' GLN . 1.5 m-70 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' HG23 ' A' ' 11' ' ' VAL . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.78 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG13 HD12 ' A' ' 36' ' ' ILE . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.811 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.574 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.475 ' HB ' HD13 ' A' ' 69' ' ' ILE . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.574 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.977 ' H ' HD12 ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.587 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.4 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.479 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.913 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.406 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.408 ' HA ' HG23 ' A' ' 31' ' ' VAL . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.441 ' C ' HD11 ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.802 HG22 HD21 ' A' ' 30' ' ' LEU . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.642 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.406 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.819 ' NE2' HG21 ' A' ' 81' ' ' THR . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.507 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.786 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.729 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.414 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.639 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.729 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 34.2 m120 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.453 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.516 ' OD1' HD13 ' A' ' 61' ' ' LEU . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.42 ' C ' HD12 ' A' ' 61' ' ' LEU . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.859 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.639 HG12 HD11 ' A' ' 30' ' ' LEU . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.495 ' OD1' HG23 ' A' ' 77' ' ' VAL . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.603 HG13 ' OE1' ' A' ' 2' ' ' GLN . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.524 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.819 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.7 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.488 HG11 ' H ' ' A' ' 84' ' ' VAL . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.931 HG21 ' OD1' ' A' ' 73' ' ' ASP . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.406 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 1.7 tt0 -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.597 HG23 ' N ' ' A' ' 12' ' ' VAL . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.597 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 19' ' ' VAL . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 16' ' ' LEU . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.406 HG12 ' HB1' ' A' ' 8' ' ' ALA . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.701 HD11 HG12 ' A' ' 69' ' ' ILE . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.444 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.444 ' N ' HG13 ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.516 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.691 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.464 ' CH2' ' O ' ' A' ' 88' ' ' LEU . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.464 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.443 HD13 HD21 ' A' ' 41' ' ' LEU . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.701 HG12 HD11 ' A' ' 30' ' ' LEU . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.931 ' OD1' HG21 ' A' ' 7' ' ' ILE . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 81' ' ' THR . 2.0 t -124.2 88.0 53.17 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -91.19 109.89 0.32 Allowed 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 123.09 2.527 . . . . 0.0 112.919 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.22 133.95 10.07 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.135 1.89 . . . . 0.0 111.845 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' H ' HG11 ' A' ' 6' ' ' VAL . 11.2 p -133.13 140.85 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.424 ' H ' ' CD ' ' A' ' 85' ' ' GLU . 54.8 mp0 -64.41 -35.62 81.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.176 -0.952 . . . . 0.0 109.921 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.456 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -148.55 158.06 43.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.143 -0.973 . . . . 0.0 109.76 -179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -72.65 133.9 44.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.447 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.464 ' O ' ' CH2' ' A' ' 47' ' ' TRP . 35.5 tp -100.27 130.58 46.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.506 179.976 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.454 ' N5 ' ' CE2' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.586 ' NE2' HG21 ' A' ' 81' ' ' THR . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.633 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.501 HG22 ' HE1' ' A' ' 15' ' ' PHE . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' ALA . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.501 ' HE1' HG22 ' A' ' 11' ' ' VAL . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.512 ' O ' HG12 ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.897 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.897 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.767 ' O ' HD12 ' A' ' 69' ' ' ILE . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.686 HD11 HG12 ' A' ' 69' ' ' ILE . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 31.7 m120 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.411 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.455 HG21 ' HB2' ' A' ' 56' ' ' ALA . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.435 ' HE1' ' HD2' ' A' ' 51' ' ' ARG . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.435 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HB2' HG21 ' A' ' 45' ' ' ILE . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.518 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.918 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE1' HG23 ' A' ' 72' ' ' ILE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' HD11 ' A' ' 72' ' ' ILE . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.767 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 77' ' ' VAL . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 73' ' ' ASP . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.598 ' O ' HG12 ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.586 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.6 t -138.48 88.0 14.91 Favored Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -94.33 107.52 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 123.359 2.706 . . . . 0.0 113.025 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.81 130.72 6.82 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.137 1.891 . . . . 0.0 111.732 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.478 HG22 ' H ' ' A' ' 86' ' ' ALA . 11.3 p -134.31 140.61 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.244 -0.91 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -65.55 -34.97 79.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.304 -0.873 . . . . 0.0 109.88 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.478 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -145.06 159.02 43.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.116 -0.99 . . . . 0.0 109.615 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -68.39 137.52 54.61 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.254 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.9 mt -88.09 141.31 28.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.152 -0.967 . . . . 0.0 109.37 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 -179.902 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.58 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' O ' ' A' ' 83' ' ' PRO . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.569 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.569 HG21 ' NE2' ' A' ' 3' ' ' HIS . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.534 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' HG23 ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.946 HD22 HG23 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.946 HG23 HD22 ' A' ' 16' ' ' LEU . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.511 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.511 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.809 HG11 ' HZ1' ' A' ' 87' ' ' LYS . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.471 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.7 m120 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.586 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.532 HD12 ' O ' ' A' ' 26' ' ' VAL . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t -130.04 88.39 48.64 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.4 Cg_exo -62.89 -175.17 0.2 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.637 2.225 . . . . 0.0 111.976 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 2' ' ' GLN . 21.0 Cg_exo -62.28 150.94 85.18 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.578 2.185 . . . . 0.0 111.574 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 45.4 t -99.03 127.91 51.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.093 -1.005 . . . . 0.0 109.854 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -146.58 164.41 32.7 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.31 137.92 51.59 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.948 -1.095 . . . . 0.0 108.908 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.809 ' HZ1' HG11 ' A' ' 26' ' ' VAL . 61.1 tttm -59.41 -36.37 75.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.502 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.8 mt -59.03 -35.69 73.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.915 . . . . 0.0 109.412 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.484 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.525 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.522 ' CD2' HG22 ' A' ' 77' ' ' VAL . 69.4 m-70 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.42 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.41 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.773 HG23 HD12 ' A' ' 36' ' ' ILE . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.745 HG21 HG11 ' A' ' 24' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' LEU . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.433 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.807 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.807 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.511 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.635 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.511 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.773 HD12 HG23 ' A' ' 11' ' ' VAL . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.503 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.454 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.577 HD13 ' S12' ' A' ' 101' ' ' PN7 . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.535 ' CE1' HG21 ' A' ' 80' ' ' THR . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.722 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.722 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG21 ' HZ ' ' A' ' 75' ' ' PHE . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.517 ' HZ ' HG21 ' A' ' 59' ' ' VAL . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.522 HG22 ' CD2' ' A' ' 3' ' ' HIS . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.535 HG21 ' CE1' ' A' ' 52' ' ' PHE . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 81' ' ' THR . 1.1 t -137.26 89.24 16.46 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -81.93 157.22 18.07 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.585 2.19 . . . . 0.0 112.227 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -63.67 147.63 92.6 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.593 2.195 . . . . 0.0 111.639 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.449 HG22 ' H ' ' A' ' 86' ' ' ALA . 7.6 p -130.81 136.02 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.294 -0.879 . . . . 0.0 109.897 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -70.8 -32.22 69.23 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.373 -0.829 . . . . 0.0 109.866 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.449 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -130.15 169.61 15.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.295 -0.878 . . . . 0.0 109.859 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.635 ' HE3' HG21 ' A' ' 26' ' ' VAL . 27.1 mttm 59.13 43.73 16.9 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.482 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.2 tp -58.38 -37.34 75.06 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.374 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.483 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.577 ' S12' HD13 ' A' ' 42' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.768 ' OE1' HG21 ' A' ' 81' ' ' THR . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.604 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.411 HG11 ' H ' ' A' ' 84' ' ' VAL . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.604 HD12 ' HA ' ' A' ' 4' ' ' ALA . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.775 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.609 HG11 ' CD1' ' A' ' 30' ' ' LEU . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.775 HG23 ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE1' HD12 ' A' ' 36' ' ' ILE . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.741 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.549 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG23 ' OD1' ' A' ' 18' ' ' ASP . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' HG11 ' A' ' 11' ' ' VAL . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.462 HG21 ' HD3' ' A' ' 67' ' ' ARG . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.741 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 3.2 m-20 -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.573 HD21 HD13 ' A' ' 61' ' ' LEU . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.464 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.596 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.591 HH22 HG11 ' A' ' 84' ' ' VAL . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.596 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HB2' ' CG2' ' A' ' 45' ' ' ILE . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.573 HD13 HD21 ' A' ' 41' ' ' LEU . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.598 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.462 ' HD3' HG21 ' A' ' 31' ' ' VAL . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.463 HG12 HD11 ' A' ' 30' ' ' LEU . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.536 ' O ' HG12 ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.768 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.7 t -122.98 87.78 50.84 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -93.2 110.16 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 123.287 2.658 . . . . 0.0 112.804 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -78.62 132.75 11.15 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 121.982 1.788 . . . . 0.0 111.733 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.591 HG11 HH22 ' A' ' 51' ' ' ARG . 41.0 t -124.33 133.13 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.317 -0.864 . . . . 0.0 109.601 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.03 -35.87 82.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.435 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -149.44 149.69 31.2 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.596 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 13.2 tttm -60.51 -39.43 87.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 72.8 mt -60.82 -34.8 75.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.442 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.581 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 95.0 mt-30 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.42 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.598 ' N9 ' ' CB ' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.502 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.891 ' O ' HG13 ' A' ' 84' ' ' VAL . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.517 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.595 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 4' ' ' ALA . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.455 ' HE2' HG22 ' A' ' 44' ' ' VAL . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.712 ' CG2' HD12 ' A' ' 36' ' ' ILE . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 24' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.589 ' O ' HD12 ' A' ' 16' ' ' LEU . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 15' ' ' PHE . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.471 ' O ' HG23 ' A' ' 24' ' ' VAL . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 12' ' ' VAL . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.684 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.476 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.712 HD12 ' CG2' ' A' ' 11' ' ' VAL . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 40' ' ' GLY . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.505 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 0.8 OUTLIER -128.97 87.73 53.73 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.517 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 17.3 Cg_exo -63.86 -174.92 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.759 2.306 . . . . 0.0 111.958 179.546 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 20.1 Cg_exo -62.52 148.96 92.55 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.44 2.093 . . . . 0.0 111.747 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 2' ' ' GLN . 48.3 t -109.19 132.57 56.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.345 -0.847 . . . . 0.0 109.732 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -121.95 152.42 39.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -88.1 127.11 35.41 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 0.0 109.491 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.514 ' HZ3' HG11 ' A' ' 26' ' ' VAL . 21.4 mttp -59.55 -35.45 74.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.6 tp -57.89 -37.31 73.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.477 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.932 -1.032 . . . . 0.0 109.477 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.619 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.619 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.91 HG21 ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.77 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.676 ' CD2' ' NZ ' ' A' ' 87' ' ' LYS . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 7' ' ' ILE . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.77 HG23 ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.55 ' OE1' HD11 ' A' ' 36' ' ' ILE . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.823 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.529 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.529 HG23 ' OD1' ' A' ' 18' ' ' ASP . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.517 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 20' ' ' ALA . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.555 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.555 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.412 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.419 HD13 ' HG ' ' A' ' 41' ' ' LEU . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.91 ' OD1' HG21 ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.555 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t -131.03 87.97 46.95 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -94.26 107.93 0.15 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.321 2.681 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -78.85 131.05 9.9 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 122.022 1.814 . . . . 0.0 112.071 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 86' ' ' ALA . 31.1 t -127.53 132.23 69.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.412 -0.805 . . . . 0.0 109.438 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.68 -35.67 81.44 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 109.743 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.438 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -153.91 160.93 42.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.676 ' NZ ' ' CD2' ' A' ' 10' ' ' PHE . 29.3 mttm -78.79 144.66 34.91 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.176 -0.953 . . . . 0.0 109.358 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -57.25 -37.44 72.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.46 -179.91 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.559 ' S12' ' O8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.55 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG13 ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.578 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.435 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.73 HD11 HG12 ' A' ' 69' ' ' ILE . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.519 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 40' ' ' GLY . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.454 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.589 ' NH2' ' O ' ' A' ' 89' ' ' GLN . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.471 ' O ' HD21 ' A' ' 61' ' ' LEU . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 57' ' ' ASP . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.73 HG12 HD11 ' A' ' 30' ' ' LEU . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.514 ' OD1' HG23 ' A' ' 77' ' ' VAL . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.514 HG23 ' OD1' ' A' ' 73' ' ' ASP . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 81' ' ' THR . 1.7 t -129.33 88.86 49.42 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -89.83 109.94 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.24 2.627 . . . . 0.0 113.16 -179.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.01 137.59 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.216 1.944 . . . . 0.0 111.586 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.16 141.42 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.144 -0.973 . . . . 0.0 109.705 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -63.12 -35.2 79.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.847 . . . . 0.0 109.477 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -145.97 155.2 42.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.568 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.9 tttt -58.75 -38.73 79.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.328 -0.858 . . . . 0.0 109.367 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.0 tp -58.28 -37.57 75.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.589 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.5 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.674 ' CE1' HG21 ' A' ' 6' ' ' VAL . 1.5 t-80 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.674 HG21 ' CE1' ' A' ' 3' ' ' HIS . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.633 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.687 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.68 HG22 ' CD1' ' A' ' 36' ' ' ILE . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.694 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HB2' HD21 ' A' ' 88' ' ' LEU . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.564 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.564 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.68 ' CD1' HG22 ' A' ' 11' ' ' VAL . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' O4 ' ' A' ' 101' ' ' PN7 . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.634 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 61' ' ' LEU . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.419 HD12 ' O ' ' A' ' 59' ' ' VAL . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.687 HD13 ' HB2' ' A' ' 8' ' ' ALA . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 77' ' ' VAL . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.496 HG23 ' OD1' ' A' ' 73' ' ' ASP . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.4 88.77 53.08 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -80.05 162.06 23.42 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.601 2.201 . . . . 0.0 112.655 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.579 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.8 Cg_endo -62.42 151.26 83.86 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.787 2.324 . . . . 0.0 111.435 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.5 p -116.55 137.19 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.383 -0.823 . . . . 0.0 110.237 -179.063 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.06 172.91 12.01 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.05 140.43 7.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.939 -1.101 . . . . 0.0 108.86 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.694 ' HZ3' ' C ' ' A' ' 21' ' ' PRO . 61.7 tttt -58.3 -36.0 72.68 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.225 -0.922 . . . . 0.0 109.332 -179.572 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.54 HD21 ' HB2' ' A' ' 22' ' ' ALA . 61.2 mt -95.08 142.1 27.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.388 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.472 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.586 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.731 ' OE1' HG22 ' A' ' 77' ' ' VAL . 83.4 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.463 ' CD2' ' O ' ' A' ' 83' ' ' PRO . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.61 ' O ' HG23 ' A' ' 11' ' ' VAL . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.754 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.428 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 7' ' ' ILE . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.513 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.513 HG23 ' OD1' ' A' ' 18' ' ' ASP . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.409 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.658 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 26.7 m120 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.453 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.435 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.763 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.763 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.407 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.592 HD12 HD21 ' A' ' 41' ' ' LEU . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 77' ' ' VAL . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.731 HG22 ' OE1' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t -130.37 88.09 48.57 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.454 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.9 Cg_exo -65.34 -175.68 0.44 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.657 2.238 . . . . 0.0 111.836 179.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.463 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 21.7 Cg_exo -62.01 150.67 85.5 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.533 2.156 . . . . 0.0 111.752 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 84' ' ' VAL . 32.7 m -89.96 128.45 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.11 -0.994 . . . . 0.0 109.991 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -141.44 157.63 44.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.498 -0.751 . . . . 0.0 109.08 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -60.2 139.75 57.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.067 -1.02 . . . . 0.0 109.111 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.658 ' HE3' HG21 ' A' ' 26' ' ' VAL . 37.6 tttm -59.57 -38.16 80.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.477 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.9 mt -60.24 -35.16 74.84 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.539 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.485 ' O ' ' O ' ' A' ' 86' ' ' ALA . 63.6 tt0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' N9 ' ' O4 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.655 ' OE1' HG21 ' A' ' 81' ' ' THR . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.408 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG11 ' H ' ' A' ' 84' ' ' VAL . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.74 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.815 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.438 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.4 ' H ' HG13 ' A' ' 26' ' ' VAL . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.744 HD11 HG12 ' A' ' 69' ' ' ILE . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.439 ' O ' ' N9 ' ' A' ' 101' ' ' PN7 . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.446 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG22 ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.679 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.404 ' CE1' HD13 ' A' ' 41' ' ' LEU . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.744 HG12 HD11 ' A' ' 30' ' ' LEU . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.628 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.487 HG23 ' OD1' ' A' ' 73' ' ' ASP . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.691 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.655 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.4 t -129.16 88.84 49.98 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.4 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -91.18 109.16 0.31 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.239 2.626 . . . . 0.0 112.972 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -82.02 133.84 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.303 2.002 . . . . 0.0 111.97 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG22 ' H ' ' A' ' 86' ' ' ALA . 13.9 p -134.26 141.09 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.25 -0.906 . . . . 0.0 109.498 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.15 -36.34 83.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.965 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.474 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -148.2 155.32 41.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.185 -0.947 . . . . 0.0 109.698 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.8 tttm -58.49 -38.24 77.23 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.299 -0.875 . . . . 0.0 109.402 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.8 tp -58.09 -37.45 74.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.374 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 . . . . . 0 N--CA 1.49 1.525 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.487 -179.985 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.538 ' O4 ' ' C7 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.471 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.673 ' ND1' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.673 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.506 ' CE2' ' CZ2' ' A' ' 47' ' ' TRP . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.657 HG22 ' O ' ' A' ' 8' ' ' ALA . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.426 ' N ' HG23 ' A' ' 12' ' ' VAL . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.576 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.576 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.549 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.436 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.549 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.426 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.4 m120 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.55 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.57 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.476 ' O ' ' ND1' ' A' ' 65' ' ' HIS . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.458 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.434 HG23 ' HE1' ' A' ' 65' ' ' HIS . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.799 ' O ' HG23 ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.429 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t -140.74 88.03 10.95 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -86.3 151.36 9.28 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.705 2.27 . . . . 0.0 111.878 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 32.7 Cg_endo -67.44 137.43 43.01 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.444 2.096 . . . . 0.0 112.224 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG22 ' H ' ' A' ' 86' ' ' ALA . 10.6 p -134.23 139.4 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.236 -0.915 . . . . 0.0 109.525 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 97.1 mt-10 -66.27 -35.83 81.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.158 -0.964 . . . . 0.0 109.344 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 85' ' ' GLU . . . 164.03 153.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.345 -0.847 . . . . 0.0 109.251 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.436 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 12.4 tttm -75.12 133.7 41.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.095 -1.003 . . . . 0.0 109.424 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.2 mt -94.28 142.08 27.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.443 179.952 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.59 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.447 ' CD2' ' HB3' ' A' ' 83' ' ' PRO . 34.2 m80 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.433 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.405 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.884 ' OD1' HG23 ' A' ' 19' ' ' VAL . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.884 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.429 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.55 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.717 ' O ' HD12 ' A' ' 69' ' ' ILE . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.55 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.564 HD11 HG12 ' A' ' 69' ' ' ILE . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.7 m-20 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.472 HD21 HD12 ' A' ' 54' ' ' ILE . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 48' ' ' LEU . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.419 HG13 HD21 ' A' ' 61' ' ' LEU . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.419 HD21 HG13 ' A' ' 59' ' ' VAL . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.414 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.459 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.509 ' OD1' HG23 ' A' ' 77' ' ' VAL . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.509 HG23 ' OD1' ' A' ' 73' ' ' ASP . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t -119.03 88.19 36.04 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.415 ' HB2' ' CE1' ' A' ' 52' ' ' PHE . 96.3 Cg_endo -91.56 113.19 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 123.229 2.619 . . . . 0.0 113.186 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.447 ' HB3' ' CD2' ' A' ' 3' ' ' HIS . 60.5 Cg_endo -80.17 130.66 8.36 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 122.037 1.825 . . . . 0.0 111.496 178.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.415 HG12 ' O ' ' A' ' 86' ' ' ALA . 25.0 t -128.95 133.42 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 109.751 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.43 -36.35 83.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.848 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.415 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -147.52 157.67 43.67 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.124 -0.985 . . . . 0.0 109.739 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -57.06 -37.84 72.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.228 -0.92 . . . . 0.0 109.419 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 36.8 tp -100.84 131.39 46.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.504 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.487 ' O3 ' ' OD1' ' A' ' 37' ' ' ASP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.437 HG11 ' H ' ' A' ' 84' ' ' VAL . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.44 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.475 ' N ' HG13 ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.451 ' OG ' ' N9 ' ' A' ' 101' ' ' PN7 . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 61' ' ' LEU . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.433 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.41 ' HE1' ' HD3' ' A' ' 51' ' ' ARG . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.904 HD12 HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.904 HH21 HD12 ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.503 ' CE1' HD13 ' A' ' 41' ' ' LEU . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.506 HG23 ' OD1' ' A' ' 73' ' ' ASP . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t -118.97 88.28 36.0 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -89.25 113.97 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.085 2.524 . . . . 0.0 112.99 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -80.3 132.71 9.34 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.094 1.862 . . . . 0.0 111.697 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.437 ' H ' HG11 ' A' ' 6' ' ' VAL . 34.3 t -125.25 132.15 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.395 -0.815 . . . . 0.0 109.621 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.87 -35.69 81.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.489 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.406 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -151.75 153.48 34.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.914 . . . . 0.0 109.608 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 15.4 tttm -59.19 -34.85 72.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.542 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.9 mt -57.02 -35.65 69.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.556 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.468 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.616 ' CE1' ' N5 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.496 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.628 ' HG2' HG12 ' A' ' 84' ' ' VAL . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' OE1' ' A' ' 89' ' ' GLN . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.428 HG21 ' CE1' ' A' ' 3' ' ' HIS . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.763 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 7' ' ' ILE . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.763 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.821 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.429 ' O ' HG12 ' A' ' 24' ' ' VAL . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.598 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.429 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.407 ' CE1' HD13 ' A' ' 41' ' ' LEU . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.598 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.535 HD12 HG23 ' A' ' 26' ' ' VAL . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.489 ' HA ' HD13 ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.04 87.97 12.09 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.48 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.5 Cg_exo -63.43 -173.58 0.18 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.81 2.34 . . . . 0.0 111.594 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.48 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.4 Cg_exo -61.73 150.78 84.34 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.389 2.06 . . . . 0.0 111.438 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 2' ' ' GLN . 4.1 m -89.53 127.31 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.075 -1.016 . . . . 0.0 110.092 -179.117 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.25 156.68 48.0 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.477 -0.764 . . . . 0.0 108.985 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -73.28 126.17 29.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.054 -1.029 . . . . 0.0 109.347 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.549 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 59.0 tttm -59.92 -38.34 82.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 66.8 mt -60.56 -34.97 74.94 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.431 ' OE1' ' CB ' ' A' ' 5' ' ' SER . 25.6 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.432 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.594 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.528 ' HB3' ' HB3' ' A' ' 4' ' ' ALA . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.415 ' C ' ' N ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.646 ' HB2' ' OD2' ' A' ' 73' ' ' ASP . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 11' ' ' VAL . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.539 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.539 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.465 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.554 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.554 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 26.1 m120 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.416 ' OG ' ' S12' ' A' ' 101' ' ' PN7 . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.473 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.567 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.526 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.886 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.708 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.708 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.619 HG23 ' O ' ' A' ' 81' ' ' THR . 4.3 t -140.66 89.27 10.36 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -83.8 129.6 4.83 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.598 2.199 . . . . 0.0 112.371 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.54 149.14 34.14 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.22 1.946 . . . . 0.0 112.223 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.5 p -131.87 138.25 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 109.491 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.35 -39.39 92.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -0.932 . . . . 0.0 109.517 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -159.81 153.66 23.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.253 -0.904 . . . . 0.0 109.511 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.485 ' HE3' ' HB3' ' A' ' 8' ' ' ALA . 32.0 tttt -59.11 -37.97 78.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.5 tp -101.67 132.02 47.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.287 -0.883 . . . . 0.0 109.494 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.562 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.532 ' O4 ' ' S12' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.571 ' O ' HG21 ' A' ' 84' ' ' VAL . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.588 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 3' ' ' HIS . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.588 HD12 ' HA ' ' A' ' 4' ' ' ALA . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.568 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' O ' HD12 ' A' ' 16' ' ' LEU . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.547 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.541 ' HB2' ' HG2' ' A' ' 87' ' ' LYS . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.544 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.544 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.445 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.681 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.402 ' CE1' HG21 ' A' ' 80' ' ' THR . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.597 HG12 ' HG3' ' A' ' 60' ' ' GLU . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.597 ' HG3' HG12 ' A' ' 59' ' ' VAL . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.509 HD23 ' C ' ' A' ' 60' ' ' GLU . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.486 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.559 HG22 ' ND1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.92 88.39 51.89 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 64.8 Cg_endo -81.89 161.26 18.57 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.69 2.26 . . . . 0.0 112.506 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -63.4 150.57 88.2 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.703 2.269 . . . . 0.0 111.761 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.571 HG21 ' O ' ' A' ' 2' ' ' GLN . 47.0 t -105.94 130.44 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.219 -0.926 . . . . 0.0 109.691 -179.75 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -145.77 12.82 1.31 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.346 -0.846 . . . . 0.0 109.114 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.88 151.5 23.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.317 -0.864 . . . . 0.0 109.632 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.568 ' HE2' ' HB3' ' A' ' 8' ' ' ALA . 15.1 mttm 58.85 45.14 15.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.526 -0.734 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' O ' ' O ' ' A' ' 89' ' ' GLN . 71.0 mt -59.31 -35.1 73.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.377 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.413 ' O ' ' O ' ' A' ' 88' ' ' LEU . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.462 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.5 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.711 ' HG2' HG22 ' A' ' 84' ' ' VAL . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.735 ' O ' HG22 ' A' ' 11' ' ' VAL . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.759 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.735 HG22 ' O ' ' A' ' 7' ' ' ILE . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.818 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.583 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.583 HG23 ' OD1' ' A' ' 18' ' ' ASP . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.511 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 21' ' ' PRO . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.45 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.459 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 39' ' ' LEU . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.565 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.786 ' O ' HG23 ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.436 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t -140.29 88.01 11.68 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 19.0 Cg_exo -63.71 -173.95 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 122.782 2.321 . . . . 0.0 111.741 179.22 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.473 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.2 Cg_exo -61.9 151.15 82.92 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.479 2.119 . . . . 0.0 111.481 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 2' ' ' GLN . 39.5 t -92.12 128.42 43.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.092 -1.005 . . . . 0.0 110.016 -179.119 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -141.32 156.12 45.89 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.37 134.31 52.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.06 -1.025 . . . . 0.0 109.357 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.45 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 16.5 tttm -60.41 -36.27 77.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 109.354 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 87' ' ' LYS . 36.7 tp 43.92 76.85 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.493 179.926 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.451 ' O3 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.734 ' HG2' HG22 ' A' ' 84' ' ' VAL . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.447 ' C ' ' O ' ' A' ' 2' ' ' GLN . 1.5 m-70 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' HG23 ' A' ' 11' ' ' VAL . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.78 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG13 HD12 ' A' ' 36' ' ' ILE . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.811 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.574 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.7 HG11 ' HZ1' ' A' ' 87' ' ' LYS . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.574 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.977 ' H ' HD12 ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.587 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.4 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.479 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.913 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.406 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.408 ' HA ' HG23 ' A' ' 31' ' ' VAL . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.441 ' C ' HD11 ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.802 HG22 HD21 ' A' ' 30' ' ' LEU . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.642 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.406 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.8 88.64 53.53 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.477 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.1 Cg_exo -61.49 -174.55 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.615 2.21 . . . . 0.0 111.829 179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.3 Cg_exo -62.36 151.11 84.56 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.593 2.195 . . . . 0.0 111.595 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.734 HG22 ' HG2' ' A' ' 2' ' ' GLN . 22.4 t -93.34 125.33 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.079 -1.013 . . . . 0.0 109.705 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -147.98 154.89 40.9 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.387 -0.821 . . . . 0.0 109.079 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.76 136.14 55.02 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.061 -1.024 . . . . 0.0 109.187 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.7 ' HZ1' HG11 ' A' ' 26' ' ' VAL . 33.6 tttm -60.05 -38.79 83.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.143 -0.973 . . . . 0.0 109.455 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.455 ' O ' ' O ' ' A' ' 89' ' ' GLN . 53.7 mt -98.89 141.51 31.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.294 -0.879 . . . . 0.0 109.427 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' A' ' 88' ' ' LEU . 60.0 tt0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.468 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.486 ' N9 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.819 ' NE2' HG21 ' A' ' 81' ' ' THR . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.507 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.786 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.729 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.414 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.639 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.729 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 34.2 m120 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.453 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.516 ' OD1' HD13 ' A' ' 61' ' ' LEU . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.42 ' C ' HD12 ' A' ' 61' ' ' LEU . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.859 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.639 HG12 HD11 ' A' ' 30' ' ' LEU . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.495 ' OD1' HG23 ' A' ' 77' ' ' VAL . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.603 HG13 ' OE1' ' A' ' 2' ' ' GLN . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.524 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.819 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.7 t -131.08 88.33 45.58 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -92.32 111.64 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.259 2.64 . . . . 0.0 112.91 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -79.42 137.03 12.89 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 122.111 1.874 . . . . 0.0 111.845 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.486 HG22 ' H ' ' A' ' 86' ' ' ALA . 12.6 p -134.19 141.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.205 -0.934 . . . . 0.0 109.523 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.39 -34.69 78.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 110.02 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.486 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -142.23 155.28 45.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.136 -0.977 . . . . 0.0 109.705 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 18.3 tttm -58.65 -37.34 75.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.274 -0.891 . . . . 0.0 109.533 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 53.7 mt -94.07 142.13 27.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.494 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.456 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.931 HG21 ' OD1' ' A' ' 73' ' ' ASP . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.406 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.597 HG23 ' N ' ' A' ' 12' ' ' VAL . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.597 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 19' ' ' VAL . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 16' ' ' LEU . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.406 HG12 ' HB1' ' A' ' 8' ' ' ALA . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.701 HD11 HG12 ' A' ' 69' ' ' ILE . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.444 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.444 ' N ' HG13 ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.516 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.691 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.45 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.464 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.443 HD13 HD21 ' A' ' 41' ' ' LEU . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.701 HG12 HD11 ' A' ' 30' ' ' LEU . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.931 ' OD1' HG21 ' A' ' 7' ' ' ILE . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 81' ' ' THR . 2.0 t . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.586 ' NE2' HG21 ' A' ' 81' ' ' THR . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.633 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.501 HG22 ' HE1' ' A' ' 15' ' ' PHE . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' ALA . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.501 ' HE1' HG22 ' A' ' 11' ' ' VAL . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.512 ' O ' HG12 ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.897 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.897 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.767 ' O ' HD12 ' A' ' 69' ' ' ILE . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.686 HD11 HG12 ' A' ' 69' ' ' ILE . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.9 m-80 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.411 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.455 HG21 ' HB2' ' A' ' 56' ' ' ALA . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.435 ' HE1' ' HD2' ' A' ' 51' ' ' ARG . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.435 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HB2' HG21 ' A' ' 45' ' ' ILE . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.518 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.918 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE1' HG23 ' A' ' 72' ' ' ILE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' HD11 ' A' ' 72' ' ' ILE . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.767 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 77' ' ' VAL . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 73' ' ' ASP . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.598 ' O ' HG12 ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.586 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.6 t . . . . . 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.569 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.569 HG21 ' NE2' ' A' ' 3' ' ' HIS . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.534 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' HG23 ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.946 HD22 HG23 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.946 HG23 HD22 ' A' ' 16' ' ' LEU . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.511 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.511 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.532 ' O ' HD12 ' A' ' 69' ' ' ILE . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.471 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.0 m-80 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.586 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.532 HD12 ' O ' ' A' ' 26' ' ' VAL . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.525 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.476 ' CE1' HG22 ' A' ' 77' ' ' VAL . 25.7 m80 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.42 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.41 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.773 HG23 HD12 ' A' ' 36' ' ' ILE . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.745 HG21 HG11 ' A' ' 24' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' LEU . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.433 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.807 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.807 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.511 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.511 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.773 HD12 HG23 ' A' ' 11' ' ' VAL . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.454 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.535 ' CE1' HG21 ' A' ' 80' ' ' THR . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.722 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.722 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.517 HG21 ' HZ ' ' A' ' 75' ' ' PHE . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.517 ' HZ ' HG21 ' A' ' 59' ' ' VAL . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.535 HG21 ' CE1' ' A' ' 52' ' ' PHE . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 81' ' ' THR . 1.1 t . . . . . 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.768 ' OE1' HG21 ' A' ' 81' ' ' THR . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.604 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.604 HD12 ' HA ' ' A' ' 4' ' ' ALA . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.775 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.609 HG11 ' CD1' ' A' ' 30' ' ' LEU . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.775 HG23 ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE1' HD12 ' A' ' 36' ' ' ILE . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.605 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.549 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG23 ' OD1' ' A' ' 18' ' ' ASP . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' HG11 ' A' ' 11' ' ' VAL . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.462 HG21 ' HD3' ' A' ' 67' ' ' ARG . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.714 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.573 HD21 HD13 ' A' ' 61' ' ' LEU . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.464 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.596 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.596 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HB2' ' CG2' ' A' ' 45' ' ' ILE . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.573 HD13 HD21 ' A' ' 41' ' ' LEU . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.462 ' HD3' HG21 ' A' ' 31' ' ' VAL . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.463 HG12 HD11 ' A' ' 30' ' ' LEU . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.536 ' O ' HG12 ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.768 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.7 t . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.502 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.505 ' CE1' ' HG1' ' A' ' 81' ' ' THR . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.595 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 4' ' ' ALA . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.455 ' HE2' HG22 ' A' ' 44' ' ' VAL . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.712 ' CG2' HD12 ' A' ' 36' ' ' ILE . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 24' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.589 ' O ' HD12 ' A' ' 16' ' ' LEU . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 15' ' ' PHE . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.471 ' O ' HG23 ' A' ' 24' ' ' VAL . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 12' ' ' VAL . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.684 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.712 HD12 ' CG2' ' A' ' 11' ' ' VAL . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 40' ' ' GLY . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.505 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.619 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.414 ' NE2' HG21 ' A' ' 81' ' ' THR . 25.2 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.619 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.91 HG21 ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.77 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 7' ' ' ILE . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.77 HG23 ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.55 ' OE1' HD11 ' A' ' 36' ' ' ILE . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.823 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.529 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.529 HG23 ' OD1' ' A' ' 18' ' ' ASP . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.517 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 20' ' ' ALA . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.555 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.555 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.412 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.419 HD13 ' HG ' ' A' ' 41' ' ' LEU . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.91 ' OD1' HG21 ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.555 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t . . . . . 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.55 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.571 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.5 tp60 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.571 ' CD2' HE21 ' A' ' 2' ' ' GLN . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.578 HG13 ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.578 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.435 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.73 HD11 HG12 ' A' ' 69' ' ' ILE . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.519 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 40' ' ' GLY . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.454 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.471 ' O ' HD21 ' A' ' 61' ' ' LEU . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 57' ' ' ASP . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.73 HG12 HD11 ' A' ' 30' ' ' LEU . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.514 ' OD1' HG23 ' A' ' 77' ' ' VAL . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.514 HG23 ' OD1' ' A' ' 73' ' ' ASP . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 81' ' ' THR . 1.7 t . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.674 ' CE1' HG21 ' A' ' 6' ' ' VAL . 1.5 t-80 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.674 HG21 ' CE1' ' A' ' 3' ' ' HIS . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.633 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.687 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.68 HG22 ' CD1' ' A' ' 36' ' ' ILE . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.564 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.564 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.68 ' CD1' HG22 ' A' ' 11' ' ' VAL . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.634 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 61' ' ' LEU . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.419 HD12 ' O ' ' A' ' 59' ' ' VAL . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.687 HD13 ' HB2' ' A' ' 8' ' ' ALA . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 77' ' ' VAL . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.496 HG23 ' OD1' ' A' ' 73' ' ' ASP . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.881 ' NE2' HG22 ' A' ' 77' ' ' VAL . 26.1 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.61 ' O ' HG23 ' A' ' 11' ' ' VAL . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.754 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 10' ' ' PHE . 4.0 pp0? -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 7' ' ' ILE . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.513 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.513 HG23 ' OD1' ' A' ' 18' ' ' ASP . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.409 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.435 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.763 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.763 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.407 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.592 HD12 HD21 ' A' ' 41' ' ' LEU . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 77' ' ' VAL . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.881 HG22 ' NE2' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.42 ' CB ' ' NE2' ' A' ' 2' ' ' GLN . 1.2 t . . . . . 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.655 ' OE1' HG21 ' A' ' 81' ' ' THR . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.408 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.74 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.815 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.438 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.4 ' H ' HG13 ' A' ' 26' ' ' VAL . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.744 HD11 HG12 ' A' ' 69' ' ' ILE . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.446 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG22 ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.679 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.404 ' CE1' HD13 ' A' ' 41' ' ' LEU . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.744 HG12 HD11 ' A' ' 30' ' ' LEU . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.628 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.487 HG23 ' OD1' ' A' ' 73' ' ' ASP . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.691 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.655 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.4 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.471 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.673 ' ND1' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.673 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.74 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.74 ' N ' HE21 ' A' ' 9' ' ' GLN . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.657 HG22 ' O ' ' A' ' 8' ' ' ALA . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.426 ' N ' HG23 ' A' ' 12' ' ' VAL . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.576 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.576 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.549 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.549 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.426 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.3 m-80 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.57 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.476 ' O ' ' ND1' ' A' ' 65' ' ' HIS . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.458 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.434 HG23 ' HE1' ' A' ' 65' ' ' HIS . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.799 ' O ' HG23 ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.429 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t . . . . . 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.433 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.1 pp0? -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.405 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.884 ' OD1' HG23 ' A' ' 19' ' ' VAL . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.884 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.429 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.55 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.717 ' O ' HD12 ' A' ' 69' ' ' ILE . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.55 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.564 HD11 HG12 ' A' ' 69' ' ' ILE . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.472 HD21 HD12 ' A' ' 54' ' ' ILE . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 48' ' ' LEU . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.419 HG13 HD21 ' A' ' 61' ' ' LEU . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.419 HD21 HG13 ' A' ' 59' ' ' VAL . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.414 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.509 ' OD1' HG23 ' A' ' 77' ' ' VAL . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.509 HG23 ' OD1' ' A' ' 73' ' ' ASP . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.7 m80 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.44 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.475 ' N ' HG13 ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 61' ' ' LEU . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.433 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.41 ' HE1' ' HD3' ' A' ' 51' ' ' ARG . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.904 HD12 HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.904 HH21 HD12 ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.503 ' CE1' HD13 ' A' ' 41' ' ' LEU . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.506 HG23 ' OD1' ' A' ' 73' ' ' ASP . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.496 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.509 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.428 HG21 ' CE1' ' A' ' 3' ' ' HIS . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.763 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 7' ' ' ILE . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.763 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.821 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.429 ' O ' HG12 ' A' ' 24' ' ' VAL . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.598 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.429 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.407 ' CE1' HD13 ' A' ' 41' ' ' LEU . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.598 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.535 HD12 HG23 ' A' ' 26' ' ' VAL . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.489 ' HA ' HD13 ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.528 ' HB3' ' HB3' ' A' ' 4' ' ' ALA . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.415 ' C ' ' N ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.646 ' HB2' ' OD2' ' A' ' 73' ' ' ASP . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 11' ' ' VAL . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.4 pp0? -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.682 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.539 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.539 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.554 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.554 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.682 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 77.6 m-20 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.473 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.567 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.526 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.886 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.708 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.708 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.619 HG23 ' O ' ' A' ' 81' ' ' THR . 4.3 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.559 ' ND1' HG22 ' A' ' 77' ' ' VAL . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.588 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 3' ' ' HIS . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.588 HD12 ' HA ' ' A' ' 4' ' ' ALA . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.547 ' O ' HD12 ' A' ' 16' ' ' LEU . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.547 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.544 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.544 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.445 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.681 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.402 ' CE1' HG21 ' A' ' 80' ' ' THR . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.597 HG12 ' HG3' ' A' ' 60' ' ' GLU . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.597 ' HG3' HG12 ' A' ' 59' ' ' VAL . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.509 HD23 ' C ' ' A' ' 60' ' ' GLU . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.486 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.559 HG22 ' ND1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.5 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.436 ' O ' ' C ' ' A' ' 3' ' ' HIS . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.735 ' O ' HG22 ' A' ' 11' ' ' VAL . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.759 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.735 HG22 ' O ' ' A' ' 7' ' ' ILE . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.818 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.583 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.583 HG23 ' OD1' ' A' ' 18' ' ' ASP . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.511 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 21' ' ' PRO . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.459 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 39' ' ' LEU . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.565 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.786 ' O ' HG23 ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.436 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t . . . . . 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.447 ' O ' ' C ' ' A' ' 3' ' ' HIS . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.529 ' CD2' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.529 HG21 ' CD2' ' A' ' 3' ' ' HIS . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' HG23 ' A' ' 11' ' ' VAL . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.78 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG13 HD12 ' A' ' 36' ' ' ILE . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.811 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.574 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.475 ' HB ' HD13 ' A' ' 69' ' ' ILE . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.574 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.977 ' H ' HD12 ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.587 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.4 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.479 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.913 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.406 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.408 ' HA ' HG23 ' A' ' 31' ' ' VAL . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.441 ' C ' HD11 ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.802 HG22 HD21 ' A' ' 30' ' ' LEU . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.642 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.406 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.819 ' NE2' HG21 ' A' ' 81' ' ' THR . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.507 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.786 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.578 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.414 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.639 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 65.9 m-80 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.453 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.516 ' OD1' HD13 ' A' ' 61' ' ' LEU . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.42 ' C ' HD12 ' A' ' 61' ' ' LEU . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.859 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.639 HG12 HD11 ' A' ' 30' ' ' LEU . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.495 ' OD1' HG23 ' A' ' 77' ' ' VAL . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.603 HG13 ' OE1' ' A' ' 2' ' ' GLN . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.524 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.819 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.7 t . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mtm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.46 0.648 . . . . 0.0 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -104.62 138.68 40.6 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 52.82 38.18 25.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 108.872 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.96 -33.8 71.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.359 -0.838 . . . . 0.0 109.642 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.25 -34.68 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.163 -0.96 . . . . 0.0 109.566 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.488 HG11 ' H ' ' A' ' 84' ' ' VAL . 69.4 t -67.22 -38.37 80.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.341 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.931 HG21 ' OD1' ' A' ' 73' ' ' ASP . 89.6 mt -59.22 -49.72 82.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.355 -0.841 . . . . 0.0 109.326 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.406 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.23 -44.87 94.02 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.406 ' O ' ' CB ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -61.97 -37.9 86.52 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.561 0.696 . . . . 0.0 109.131 179.18 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -61.94 -52.37 64.32 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.348 -0.845 . . . . 0.0 109.853 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.597 HG23 ' N ' ' A' ' 12' ' ' VAL . 28.4 m -75.76 -47.2 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 111.208 -179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.597 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.1 t -64.03 -40.75 90.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.107 -0.996 . . . . 0.0 111.021 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 9' ' ' GLN . 84.5 tt0 -60.12 -33.13 71.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.039 -1.038 . . . . 0.0 109.583 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -37.32 85.06 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 110.448 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 50.4 m-85 -89.73 -54.14 4.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.926 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 19' ' ' VAL . 2.6 tp -128.53 84.16 64.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 110.783 -178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -80.6 -20.76 7.79 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.78 2.32 . . . . 0.0 112.282 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.73 -4.88 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.086 -1.009 . . . . 0.0 109.314 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 16' ' ' LEU . 61.4 t -114.01 144.04 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.13 115.98 16.91 Favored Pre-proline 0 C--N 1.303 -1.45 0 O-C-N 120.88 -1.138 . . . . 0.0 108.695 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -61.65 -32.75 87.25 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 C-N-CA 121.638 1.559 . . . . 0.0 111.923 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -14.97 61.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.05 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -95.33 6.0 50.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.484 -0.76 . . . . 0.0 109.347 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -101.6 137.49 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -62.51 92.85 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.177 -0.952 . . . . 0.0 109.423 -179.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.406 HG12 ' HB1' ' A' ' 8' ' ' ALA . 5.2 m -61.5 4.85 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.346 -0.847 . . . . 0.0 109.325 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.95 11.04 28.74 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.343 -0.848 . . . . 0.0 108.969 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.3 tp -86.89 133.95 33.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.625 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -64.44 122.21 16.19 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.362 -0.836 . . . . 0.0 108.897 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.701 HD11 HG12 ' A' ' 69' ' ' ILE . 60.7 mt -61.26 -10.71 7.37 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.191 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.444 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.25 -38.64 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.191 -0.943 . . . . 0.0 109.115 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.444 ' N ' HG13 ' A' ' 31' ' ' VAL . 92.4 m-20 -56.34 -37.72 70.39 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.612 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.4 m-80 -87.77 16.36 5.86 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -41.92 -15.4 0.02 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.612 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.67 -37.37 19.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.792 -1.417 . . . . 0.0 108.429 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.645 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.8 tt -73.8 -24.81 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.474 -0.766 . . . . 0.0 110.334 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.581 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 86.6 m-20 -58.34 -30.16 66.51 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 111.291 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.16 -64.39 1.29 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.029 -1.044 . . . . 0.0 111.303 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.4 mp -69.82 -50.48 42.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.991 -1.068 . . . . 0.0 110.539 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.516 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.04 -36.92 73.08 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.849 -1.301 . . . . 0.0 109.849 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.691 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.3 tt -59.5 -43.1 93.44 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.474 -1.015 . . . . 0.0 109.881 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.53 -44.37 97.17 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.181 -0.95 . . . . 0.0 109.082 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -71.96 -40.71 68.48 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.293 -0.879 . . . . 0.0 110.084 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.0 t -67.5 -46.7 82.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.265 -0.897 . . . . 0.0 110.665 -178.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.544 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.4 mp -63.22 -44.08 99.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 109.476 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.76 -44.41 90.13 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.955 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.464 ' CH2' ' O ' ' A' ' 88' ' ' LEU . 1.1 t90 -78.82 -49.21 13.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 110.128 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.464 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.3 tp -60.41 -41.97 95.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.519 -0.738 . . . . 0.0 110.564 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -67.15 -37.77 84.36 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.972 -1.08 . . . . 0.0 109.5 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.401 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 20.8 t70 -66.58 -41.01 89.19 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 38.3 ttp180 -60.77 -40.04 91.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.523 -0.736 . . . . 0.0 110.757 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -107.62 -6.17 17.07 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.07 -1.019 . . . . 0.0 110.021 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.52 36.66 92.8 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -94.49 124.83 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.238 . . . . 0.0 109.673 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.25 139.1 57.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.134 -0.979 . . . . 0.0 109.571 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.17 -30.02 70.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.42 -34.4 66.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.393 -0.817 . . . . 0.0 109.769 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.87 -35.24 44.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.649 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.1 p -128.58 143.76 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.426 -0.796 . . . . 0.0 109.536 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -91.7 143.35 26.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.911 . . . . 0.0 109.449 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.443 HD13 HD21 ' A' ' 41' ' ' LEU . 49.7 mt -91.42 134.43 34.63 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.22 -0.925 . . . . 0.0 109.645 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -167.94 156.52 8.44 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.289 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.07 -28.95 80.7 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.534 2.156 . . . . 0.0 111.667 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.88 -27.59 69.26 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.424 -0.797 . . . . 0.0 109.217 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.489 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.5 -27.05 66.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.384 -0.823 . . . . 0.0 109.551 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.581 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 97.9 m-85 -100.29 5.69 44.57 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.225 -0.922 . . . . 0.0 109.632 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -56.97 -39.03 73.85 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.311 -0.868 . . . . 0.0 109.762 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -150.44 144.83 25.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.04 -1.038 . . . . 0.0 110.011 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.701 HG12 HD11 ' A' ' 30' ' ' LEU . 87.4 mt -62.34 -36.95 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 O-C-N 121.332 -0.855 . . . . 0.0 109.972 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 42.7 ttp180 -60.78 -41.11 94.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 110.267 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -60.37 -45.27 94.11 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.017 -1.052 . . . . 0.0 109.567 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 83.0 mt -65.05 -38.23 82.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.371 -0.83 . . . . 0.0 109.619 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.931 ' OD1' HG21 ' A' ' 7' ' ' ILE . 73.4 m-20 -56.19 -39.69 72.79 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.434 -0.791 . . . . 0.0 109.789 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.35 -45.13 81.24 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.198 -0.939 . . . . 0.0 110.095 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 m-85 -64.2 -44.25 92.56 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.09 -1.007 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.0 t -66.44 -44.61 90.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.232 -0.917 . . . . 0.0 109.748 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.1 t -64.83 -40.61 89.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.178 -0.951 . . . . 0.0 109.645 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.28 -32.91 73.24 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.24 -50.64 3.3 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.237 . . . . 0.0 110.847 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 33.0 m -161.07 138.76 9.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.018 -1.051 . . . . 0.0 110.161 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 81' ' ' THR . 2.0 t -124.2 88.0 53.17 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 108.999 179.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -91.19 109.89 0.32 Allowed 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 123.09 2.527 . . . . 0.0 112.919 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.22 133.95 10.07 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.135 1.89 . . . . 0.0 111.845 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' H ' HG11 ' A' ' 6' ' ' VAL . 11.2 p -133.13 140.85 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.424 ' H ' ' CD ' ' A' ' 85' ' ' GLU . 54.8 mp0 -64.41 -35.62 81.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.176 -0.952 . . . . 0.0 109.921 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.456 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -148.55 158.06 43.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.143 -0.973 . . . . 0.0 109.76 -179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -72.65 133.9 44.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.447 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.464 ' O ' ' CH2' ' A' ' 47' ' ' TRP . 35.5 tp -100.27 130.58 46.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.506 179.976 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.454 ' N5 ' ' CE2' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.468 0.651 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.586 ' NE2' HG21 ' A' ' 81' ' ' THR . 63.7 tt0 -95.82 119.61 34.62 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.0 m170 54.77 30.47 13.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 108.841 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.65 -35.29 77.53 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.424 -0.798 . . . . 0.0 109.748 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -62.89 -32.17 73.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.23 -0.919 . . . . 0.0 109.884 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -64.61 -40.8 90.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.449 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.4 mt -59.75 -43.19 91.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.709 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.633 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.4 -48.12 79.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.218 -0.926 . . . . 0.0 109.137 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.418 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -69.36 -33.25 72.8 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.381 -0.824 . . . . 0.0 109.263 179.517 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 51.8 t80 -63.09 -51.89 64.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.15 -0.969 . . . . 0.0 109.762 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.501 HG22 ' HE1' ' A' ' 15' ' ' PHE . 8.4 p -73.8 -40.07 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.181 -0.95 . . . . 0.0 110.498 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 8' ' ' ALA . 53.3 t -60.65 -40.92 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.31 -0.869 . . . . 0.0 110.447 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 58.0 mm-40 -60.41 -28.98 68.68 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.199 -0.938 . . . . 0.0 109.517 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 51.3 tp10 -65.55 -30.51 71.26 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.567 -0.708 . . . . 0.0 111.112 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.501 ' HE1' HG22 ' A' ' 11' ' ' VAL . 42.1 p90 -130.46 -32.77 1.71 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.955 -1.091 . . . . 0.0 111.696 -179.13 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.512 ' O ' HG12 ' A' ' 12' ' ' VAL . 1.0 OUTLIER -128.78 80.43 72.69 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.729 -1.232 . . . . 0.0 110.6 -179.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -94.4 -22.35 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.543 2.829 . . . . 0.0 112.759 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.897 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -76.55 -3.63 38.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.011 -1.055 . . . . 0.0 109.595 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.897 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.03 144.64 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.515 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -60.47 115.55 14.02 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.748 -1.22 . . . . 0.0 108.004 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -61.3 -24.95 79.67 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 121.383 1.389 . . . . 0.0 112.234 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.73 -15.98 61.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.887 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 37.2 p30 -97.03 9.55 41.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.057 -1.027 . . . . 0.0 109.621 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.86 138.07 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 58.7 t0 -65.33 88.75 0.08 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.153 -0.967 . . . . 0.0 109.266 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.767 ' O ' HD12 ' A' ' 69' ' ' ILE . 4.2 m -60.84 4.78 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.348 -0.845 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -100.17 14.05 32.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.163 179.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.5 tp -89.71 135.38 33.65 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.423 -0.798 . . . . 0.0 109.718 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.509 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 40.3 p30 -62.74 121.59 13.79 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.346 -0.847 . . . . 0.0 108.918 179.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.686 HD11 HG12 ' A' ' 69' ' ' ILE . 56.4 mt -67.17 -3.7 8.33 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.116 -0.99 . . . . 0.0 109.677 -179.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.0 t -50.77 -43.11 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.025 -1.047 . . . . 0.0 109.22 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.69 -36.47 67.17 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.9 m-80 -85.03 16.65 3.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.69 -17.27 0.02 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.816 -1.313 . . . . 0.0 109.816 -179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -55.78 -39.02 53.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.807 -1.408 . . . . 0.0 108.093 178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.614 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.37 -24.56 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.65 -0.656 . . . . 0.0 110.098 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.414 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.06 -28.7 68.01 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.186 -0.946 . . . . 0.0 111.388 -178.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 36.5 m -113.14 -64.71 1.27 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.006 -1.059 . . . . 0.0 111.408 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.411 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.9 mp -68.71 -50.34 51.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.987 -1.071 . . . . 0.0 110.461 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.34 -38.29 70.73 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 36' ' ' ILE . 12.4 tp -59.15 -41.5 88.5 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.519 -0.989 . . . . 0.0 109.296 -179.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.7 tp -59.15 -42.84 91.66 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -66.22 -37.83 86.49 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.411 -0.806 . . . . 0.0 109.223 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -65.08 -48.89 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.438 -0.789 . . . . 0.0 110.296 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.455 HG21 ' HB2' ' A' ' 56' ' ' ALA . 37.5 mm -61.59 -41.58 90.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 120.859 -1.151 . . . . 0.0 109.652 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.95 -41.49 96.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.034 . . . . 0.0 109.546 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.435 ' HE1' ' HD2' ' A' ' 51' ' ' ARG . 0.7 OUTLIER -78.36 -48.56 15.31 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.257 -0.902 . . . . 0.0 109.937 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -63.05 -40.66 98.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.391 -0.818 . . . . 0.0 110.738 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -66.82 -36.24 81.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.043 -1.035 . . . . 0.0 109.834 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -64.1 -40.32 95.96 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.992 . . . . 0.0 110.075 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.435 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 35.5 mtp180 -65.88 -42.14 90.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.278 -0.889 . . . . 0.0 111.519 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -106.88 -5.99 17.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.937 -1.102 . . . . 0.0 110.264 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 64.16 36.42 93.22 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -96.0 124.56 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.167 -1.196 . . . . 0.0 109.716 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.15 137.39 58.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.332 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HB2' HG21 ' A' ' 45' ' ' ILE . . . -65.31 -35.97 82.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.336 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.33 -31.86 70.69 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 0.0 109.886 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -50.34 -37.21 35.72 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.895 . . . . 0.0 109.89 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.5 m -129.68 151.78 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.342 -0.849 . . . . 0.0 109.712 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.518 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -120.19 137.13 54.37 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.498 -0.751 . . . . 0.0 109.276 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.918 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.5 mm? -106.18 142.16 36.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.303 -0.873 . . . . 0.0 109.495 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.68 165.03 35.97 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.393 -0.817 . . . . 0.0 109.21 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -51.2 -33.8 45.91 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.105 1.87 . . . . 0.0 111.797 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.57 -31.06 71.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE1' HG23 ' A' ' 72' ' ' ILE . 55.1 t-80 -67.75 -26.69 66.25 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.305 -0.872 . . . . 0.0 109.661 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' HD11 ' A' ' 72' ' ' ILE . 74.8 m-85 -98.17 5.79 48.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.215 -0.928 . . . . 0.0 109.422 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -55.34 -37.97 68.13 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.308 -0.87 . . . . 0.0 109.612 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 56.0 m -146.96 149.05 32.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -0.959 . . . . 0.0 110.13 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.767 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.4 mt -64.16 -36.92 78.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 O-C-N 121.327 -0.858 . . . . 0.0 109.973 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.9 mtm180 -61.16 -40.38 93.64 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.216 -0.928 . . . . 0.0 110.145 -179.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -61.39 -42.23 98.39 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.029 -1.044 . . . . 0.0 109.501 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 81.1 mt -67.24 -38.85 81.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 109.786 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 77' ' ' VAL . 63.0 t0 -58.51 -42.43 87.65 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.339 -0.851 . . . . 0.0 110.322 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.5 -40.15 89.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.1 -1.0 . . . . 0.0 110.244 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -61.8 -51.24 69.11 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.157 -0.964 . . . . 0.0 109.655 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 80' ' ' THR . 55.3 t -67.23 -46.69 83.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.168 -0.958 . . . . 0.0 109.912 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 73' ' ' ASP . 40.5 t -58.31 -39.66 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.065 -1.022 . . . . 0.0 109.458 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.6 69.18 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.64 -51.75 3.02 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -1.206 . . . . 0.0 110.855 -179.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.598 ' O ' HG12 ' A' ' 76' ' ' VAL . 18.0 p -147.66 153.98 40.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 110.042 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.586 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.6 t -138.48 88.0 14.91 Favored Pre-proline 0 C--N 1.303 -1.445 0 O-C-N 121.057 -1.027 . . . . 0.0 109.229 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -94.33 107.52 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 123.359 2.706 . . . . 0.0 113.025 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -81.81 130.72 6.82 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.137 1.891 . . . . 0.0 111.732 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.478 HG22 ' H ' ' A' ' 86' ' ' ALA . 11.3 p -134.31 140.61 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.244 -0.91 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -65.55 -34.97 79.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.304 -0.873 . . . . 0.0 109.88 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.478 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -145.06 159.02 43.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.116 -0.99 . . . . 0.0 109.615 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -68.39 137.52 54.61 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -0.915 . . . . 0.0 109.254 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.9 mt -88.09 141.31 28.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.152 -0.967 . . . . 0.0 109.37 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 -179.902 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.58 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.0 mtt . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' O ' ' A' ' 83' ' ' PRO . 92.8 mt-30 -58.65 -34.25 70.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 108.949 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.569 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -167.23 26.91 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 108.985 179.812 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.23 -35.54 79.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.447 -0.783 . . . . 0.0 110.012 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.27 -41.14 88.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.021 -1.049 . . . . 0.0 109.749 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.569 HG21 ' NE2' ' A' ' 3' ' ' HIS . 79.2 t -66.48 -37.51 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.228 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.534 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.2 mt -59.61 -50.44 79.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.247 -0.908 . . . . 0.0 109.583 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -47.06 82.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.198 -0.939 . . . . 0.0 108.928 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.99 -39.43 94.11 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.543 0.687 . . . . 0.0 109.845 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.573 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.6 t80 -64.18 -51.07 65.58 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.257 -0.902 . . . . 0.0 110.446 -179.069 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.6 m -74.37 -45.49 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.22 -0.925 . . . . 0.0 111.151 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' HG23 ' A' ' 11' ' ' VAL . 58.9 t -60.08 -39.33 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.145 -0.972 . . . . 0.0 110.748 -178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -63.26 -33.2 74.99 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 110.378 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.18 -33.28 75.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.017 -1.052 . . . . 0.0 109.729 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -95.44 -58.19 2.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -0.982 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.946 HD22 HG23 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -131.34 83.63 58.87 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.198 -0.939 . . . . 0.0 110.922 -178.627 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -84.23 -12.73 7.92 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.768 2.312 . . . . 0.0 112.119 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.26 -4.77 43.71 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.117 -0.99 . . . . 0.0 108.683 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.946 HG23 HD22 ' A' ' 16' ' ' LEU . 47.1 t -113.72 141.81 28.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.511 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.26 115.8 16.35 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 108.638 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -63.89 -31.19 67.67 Favored 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 121.599 1.533 . . . . 0.0 111.797 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.59 -14.67 61.67 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.363 -0.836 . . . . 0.0 109.069 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.511 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 91.6 m-20 -88.98 7.7 33.34 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.397 -0.814 . . . . 0.0 109.27 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.3 t -92.86 137.64 21.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 49.1 t0 -65.62 84.97 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.184 -0.947 . . . . 0.0 109.352 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.809 HG11 ' HZ1' ' A' ' 87' ' ' LYS . 11.3 m -62.96 4.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.5 m-20 -99.09 6.6 46.47 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.251 -0.906 . . . . 0.0 108.56 179.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -95.79 138.15 33.84 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.593 -0.692 . . . . 0.0 109.301 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -60.77 121.39 12.18 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.471 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.53 8.43 0.83 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.769 -179.019 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.71 -40.1 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.105 -0.997 . . . . 0.0 108.769 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -59.12 -36.07 74.56 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.0 m-80 -85.25 15.63 4.16 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 179.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.6 -15.08 0.02 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.47 -36.36 17.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.028 -1.277 . . . . 0.0 108.575 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.608 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.52 -24.72 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.431 -0.793 . . . . 0.0 110.066 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -59.55 -31.38 69.36 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.32 -0.862 . . . . 0.0 111.058 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 m -112.83 -64.39 1.31 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.083 -1.011 . . . . 0.0 111.228 -178.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.586 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -66.78 -51.96 49.71 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.001 -1.062 . . . . 0.0 110.626 -178.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.51 69.02 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.608 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.6 tp -58.63 -40.98 84.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.313 -1.11 . . . . 0.0 109.257 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.5 tp -65.73 -43.9 87.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.315 -0.865 . . . . 0.0 109.12 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -64.06 -34.76 78.77 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.379 -0.826 . . . . 0.0 109.583 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.4 t -59.12 -43.09 88.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.354 -0.841 . . . . 0.0 110.047 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -59.62 -50.05 81.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.13 -0.981 . . . . 0.0 109.578 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.66 -43.85 92.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.329 -0.857 . . . . 0.0 109.937 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.573 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.9 t90 -68.41 -40.86 81.09 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.208 -0.932 . . . . 0.0 109.504 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.3 tp -58.37 -47.38 84.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.332 -0.855 . . . . 0.0 109.364 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -66.29 -39.89 89.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.295 -0.878 . . . . 0.0 108.909 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -63.4 -39.48 94.63 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.446 -0.784 . . . . 0.0 110.545 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -85.13 -49.55 8.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.289 -0.882 . . . . 0.0 112.078 -178.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -98.17 -4.26 35.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.741 -1.224 . . . . 0.0 111.435 -177.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.78 28.91 73.43 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.8 mt -97.99 141.75 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.83 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 153.12 27.55 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.508 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.62 -34.23 69.07 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.399 -0.813 . . . . 0.0 109.993 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.5 m-20 53.92 49.0 19.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -0.987 . . . . 0.0 108.734 -179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.411 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.5 m-20 -41.56 117.18 0.87 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.512 -0.743 . . . . 0.0 109.941 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 p -137.97 145.91 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -84.34 126.6 33.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.997 -1.065 . . . . 0.0 109.828 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 30.4 mt -114.42 141.98 46.96 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.617 -0.677 . . . . 0.0 109.618 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.09 158.19 35.27 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.232 -0.917 . . . . 0.0 109.225 179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -58.47 -28.81 86.64 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.685 2.257 . . . . 0.0 111.952 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.07 -29.6 70.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.379 -0.826 . . . . 0.0 109.484 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.8 t-80 -67.5 -26.61 66.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.803 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -97.4 7.15 47.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.497 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.5 tpt180 -56.52 -38.64 72.09 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 110.027 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 89.4 p -139.35 155.52 47.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.077 . . . . 0.0 110.313 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.532 HD12 ' O ' ' A' ' 26' ' ' VAL . 88.8 mt -61.49 -35.5 67.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 O-C-N 121.473 -0.767 . . . . 0.0 110.064 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.0 ttp180 -59.23 -40.39 85.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.111 -0.993 . . . . 0.0 110.068 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 30.4 t -59.59 -42.25 92.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.993 -1.067 . . . . 0.0 108.972 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.1 mt -64.69 -38.25 82.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.374 -0.829 . . . . 0.0 109.278 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' VAL . 84.9 m-20 -55.31 -39.11 69.53 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.422 -0.799 . . . . 0.0 109.421 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.03 -40.73 96.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -62.99 -50.01 72.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.575 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.2 t -67.98 -40.99 84.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.87 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 60.4 t -62.3 -41.97 93.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 O-C-N 121.177 -0.952 . . . . 0.0 109.882 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.06 -36.01 89.15 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -95.26 -49.82 5.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.261 . . . . 0.0 110.251 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.1 m -128.21 136.49 51.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.455 -0.778 . . . . 0.0 109.502 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' THR . 1.2 t -130.04 88.39 48.64 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.414 -0.804 . . . . 0.0 109.455 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.4 Cg_exo -62.89 -175.17 0.2 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.637 2.225 . . . . 0.0 111.976 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 2' ' ' GLN . 21.0 Cg_exo -62.28 150.94 85.18 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 122.578 2.185 . . . . 0.0 111.574 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 45.4 t -99.03 127.91 51.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.093 -1.005 . . . . 0.0 109.854 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -146.58 164.41 32.7 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.31 137.92 51.59 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.948 -1.095 . . . . 0.0 108.908 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.809 ' HZ1' HG11 ' A' ' 26' ' ' VAL . 61.1 tttm -59.41 -36.37 75.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.502 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.8 mt -59.03 -35.69 73.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.915 . . . . 0.0 109.412 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.484 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.525 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.2 mtm . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.339 0.59 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -58.67 -36.77 74.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.272 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.52 ' CD2' ' O ' ' A' ' 82' ' ' PRO . 25.7 m80 -132.38 21.53 4.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.399 -0.813 . . . . 0.0 109.314 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -59.02 -36.62 75.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 110.027 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.3 m -60.23 -41.88 94.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.935 -1.103 . . . . 0.0 109.697 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.73 -42.56 95.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.037 -1.039 . . . . 0.0 108.345 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.42 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.9 mt -59.55 -47.93 89.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.468 -0.77 . . . . 0.0 109.048 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.97 -45.17 90.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.7 OUTLIER -68.49 -34.43 75.91 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.397 -0.814 . . . . 0.0 109.651 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.41 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.3 t80 -63.36 -50.87 68.22 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.147 -0.971 . . . . 0.0 109.341 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.773 HG23 HD12 ' A' ' 36' ' ' ILE . 11.6 p -73.99 -46.65 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.817 . . . . 0.0 110.424 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.745 HG21 HG11 ' A' ' 24' ' ' VAL . 53.3 t -60.18 -35.4 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.322 -0.861 . . . . 0.0 110.89 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -56.47 -35.21 67.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.071 -1.018 . . . . 0.0 109.394 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.56 -35.28 79.84 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.478 -0.764 . . . . 0.0 110.81 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' LEU . 51.5 m-85 -100.65 -57.61 2.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.872 -1.143 . . . . 0.0 111.118 -178.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.433 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.5 mp -123.1 83.73 51.17 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.333 -0.854 . . . . 0.0 110.812 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -90.49 -23.42 0.61 Allowed 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 123.201 2.601 . . . . 0.0 111.845 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.76 -4.38 43.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.0 t -113.22 146.33 17.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.67 115.37 13.4 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 120.774 -1.204 . . . . 0.0 108.7 -179.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.807 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.5 Cg_endo -63.5 -25.87 70.15 Favored 'Trans proline' 0 C--N 1.316 -1.143 0 C-N-CA 121.552 1.502 . . . . 0.0 111.57 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.29 -18.34 64.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.439 -0.788 . . . . 0.0 109.449 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -82.32 -6.62 59.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.807 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.4 m -68.43 140.82 18.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.17 -0.956 . . . . 0.0 108.803 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.511 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.5 m-20 -69.41 82.26 0.39 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.077 -1.014 . . . . 0.0 109.28 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.635 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.1 m -62.78 4.66 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.382 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.511 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -95.31 4.59 53.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.7 tp -100.44 138.4 37.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -60.99 121.9 13.57 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.97 5.74 0.85 Allowed 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.237 -0.915 . . . . 0.0 110.184 -178.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 29' ' ' ASP . 55.1 t -56.85 -38.88 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.05 -1.031 . . . . 0.0 109.106 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.39 -36.63 66.61 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -85.1 15.72 3.96 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 178.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.66 -14.98 0.02 OUTLIER Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.92 -35.68 18.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.96 -1.317 . . . . 0.0 108.379 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.773 HD12 HG23 ' A' ' 11' ' ' VAL . 3.7 tt -71.3 -24.89 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.517 -0.739 . . . . 0.0 110.12 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 90.0 m-20 -61.36 -29.59 70.0 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.217 -0.927 . . . . 0.0 111.416 -178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.503 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 1.5 m -108.0 -64.76 1.18 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.824 -1.172 . . . . 0.0 111.225 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.454 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -72.49 -50.74 23.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.084 -1.01 . . . . 0.0 110.71 -178.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -67.52 -37.81 90.11 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.99 -42.33 89.78 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.427 -1.043 . . . . 0.0 109.18 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.577 HD13 ' S12' ' A' ' 101' ' ' PN7 . 37.3 tp -59.44 -43.5 93.11 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.386 -0.926 . . . . 0.0 108.53 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -67.66 -36.31 80.5 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.335 -0.853 . . . . 0.0 109.493 179.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.2 t -64.21 -48.58 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.377 -0.827 . . . . 0.0 110.553 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.6 mm -60.8 -42.38 92.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.03 -1.044 . . . . 0.0 109.691 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.91 -44.07 86.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.207 -0.933 . . . . 0.0 109.729 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -71.26 -40.21 71.12 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.43 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.3 tp -57.32 -42.31 81.59 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.347 -0.846 . . . . 0.0 109.225 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -64.18 -39.76 94.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.385 -0.822 . . . . 0.0 109.348 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -67.13 -38.05 84.91 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.215 -0.928 . . . . 0.0 110.884 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -86.2 -49.91 7.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.056 -1.027 . . . . 0.0 112.073 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.535 ' CE1' HG21 ' A' ' 80' ' ' THR . 97.4 m-85 -93.85 -5.15 48.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.674 -1.266 . . . . 0.0 111.078 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.74 26.0 74.91 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 73.2 mt -93.59 131.05 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.229 -1.159 . . . . 0.0 109.334 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.722 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.51 143.58 55.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.516 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.27 -35.82 80.16 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.383 -0.823 . . . . 0.0 109.958 -179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -95.81 5.77 50.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.226 -0.921 . . . . 0.0 109.938 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.722 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 53.4 t0 -56.34 -39.45 72.85 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.153 -0.967 . . . . 0.0 109.737 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG21 ' HZ ' ' A' ' 75' ' ' PHE . 28.2 m -133.7 156.01 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.379 -0.826 . . . . 0.0 109.616 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -108.71 135.56 49.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.2 mt -108.87 143.02 38.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.338 -0.851 . . . . 0.0 109.6 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.5 159.64 39.34 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.413 -0.805 . . . . 0.0 109.431 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.54 -34.23 96.89 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.8 2.333 . . . . 0.0 112.017 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -65.75 -28.62 69.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.412 -0.805 . . . . 0.0 109.697 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -67.97 -26.52 65.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.343 -0.848 . . . . 0.0 110.012 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -92.66 7.68 42.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 109.949 -179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -56.14 -38.87 71.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.175 -0.953 . . . . 0.0 110.149 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.0 p -140.96 157.37 45.44 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.961 -1.087 . . . . 0.0 110.313 -179.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.2 mt -62.85 -36.42 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.791 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.2 mtm180 -60.72 -37.89 83.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.308 -0.87 . . . . 0.0 110.302 -179.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.1 t -60.08 -45.91 91.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.783 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 73.9 mt -64.24 -39.5 85.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.167 -0.958 . . . . 0.0 109.706 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.579 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 55.9 t0 -57.92 -38.16 75.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.64 -45.99 84.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.11 -0.994 . . . . 0.0 109.869 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.517 ' HZ ' HG21 ' A' ' 59' ' ' VAL . 71.3 t80 -63.68 -44.7 92.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.124 -0.985 . . . . 0.0 109.373 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.505 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.7 t -62.78 -43.83 99.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.457 -0.777 . . . . 0.0 109.723 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.2 t -62.63 -41.03 90.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.19 -0.944 . . . . 0.0 109.8 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.67 -30.32 65.48 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.71 -49.92 4.02 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.975 -1.309 . . . . 0.0 110.157 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.535 HG21 ' CE1' ' A' ' 52' ' ' PHE . 10.7 t -140.67 153.4 45.97 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.289 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 81' ' ' THR . 1.1 t -137.26 89.24 16.46 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.186 -0.946 . . . . 0.0 109.71 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.52 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 66.6 Cg_endo -81.93 157.22 18.07 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.585 2.19 . . . . 0.0 112.227 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -63.67 147.63 92.6 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.593 2.195 . . . . 0.0 111.639 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.449 HG22 ' H ' ' A' ' 86' ' ' ALA . 7.6 p -130.81 136.02 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.294 -0.879 . . . . 0.0 109.897 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -70.8 -32.22 69.23 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.373 -0.829 . . . . 0.0 109.866 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.449 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -130.15 169.61 15.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.295 -0.878 . . . . 0.0 109.859 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.635 ' HE3' HG21 ' A' ' 26' ' ' VAL . 27.1 mttm 59.13 43.73 16.9 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.482 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.2 tp -58.38 -37.34 75.06 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.374 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.483 179.981 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.577 ' S12' HD13 ' A' ' 42' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.0 mtt . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.768 ' OE1' HG21 ' A' ' 81' ' ' THR . 94.1 mt-30 -58.73 -35.82 73.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.371 -0.831 . . . . 0.0 109.294 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 94.9 m-70 -156.01 44.94 0.44 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.121 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.604 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.77 -34.13 74.0 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.85 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 m -58.89 -40.54 84.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.067 -1.021 . . . . 0.0 109.39 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.411 HG11 ' H ' ' A' ' 84' ' ' VAL . 62.3 t -67.37 -36.94 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.246 -0.909 . . . . 0.0 109.211 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.604 HD12 ' HA ' ' A' ' 4' ' ' ALA . 84.2 mt -59.43 -50.31 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.3 -0.875 . . . . 0.0 109.727 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.775 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.57 -44.74 93.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 108.909 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.35 -41.51 96.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.716 0.769 . . . . 0.0 108.94 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.69 -49.62 76.78 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.489 0.662 . . . . 0.0 109.346 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.609 HG11 ' CD1' ' A' ' 30' ' ' LEU . 47.7 t -73.23 -44.25 55.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.467 -0.771 . . . . 0.0 109.871 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.775 HG23 ' O ' ' A' ' 8' ' ' ALA . 66.1 t -64.14 -35.74 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.387 -0.821 . . . . 0.0 109.957 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -55.61 -29.89 59.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.982 . . . . 0.0 109.423 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE1' HD12 ' A' ' 36' ' ' ILE . 84.6 tt0 -65.19 -30.85 71.79 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.315 -0.865 . . . . 0.0 109.716 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.605 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 29.6 p90 -143.61 43.85 1.5 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -0.978 . . . . 0.0 109.69 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.12 131.17 63.58 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 120.928 -1.107 . . . . 0.0 110.296 -179.623 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.41 -150.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.191 1.927 . . . . 0.0 110.461 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.549 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.36 12.85 1.75 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.799 -1.188 . . . . 0.0 108.728 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG23 ' OD1' ' A' ' 18' ' ' ASP . 37.9 t -113.42 136.05 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.583 -0.698 . . . . 0.0 109.676 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.57 138.9 83.45 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.145 -0.972 . . . . 0.0 108.883 179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.42 -31.24 17.35 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.79 1.66 . . . . 0.0 112.04 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -24.45 67.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.175 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -96.95 2.41 51.55 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.443 -0.786 . . . . 0.0 109.074 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -106.45 137.05 38.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.44 99.11 0.39 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 109.514 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.8 m -60.97 4.89 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.337 -0.852 . . . . 0.0 109.379 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -92.71 10.97 28.45 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.265 -0.897 . . . . 0.0 109.01 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.9 tp -84.81 133.22 34.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.346 -0.846 . . . . 0.0 109.402 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 67' ' ' ARG . 89.2 m-20 -68.78 122.21 18.1 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.609 ' CD1' HG11 ' A' ' 11' ' ' VAL . 49.0 mt -72.22 4.7 3.37 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.289 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.462 HG21 ' HD3' ' A' ' 67' ' ' ARG . 84.6 t -53.44 -42.5 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.151 -0.968 . . . . 0.0 108.722 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -55.42 -35.08 65.0 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.714 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -83.19 15.48 2.87 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' ' OD1' ' A' ' 37' ' ' ASP . . . -42.01 -15.83 0.02 OUTLIER Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.588 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -50.93 -32.06 11.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 O-C-N 120.438 -1.625 . . . . 0.0 108.171 179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.2 tt -82.19 -11.8 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.664 -0.648 . . . . 0.0 110.271 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.665 ' OD1' ' N ' ' A' ' 38' ' ' SER . 35.5 p-10 -58.16 -39.35 78.62 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 112.929 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.665 ' N ' ' OD1' ' A' ' 37' ' ' ASP . 0.3 OUTLIER -115.86 -63.14 1.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.947 -1.096 . . . . 0.0 111.358 -178.268 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.73 -49.63 75.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.096 -1.003 . . . . 0.0 110.003 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -44.59 49.77 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.573 HD21 HD13 ' A' ' 61' ' ' LEU . 6.9 tp -58.79 -41.09 85.88 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.465 -1.021 . . . . 0.0 109.74 -179.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -59.06 -44.25 91.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.155 -0.966 . . . . 0.0 108.945 -179.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -67.58 -36.42 80.87 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.318 -0.864 . . . . 0.0 109.485 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.1 t -63.88 -47.23 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.389 -0.82 . . . . 0.0 111.0 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.464 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 37.3 mm -60.71 -44.9 98.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.747 -1.221 . . . . 0.0 109.826 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.5 -44.76 77.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 110.325 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.1 t90 -77.67 -44.58 27.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 110.568 -179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.446 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 39.1 tp -56.88 -44.43 82.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.226 -0.921 . . . . 0.0 110.234 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.596 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.4 tt0 -64.29 -39.65 94.35 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.037 -1.04 . . . . 0.0 109.039 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.33 -39.37 89.2 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.34 -0.85 . . . . 0.0 109.896 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.591 HH22 HG11 ' A' ' 84' ' ' VAL . 75.1 ttt180 -61.84 -45.59 93.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.369 -0.832 . . . . 0.0 111.051 -178.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -106.44 -7.53 17.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.009 -1.057 . . . . 0.0 110.046 -179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.596 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.01 30.35 70.05 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.9 pt -111.57 144.16 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -1.146 . . . . 0.0 109.979 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.52 155.06 26.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.813 . . . . 0.0 109.559 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HB2' ' CG2' ' A' ' 45' ' ' ILE . . . -56.82 -30.36 63.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.276 -0.89 . . . . 0.0 109.389 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 55.13 45.44 26.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.387 -0.821 . . . . 0.0 109.394 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.514 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -154.32 83.38 1.12 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.342 -0.849 . . . . 0.0 109.521 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.43 -43.21 93.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.209 -0.932 . . . . 0.0 110.244 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -122.95 138.44 54.68 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.359 -0.838 . . . . 0.0 110.084 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.573 HD13 HD21 ' A' ' 41' ' ' LEU . 22.3 mt -107.83 137.24 46.18 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.481 -0.762 . . . . 0.0 109.24 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -139.16 152.79 70.49 Favored Pre-proline 0 N--CA 1.488 1.452 0 O-C-N 121.142 -0.974 . . . . 0.0 109.613 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.17 -27.99 79.16 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.607 2.205 . . . . 0.0 112.283 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -61.16 -28.77 69.36 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.43 -0.794 . . . . 0.0 109.926 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -72.36 -26.26 61.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.291 -0.88 . . . . 0.0 111.226 -178.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.598 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 87.6 m-85 -105.99 10.54 32.23 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.044 -1.035 . . . . 0.0 111.672 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.462 ' HD3' HG21 ' A' ' 31' ' ' VAL . 27.7 mmt180 -57.18 -31.85 65.84 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.646 -1.284 . . . . 0.0 110.543 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.9 p -150.26 154.54 38.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.948 -1.095 . . . . 0.0 110.467 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.463 HG12 HD11 ' A' ' 30' ' ' LEU . 90.6 mt -66.25 -36.14 76.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.564 -0.71 . . . . 0.0 110.198 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.3 mtm180 -60.48 -37.83 82.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.411 -178.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.6 p -62.03 -41.4 98.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.962 -1.086 . . . . 0.0 109.375 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.8 mt -68.53 -38.61 79.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.352 -0.843 . . . . 0.0 109.653 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.0 t0 -56.58 -41.4 76.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.408 -0.808 . . . . 0.0 110.28 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.2 -43.14 87.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.895 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -63.39 -46.9 84.29 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.216 -0.928 . . . . 0.0 109.668 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 80' ' ' THR . 70.1 t -65.98 -43.95 92.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 O-C-N 121.266 -0.896 . . . . 0.0 109.96 -179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.3 t -62.7 -40.75 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.05 -1.031 . . . . 0.0 109.708 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.05 -32.68 67.31 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.3 -50.61 3.3 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -1.199 . . . . 0.0 110.692 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.536 ' O ' HG12 ' A' ' 76' ' ' VAL . 52.7 m -156.69 139.22 14.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.081 -1.012 . . . . 0.0 109.98 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.768 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.7 t -122.98 87.78 50.84 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.345 -0.847 . . . . 0.0 109.104 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -93.2 110.16 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 C-N-CA 123.287 2.658 . . . . 0.0 112.804 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -78.62 132.75 11.15 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 121.982 1.788 . . . . 0.0 111.733 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.591 HG11 HH22 ' A' ' 51' ' ' ARG . 41.0 t -124.33 133.13 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.317 -0.864 . . . . 0.0 109.601 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.03 -35.87 82.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.435 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -149.44 149.69 31.2 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.596 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 13.2 tttm -60.51 -39.43 87.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.487 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 72.8 mt -60.82 -34.8 75.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.442 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.581 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 95.0 mt-30 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.42 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.598 ' N9 ' ' CB ' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.502 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 69.2 mtm . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.376 0.608 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.891 ' O ' HG13 ' A' ' 84' ' ' VAL . 93.5 mt-30 -59.61 -37.5 78.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.371 -0.831 . . . . 0.0 109.556 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.517 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 27.3 m-70 -118.44 13.19 13.49 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.431 -0.793 . . . . 0.0 109.329 -179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.595 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.87 -32.77 71.02 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.245 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 t -58.55 -45.69 88.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.07 -1.019 . . . . 0.0 109.805 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.9 t -66.34 -38.85 82.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -0.943 . . . . 0.0 108.82 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 4' ' ' ALA . 95.8 mt -59.51 -50.36 80.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.451 -0.781 . . . . 0.0 109.727 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -43.72 95.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.23 -0.919 . . . . 0.0 108.781 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -39.92 92.43 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.567 -0.708 . . . . 0.0 109.536 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.455 ' HE2' HG22 ' A' ' 44' ' ' VAL . 41.8 t80 -63.56 -50.13 70.71 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.391 -0.818 . . . . 0.0 110.089 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.712 ' CG2' HD12 ' A' ' 36' ' ' ILE . 14.7 p -73.63 -48.24 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.361 -0.837 . . . . 0.0 110.831 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 24' ' ' VAL . 67.7 t -60.24 -36.18 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.161 -0.962 . . . . 0.0 110.758 -178.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -59.45 -34.52 72.63 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.162 -0.961 . . . . 0.0 110.072 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.97 -33.46 75.62 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.249 -0.907 . . . . 0.0 111.126 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.589 ' O ' HD12 ' A' ' 16' ' ' LEU . 37.8 m-85 -106.09 -56.45 2.18 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.961 -1.087 . . . . 0.0 111.391 -178.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 15' ' ' PHE . 4.6 mp -123.48 83.7 52.92 Favored Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.225 -0.922 . . . . 0.0 111.09 -178.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -89.11 -15.2 2.52 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.157 2.572 . . . . 0.0 112.15 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.447 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.4 p30 -77.0 -3.62 39.94 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.776 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.4 p -115.15 148.56 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.35 115.65 15.76 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.847 -1.158 . . . . 0.0 108.408 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.471 ' O ' HG23 ' A' ' 24' ' ' VAL . 2.1 Cg_endo -63.17 -27.44 72.91 Favored 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 121.424 1.416 . . . . 0.0 111.708 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.29 -17.75 63.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.382 -0.824 . . . . 0.0 109.322 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -82.34 -6.69 59.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.308 -0.87 . . . . 0.0 109.19 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.883 HG21 HG21 ' A' ' 12' ' ' VAL . 46.1 t -65.85 136.15 27.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 27' ' ' ASP . 50.7 t0 -67.66 83.25 0.18 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.112 -0.993 . . . . 0.0 109.262 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.684 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -60.25 4.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.2 m-20 -100.91 5.28 43.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 108.88 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -100.15 138.07 37.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.474 -0.766 . . . . 0.0 109.534 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -60.85 121.74 13.09 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -69.2 7.43 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.069 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -52.4 -38.62 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.036 -1.04 . . . . 0.0 108.853 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.98 -36.55 72.79 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.1 m-20 -85.57 15.44 4.6 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.476 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.97 -14.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.3 t -51.29 -34.97 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -1.131 . . . . 0.0 108.78 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.712 HD12 ' CG2' ' A' ' 11' ' ' VAL . 4.7 tt -70.27 -23.09 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.451 -0.78 . . . . 0.0 110.385 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.8 m-20 -55.04 -35.87 64.94 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.412 -0.805 . . . . 0.0 111.853 -177.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 67.8 m -114.57 -64.57 1.3 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.941 -1.1 . . . . 0.0 111.539 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.5 -52.07 62.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.094 -1.004 . . . . 0.0 110.239 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.62 -38.78 67.95 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.584 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.3 tp -58.9 -41.63 87.63 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.257 -1.143 . . . . 0.0 109.349 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.88 -44.3 97.08 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.175 -0.953 . . . . 0.0 108.925 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -67.97 -39.8 83.27 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.328 -0.858 . . . . 0.0 109.635 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 40' ' ' GLY . 83.0 t -65.16 -45.07 95.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.331 -0.856 . . . . 0.0 109.972 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.56 -48.75 87.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.568 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.65 -43.11 97.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.37 -0.831 . . . . 0.0 109.893 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -72.37 -41.74 66.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.76 -45.91 90.79 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -65.79 -40.27 91.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 108.967 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -65.38 -37.24 86.39 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.34 -0.85 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -86.27 -50.03 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.271 -0.893 . . . . 0.0 112.002 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -98.0 -4.47 36.1 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.758 -1.214 . . . . 0.0 111.436 -177.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.92 28.83 72.71 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.3 mt -95.52 138.89 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -1.11 . . . . 0.0 109.736 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.65 151.61 33.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.684 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.03 -31.08 68.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.396 -0.815 . . . . 0.0 109.821 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.5 45.49 26.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.89 . . . . 0.0 109.284 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.38 17.28 13.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.396 -0.815 . . . . 0.0 109.719 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.36 -43.84 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.087 -1.008 . . . . 0.0 109.774 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -144.28 122.99 12.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.143 -0.973 . . . . 0.0 109.807 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 mp -129.13 140.01 51.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.438 -0.789 . . . . 0.0 109.251 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.07 150.89 47.1 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.032 -1.043 . . . . 0.0 109.581 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.74 -24.17 74.63 Favored 'Trans proline' 0 N--CA 1.493 1.459 0 C-N-CA 122.63 2.22 . . . . 0.0 112.254 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.98 -32.41 71.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.309 -0.869 . . . . 0.0 110.02 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -73.12 -26.14 61.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -0.924 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.412 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 97.1 m-85 -95.34 7.12 47.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.972 -1.08 . . . . 0.0 110.928 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -60.17 -37.38 79.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.877 -1.139 . . . . 0.0 110.554 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.6 p -142.66 154.18 44.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.834 -1.166 . . . . 0.0 110.467 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.5 mt -65.48 -35.91 76.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.535 -0.728 . . . . 0.0 109.846 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 64.2 mtm180 -60.57 -37.89 82.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.327 -0.858 . . . . 0.0 110.475 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.3 t -58.92 -46.29 88.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.864 -1.148 . . . . 0.0 109.273 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.6 mt -68.37 -37.93 78.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.374 -0.829 . . . . 0.0 109.573 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.538 ' OD1' ' CD1' ' A' ' 7' ' ' ILE . 80.7 m-20 -55.51 -41.71 73.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.42 -0.8 . . . . 0.0 110.168 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.26 -45.8 79.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.075 -1.016 . . . . 0.0 109.738 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -63.7 -46.3 86.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.345 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -66.27 -44.97 90.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.312 -0.867 . . . . 0.0 109.946 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.5 t -62.47 -40.63 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 O-C-N 121.131 -0.98 . . . . 0.0 109.804 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -33.08 67.53 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.12 -50.25 3.41 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.13 -1.218 . . . . 0.0 110.716 -179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 50.0 m -131.91 138.15 48.27 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.282 -0.886 . . . . 0.0 110.046 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.505 ' HG1' ' CE1' ' A' ' 3' ' ' HIS . 0.8 OUTLIER -128.97 87.73 53.73 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.354 -0.841 . . . . 0.0 109.393 179.556 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.517 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 17.3 Cg_exo -63.86 -174.92 0.26 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.759 2.306 . . . . 0.0 111.958 179.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 20.1 Cg_exo -62.52 148.96 92.55 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.44 2.093 . . . . 0.0 111.747 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 2' ' ' GLN . 48.3 t -109.19 132.57 56.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.345 -0.847 . . . . 0.0 109.732 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -121.95 152.42 39.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -88.1 127.11 35.41 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 0.0 109.491 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.514 ' HZ3' HG11 ' A' ' 26' ' ' VAL . 21.4 mttp -59.55 -35.45 74.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.6 tp -57.89 -37.31 73.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.477 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.932 -1.032 . . . . 0.0 109.477 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.583 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.619 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.5 mtm . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.391 0.615 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.414 ' NE2' HG21 ' A' ' 81' ' ' THR . 25.2 mt-30 -101.78 132.16 47.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.386 -0.821 . . . . 0.0 108.793 179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 53.13 36.5 22.54 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.111 -0.993 . . . . 0.0 108.931 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.619 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.26 -33.2 71.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.336 -0.852 . . . . 0.0 109.818 -179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.0 p -61.63 -34.71 76.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 0.0 109.858 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.4 t -66.41 -39.45 84.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.354 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.91 HG21 ' OD1' ' A' ' 73' ' ' ASP . 95.5 mt -59.72 -43.81 92.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.316 -0.865 . . . . 0.0 109.961 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.77 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.02 -47.43 83.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.133 -0.979 . . . . 0.0 109.294 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.435 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.43 -34.85 75.05 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.281 -0.887 . . . . 0.0 108.839 179.381 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.676 ' CD2' ' NZ ' ' A' ' 87' ' ' LYS . 71.9 t80 -64.78 -50.86 65.15 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.437 -0.789 . . . . 0.0 109.325 179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 7' ' ' ILE . 52.3 t -69.89 -43.81 79.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.408 -0.808 . . . . 0.0 109.711 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.77 HG23 ' O ' ' A' ' 8' ' ' ALA . 86.5 t -64.23 -34.38 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.566 -0.709 . . . . 0.0 110.132 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -54.77 -32.37 59.98 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.107 -0.996 . . . . 0.0 109.747 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.55 ' OE1' HD11 ' A' ' 36' ' ' ILE . 86.0 tt0 -65.37 -31.84 73.16 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.857 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.9 p90 -140.09 44.26 1.9 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.071 -1.018 . . . . 0.0 109.827 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.823 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.71 130.91 62.37 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.981 -1.075 . . . . 0.0 110.05 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -76.37 -151.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 121.976 1.784 . . . . 0.0 110.361 178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.529 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -78.34 13.09 1.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.836 -1.165 . . . . 0.0 108.699 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.529 HG23 ' OD1' ' A' ' 18' ' ' ASP . 21.9 t -113.54 136.48 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.559 -0.713 . . . . 0.0 109.744 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.517 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -72.67 137.36 80.27 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.165 -0.959 . . . . 0.0 108.956 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -48.75 -32.85 23.15 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.762 1.641 . . . . 0.0 111.994 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.52 -26.18 67.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 109.203 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -98.96 4.22 47.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.408 -0.807 . . . . 0.0 109.022 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 20' ' ' ALA . 47.6 t -105.74 137.45 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.555 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.2 m-20 -66.15 97.45 0.38 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.75 4.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 109.3 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.555 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -92.11 10.39 29.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.273 -0.892 . . . . 0.0 108.814 179.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.5 tp -85.5 131.84 34.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.47 -0.769 . . . . 0.0 109.43 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.7 m-20 -68.98 121.38 16.51 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.412 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.54 7.83 0.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.225 -0.922 . . . . 0.0 109.08 -179.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -52.37 -40.32 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.278 -0.889 . . . . 0.0 109.028 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.8 t0 -58.14 -37.84 75.41 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.7 m-80 -87.62 15.2 7.07 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.69 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -51.03 -32.36 11.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.859 -1.377 . . . . 0.0 108.457 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 11.3 tt -70.86 -24.15 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.541 -0.724 . . . . 0.0 109.902 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.2 m-20 -57.16 -33.86 67.86 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.478 -0.764 . . . . 0.0 112.05 -177.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -114.4 -65.01 1.23 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.919 -1.113 . . . . 0.0 111.55 -178.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.51 -51.97 60.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.023 -1.048 . . . . 0.0 110.131 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.68 -39.31 66.93 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.06 -40.86 86.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -1.132 . . . . 0.0 109.454 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -62.44 -44.26 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.295 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -67.67 -41.69 83.31 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.295 -0.878 . . . . 0.0 109.86 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 48' ' ' LEU . 84.4 t -67.71 -41.66 85.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.855 . . . . 0.0 110.292 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.419 HD13 ' HG ' ' A' ' 41' ' ' LEU . 1.1 mp -61.03 -45.45 98.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.988 -1.07 . . . . 0.0 109.631 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.6 -45.29 91.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.901 -1.124 . . . . 0.0 110.149 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.473 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -78.86 -49.26 13.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.172 -0.955 . . . . 0.0 110.673 -179.752 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -58.44 -44.18 89.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.34 -0.85 . . . . 0.0 110.665 -178.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.481 ' OE1' ' O ' ' A' ' 54' ' ' ILE . 72.9 mm-40 -64.22 -39.58 94.25 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.997 -1.064 . . . . 0.0 109.237 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -67.32 -40.06 85.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 109.854 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.2 ttt180 -59.03 -40.88 86.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 110.688 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -103.28 -1.8 28.19 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.054 -1.029 . . . . 0.0 110.37 -179.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.04 36.41 91.93 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.481 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 71.3 mt -98.64 144.52 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.342 -1.093 . . . . 0.0 109.544 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -70.25 136.9 50.35 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.061 -1.025 . . . . 0.0 109.293 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.8 -33.06 74.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.183 -0.948 . . . . 0.0 109.681 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -92.22 5.19 51.35 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.921 . . . . 0.0 109.917 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -55.65 -38.64 69.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -132.21 159.03 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.387 -0.821 . . . . 0.0 109.455 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -97.55 137.83 35.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.356 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.8 mt -104.96 136.74 43.87 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.33 -0.856 . . . . 0.0 109.816 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 158.23 75.45 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.365 -0.834 . . . . 0.0 109.201 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -60.97 -33.86 91.67 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.625 2.216 . . . . 0.0 111.9 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.49 -28.34 69.13 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.405 -0.809 . . . . 0.0 109.144 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.676 ' NE2' ' CD2' ' A' ' 75' ' ' PHE . 63.0 t-80 -68.33 -26.09 65.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.575 -0.703 . . . . 0.0 110.432 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -97.83 8.11 45.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 110.914 -178.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -59.79 -40.07 87.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.784 -1.198 . . . . 0.0 110.775 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.2 p -141.61 151.95 43.56 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.892 -1.13 . . . . 0.0 110.375 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.25 -36.79 78.25 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 O-C-N 121.466 -0.771 . . . . 0.0 109.873 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.0 mtm180 -61.11 -39.64 90.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.25 -0.906 . . . . 0.0 110.048 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.4 t -60.89 -44.64 96.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.103 -0.998 . . . . 0.0 109.231 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.553 HG23 ' HE1' ' A' ' 65' ' ' HIS . 75.8 mt -62.65 -38.56 81.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.476 -0.765 . . . . 0.0 109.487 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.91 ' OD1' HG21 ' A' ' 7' ' ' ILE . 82.1 m-20 -56.76 -38.89 73.08 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.441 -0.787 . . . . 0.0 109.853 -179.596 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.86 -44.54 85.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.163 -0.96 . . . . 0.0 110.137 -179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CD2' ' NE2' ' A' ' 65' ' ' HIS . 74.9 m-85 -65.15 -46.76 79.56 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.015 -1.053 . . . . 0.0 109.445 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 80' ' ' THR . 60.7 t -65.7 -44.35 93.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.17 -0.956 . . . . 0.0 109.429 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.6 t -62.05 -38.18 80.18 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.158 -0.964 . . . . 0.0 109.406 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.55 -33.05 65.76 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.05 -51.03 3.23 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.177 -1.19 . . . . 0.0 110.265 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.555 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.1 t -162.01 149.38 14.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.622 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t -131.03 87.97 46.95 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -94.26 107.93 0.15 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 123.321 2.681 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -78.85 131.05 9.9 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 122.022 1.814 . . . . 0.0 112.071 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 86' ' ' ALA . 31.1 t -127.53 132.23 69.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.412 -0.805 . . . . 0.0 109.438 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.68 -35.67 81.44 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 109.743 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.438 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -153.91 160.93 42.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.676 ' NZ ' ' CD2' ' A' ' 10' ' ' PHE . 29.3 mttm -78.79 144.66 34.91 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.176 -0.953 . . . . 0.0 109.358 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -57.25 -37.44 72.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.46 -179.91 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.559 ' S12' ' O8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.55 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 57.9 mtt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.571 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.5 tp60 -95.88 117.84 31.36 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.277 -0.889 . . . . 0.0 108.611 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.571 ' CD2' HE21 ' A' ' 2' ' ' GLN . 26.2 m170 53.01 28.47 6.73 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.134 -0.979 . . . . 0.0 108.621 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.49 -35.32 77.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.495 -0.753 . . . . 0.0 109.803 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.7 -39.04 83.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 109.884 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.2 t -63.64 -41.5 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.114 -0.991 . . . . 0.0 109.336 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.492 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.8 mt -59.5 -48.47 87.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.847 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -45.15 91.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.227 -0.921 . . . . 0.0 109.591 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.424 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.25 -32.68 72.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.268 -0.895 . . . . 0.0 109.675 179.866 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -58.99 -51.64 69.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 110.116 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG13 ' N ' ' A' ' 12' ' ' VAL . 10.6 p -74.5 -45.82 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.078 -1.013 . . . . 0.0 110.779 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.578 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.3 t -64.19 -38.39 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.265 -0.897 . . . . 0.0 111.379 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -58.93 -32.34 69.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.046 -1.034 . . . . 0.0 110.046 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.51 -34.21 77.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -0.864 . . . . 0.0 111.311 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -109.14 -49.17 3.16 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.031 -1.043 . . . . 0.0 111.407 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.4 mt -125.41 82.68 62.48 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.13 -0.981 . . . . 0.0 110.551 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -90.97 -17.53 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.352 2.702 . . . . 0.0 112.143 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -76.3 -4.45 42.12 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.195 -0.94 . . . . 0.0 108.868 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.56 143.78 22.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -60.82 115.56 14.46 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 120.808 -1.183 . . . . 0.0 108.563 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -63.79 -33.54 64.74 Favored 'Trans proline' 0 N--CA 1.488 1.151 0 C-N-CA 121.489 1.46 . . . . 0.0 111.868 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.96 -15.06 61.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.34 -0.85 . . . . 0.0 108.93 179.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.435 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -93.75 5.19 52.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.462 -0.774 . . . . 0.0 109.081 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.7 t -100.71 139.34 22.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.2 t0 -64.47 94.16 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.178 -179.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.7 m -60.84 5.15 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.1 m-20 -90.97 11.87 21.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.934 . . . . 0.0 109.006 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.8 tp -85.1 132.32 34.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.579 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.511 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -66.66 121.47 15.46 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.387 -0.821 . . . . 0.0 109.188 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.73 HD11 HG12 ' A' ' 69' ' ' ILE . 54.5 mt -64.13 -4.96 4.02 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 109.208 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.0 p -50.35 -39.13 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.961 . . . . 0.0 109.155 -179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.452 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.2 -38.12 76.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.599 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -89.08 15.81 8.13 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -17.55 0.03 OUTLIER Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.599 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.96 -35.03 17.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.893 -1.357 . . . . 0.0 108.53 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.607 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.5 tt -71.55 -24.58 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.556 -0.715 . . . . 0.0 110.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.0 m-20 -58.43 -31.95 68.23 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 111.322 -178.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 37.3 m -113.39 -64.62 1.28 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.041 -1.037 . . . . 0.0 111.523 -178.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.519 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.19 -51.39 58.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.099 -1.001 . . . . 0.0 110.375 -178.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.19 70.27 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -59.42 -43.17 93.1 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.446 -1.032 . . . . 0.0 109.545 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.6 tp -59.13 -44.24 92.02 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 108.962 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -68.14 -35.62 78.37 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.316 -0.865 . . . . 0.0 109.564 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 40' ' ' GLY . 93.9 t -66.19 -47.09 85.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.363 -0.836 . . . . 0.0 111.011 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.543 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 35.9 mm -60.53 -43.31 94.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 120.733 -1.229 . . . . 0.0 110.048 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.17 -44.88 82.8 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.116 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.529 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.9 OUTLIER -79.39 -49.21 12.71 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.058 -1.026 . . . . 0.0 110.053 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.454 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.9 tp -59.75 -41.74 91.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.45 -0.781 . . . . 0.0 110.585 -178.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.613 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.1 pp20? -65.06 -38.54 91.13 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.936 -1.102 . . . . 0.0 108.95 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -67.29 -36.37 81.39 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.141 -0.974 . . . . 0.0 109.096 179.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.589 ' NH2' ' O ' ' A' ' 89' ' ' GLN . 61.3 ttt85 -59.93 -45.03 93.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.634 -0.666 . . . . 0.0 111.13 -179.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -118.26 -3.14 11.04 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.081 -1.012 . . . . 0.0 110.961 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.613 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.94 41.7 71.29 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.67 141.89 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.25 -1.147 . . . . 0.0 109.805 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.41 147.36 48.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.637 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.7 -30.42 70.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.837 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.471 ' O ' HD21 ' A' ' 61' ' ' LEU . 85.0 m-20 54.61 45.92 25.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.342 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.4 p30 -90.29 14.74 11.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.425 -0.797 . . . . 0.0 109.684 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 54.6 t -53.87 -41.74 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.933 . . . . 0.0 109.725 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -157.52 102.3 1.89 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.136 -0.978 . . . . 0.0 110.189 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 57' ' ' ASP . 26.9 mt -113.67 140.97 47.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.527 -0.733 . . . . 0.0 109.313 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.28 158.39 73.65 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.27 -23.31 75.22 Favored 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.852 2.368 . . . . 0.0 112.226 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.97 -30.46 70.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.533 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -67.69 -26.95 66.43 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.325 -0.86 . . . . 0.0 109.818 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -102.38 6.32 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.287 -0.883 . . . . 0.0 109.688 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -56.07 -39.68 72.44 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.794 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.5 p -144.25 154.42 43.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.94 -1.1 . . . . 0.0 110.018 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.73 HG12 HD11 ' A' ' 30' ' ' LEU . 82.7 mt -65.14 -36.83 78.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 O-C-N 121.389 -0.819 . . . . 0.0 109.826 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -61.21 -38.05 85.19 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.273 -0.892 . . . . 0.0 110.326 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 t -59.65 -46.36 89.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.934 -1.104 . . . . 0.0 109.514 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.7 mt -68.39 -38.62 79.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.266 -0.896 . . . . 0.0 109.711 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.514 ' OD1' HG23 ' A' ' 77' ' ' VAL . 57.8 t0 -57.4 -41.17 79.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.366 -0.834 . . . . 0.0 110.425 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.11 -42.47 89.19 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.096 -1.003 . . . . 0.0 109.822 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -62.55 -48.69 78.39 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.185 -0.947 . . . . 0.0 109.384 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 63.0 t -66.81 -46.77 84.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.514 HG23 ' OD1' ' A' ' 73' ' ' ASP . 42.9 t -61.43 -38.97 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.049 -1.032 . . . . 0.0 109.522 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -32.6 65.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.004 -1.239 . . . . 0.0 110.004 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -51.21 3.14 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.132 -1.216 . . . . 0.0 110.349 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.9 t -159.62 148.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.753 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 81' ' ' THR . 1.7 t -129.33 88.86 49.42 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.234 -0.916 . . . . 0.0 109.148 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -89.83 109.94 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.24 2.627 . . . . 0.0 113.16 -179.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.01 137.59 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.216 1.944 . . . . 0.0 111.586 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.16 141.42 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.144 -0.973 . . . . 0.0 109.705 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -63.12 -35.2 79.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.847 . . . . 0.0 109.477 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -145.97 155.2 42.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.231 -0.918 . . . . 0.0 109.568 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.9 tttt -58.75 -38.73 79.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.328 -0.858 . . . . 0.0 109.367 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.0 tp -58.28 -37.57 75.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.589 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.5 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 89.4 mtp . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.343 0.592 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -59.44 -37.2 77.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.335 -0.853 . . . . 0.0 109.307 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.674 ' CE1' HG21 ' A' ' 6' ' ' VAL . 1.5 t-80 -137.8 15.3 2.9 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.32 -33.83 72.94 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.364 -0.835 . . . . 0.0 110.078 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -58.91 -41.79 88.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.026 -1.046 . . . . 0.0 109.629 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.674 HG21 ' CE1' ' A' ' 3' ' ' HIS . 79.7 t -68.54 -36.43 74.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.217 -0.927 . . . . 0.0 109.088 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.633 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.7 mt -58.94 -49.09 84.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.343 -0.848 . . . . 0.0 109.563 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.687 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.46 -46.61 85.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 108.83 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -38.88 92.72 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.638 0.733 . . . . 0.0 109.184 179.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' O ' ' A' ' 6' ' ' VAL . 56.1 t80 -64.62 -43.85 92.42 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.607 -0.683 . . . . 0.0 110.124 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.68 HG22 ' CD1' ' A' ' 36' ' ' ILE . 74.8 t -64.95 -50.32 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.324 -0.86 . . . . 0.0 110.401 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.647 ' O ' ' N ' ' A' ' 16' ' ' LEU . 28.0 m -66.29 -33.46 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.048 -1.032 . . . . 0.0 109.811 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -53.7 -33.24 54.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.97 -1.081 . . . . 0.0 110.001 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -65.58 -29.73 70.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.945 -1.097 . . . . 0.0 108.263 179.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -163.74 68.29 0.19 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.647 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.45 134.2 55.19 Favored Pre-proline 0 N--CA 1.484 1.252 0 O-C-N 121.194 -0.941 . . . . 0.0 109.985 -178.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -68.2 -156.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 121.643 1.562 . . . . 0.0 110.814 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -83.84 17.73 2.24 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.206 -0.934 . . . . 0.0 108.504 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.11 136.51 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.634 -0.666 . . . . 0.0 110.491 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.09 139.01 75.77 Favored Pre-proline 0 N--CA 1.488 1.429 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 178.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.694 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 51.6 Cg_exo -48.38 -34.17 24.64 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.501 1.467 . . . . 0.0 111.603 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HB2' HD21 ' A' ' 88' ' ' LEU . . . -69.75 -17.56 63.44 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.464 -0.773 . . . . 0.0 109.171 179.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.68 3.65 45.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.451 -0.78 . . . . 0.0 109.233 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.5 t -103.71 134.51 44.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.564 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.07 96.13 0.78 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.199 -0.938 . . . . 0.0 109.247 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.2 m -59.54 4.09 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.499 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.564 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -97.22 8.71 44.0 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.0 tp -90.82 137.23 32.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.622 -0.674 . . . . 0.0 109.496 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -61.01 121.96 13.76 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.51 10.36 0.49 Allowed 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.254 -0.904 . . . . 0.0 110.451 -178.611 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.7 t -52.93 -41.58 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.86 -1.15 . . . . 0.0 108.85 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.62 -36.9 67.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -87.44 14.41 8.17 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.05 -14.31 0.02 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.2 t -51.47 -37.3 18.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.141 -1.211 . . . . 0.0 108.769 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.68 ' CD1' HG22 ' A' ' 11' ' ' VAL . 5.1 tt -71.24 -24.7 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.422 -0.799 . . . . 0.0 110.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' O4 ' ' A' ' 101' ' ' PN7 . 85.8 m-20 -56.66 -34.8 67.7 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.371 -0.831 . . . . 0.0 111.366 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.37 -64.1 1.35 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.075 -1.015 . . . . 0.0 111.557 -178.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 53.7 tp -65.98 -52.17 51.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.006 -1.059 . . . . 0.0 110.915 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.634 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.06 -36.52 72.47 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.9 tp -58.47 -41.56 85.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -1.122 . . . . 0.0 109.134 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.2 tp -64.01 -44.1 93.63 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.278 -0.889 . . . . 0.0 108.87 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.2 mttm -66.23 -35.39 80.29 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.449 -0.782 . . . . 0.0 109.753 179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.1 t -61.1 -43.48 96.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.354 -0.842 . . . . 0.0 110.263 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.12 -45.27 96.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.661 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.92 -43.44 83.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 110.408 -179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.425 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -75.59 -42.77 51.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.075 -179.45 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.425 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.02 -42.42 80.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 -179.264 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.6 tm-20 -63.86 -41.65 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.143 -0.973 . . . . 0.0 109.387 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -66.39 -48.2 70.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.278 -0.889 . . . . 0.0 110.652 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -65.3 -41.82 93.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.333 -0.855 . . . . 0.0 111.487 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -105.31 -5.69 20.31 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.899 -1.125 . . . . 0.0 111.098 -178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.38 31.3 73.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.552 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 74.6 mt -98.42 147.21 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.322 -1.104 . . . . 0.0 109.827 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.34 152.7 28.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.157 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.44 -40.07 74.17 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.27 -0.894 . . . . 0.0 109.839 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 50.46 50.45 18.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.04 -1.038 . . . . 0.0 108.858 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -70.96 115.67 10.36 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.295 -0.878 . . . . 0.0 110.064 -179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 61' ' ' LEU . 24.6 m -130.82 162.69 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -82.95 121.49 27.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.968 -1.082 . . . . 0.0 109.58 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.419 HD12 ' O ' ' A' ' 59' ' ' VAL . 3.4 mp -116.28 144.94 43.57 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.584 -0.698 . . . . 0.0 109.445 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.01 159.07 33.06 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.59 -22.73 61.64 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.802 2.335 . . . . 0.0 111.998 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.48 -32.09 72.93 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 109.983 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -70.33 -26.43 63.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.668 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -98.44 11.67 37.46 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.995 -1.066 . . . . 0.0 110.641 -178.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -58.54 -36.69 74.26 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.784 -1.197 . . . . 0.0 111.105 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.4 t -136.48 146.24 46.07 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.98 -1.075 . . . . 0.0 110.461 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.687 HD13 ' HB2' ' A' ' 8' ' ' ALA . 89.9 mt -60.7 -36.84 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.457 -0.777 . . . . 0.0 109.836 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -60.85 -38.22 84.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 110.14 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -60.06 -42.01 93.59 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.029 -1.045 . . . . 0.0 109.533 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.9 mt -68.02 -38.83 80.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.331 -0.856 . . . . 0.0 109.819 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 77' ' ' VAL . 50.0 t0 -57.84 -39.69 78.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.29 -0.881 . . . . 0.0 109.979 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.35 -42.73 96.08 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.065 -1.022 . . . . 0.0 109.508 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -63.73 -47.56 80.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.3 -0.875 . . . . 0.0 109.363 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.49 -43.62 90.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.33 -0.856 . . . . 0.0 109.951 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.496 HG23 ' OD1' ' A' ' 73' ' ' ASP . 54.6 t -62.84 -41.65 93.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.123 -0.985 . . . . 0.0 109.999 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.38 -31.75 70.86 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -49.69 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -1.227 . . . . 0.0 110.43 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.4 m -124.4 137.35 54.46 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.419 -0.801 . . . . 0.0 109.725 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.4 88.77 53.08 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.411 -0.806 . . . . 0.0 109.184 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -80.05 162.06 23.42 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.601 2.201 . . . . 0.0 112.655 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.579 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.8 Cg_endo -62.42 151.26 83.86 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.787 2.324 . . . . 0.0 111.435 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.5 p -116.55 137.19 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.383 -0.823 . . . . 0.0 110.237 -179.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.06 172.91 12.01 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.05 140.43 7.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.939 -1.101 . . . . 0.0 108.86 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.694 ' HZ3' ' C ' ' A' ' 21' ' ' PRO . 61.7 tttt -58.3 -36.0 72.68 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.225 -0.922 . . . . 0.0 109.332 -179.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.54 HD21 ' HB2' ' A' ' 22' ' ' ALA . 61.2 mt -95.08 142.1 27.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.388 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.472 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.586 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.8 mtm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.14 0.495 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.881 ' NE2' HG22 ' A' ' 77' ' ' VAL . 26.1 mt-30 53.49 77.97 0.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 108.893 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.463 ' CD2' ' O ' ' A' ' 83' ' ' PRO . 3.6 m170 59.55 41.99 18.13 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.34 -33.57 74.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.751 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -59.59 -40.76 88.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.147 -0.971 . . . . 0.0 110.013 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.5 t -63.02 -41.87 94.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.099 -1.001 . . . . 0.0 108.565 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.61 ' O ' HG23 ' A' ' 11' ' ' VAL . 86.6 mt -64.03 -47.9 88.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.99 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.754 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.94 -49.48 72.39 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.433 HE21 ' HB2' ' A' ' 10' ' ' PHE . 4.0 pp0? -69.43 -41.76 75.89 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.115 -0.991 . . . . 0.0 109.765 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.692 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.5 t80 -64.75 -48.72 73.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.072 -1.018 . . . . 0.0 109.391 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 7' ' ' ILE . 100.0 t -66.11 -45.86 89.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.358 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 8' ' ' ALA . 93.0 t -64.52 -35.0 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.445 -0.784 . . . . 0.0 109.481 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.58 -30.32 60.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -0.915 . . . . 0.0 109.345 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -65.31 -30.94 71.84 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.361 -0.837 . . . . 0.0 109.582 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.6 p90 -144.11 45.08 1.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.159 -0.963 . . . . 0.0 109.67 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.94 63.14 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.971 -1.081 . . . . 0.0 110.229 -179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.65 -150.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.039 1.826 . . . . 0.0 110.342 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.513 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.0 13.44 1.76 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.809 -1.182 . . . . 0.0 108.724 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.513 HG23 ' OD1' ' A' ' 18' ' ' ASP . 31.3 t -113.45 136.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.545 -0.722 . . . . 0.0 109.876 -179.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.35 137.86 81.19 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 108.901 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.409 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.3 Cg_exo -48.63 -33.36 23.92 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 121.706 1.604 . . . . 0.0 111.714 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.37 -24.2 63.85 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.384 -0.822 . . . . 0.0 109.362 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -104.75 8.59 35.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.415 -0.803 . . . . 0.0 109.656 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -99.36 143.81 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.237 -0.914 . . . . 0.0 108.957 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.28 90.48 0.5 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 109.477 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.658 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.7 m -61.49 4.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.93 8.55 36.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.002 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.6 tp -91.89 133.5 35.61 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.438 -0.789 . . . . 0.0 109.403 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -66.08 121.72 15.78 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.62 7.46 2.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.817 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.01 -40.17 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.032 -1.043 . . . . 0.0 108.979 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 31' ' ' VAL . 56.5 t0 -58.2 -36.0 72.46 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -85.8 15.73 4.59 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.453 ' O ' ' O8 ' ' A' ' 101' ' ' PN7 . . . -42.64 -15.06 0.02 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.53 -36.04 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.155 -1.203 . . . . 0.0 108.629 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.3 tt -70.52 -22.22 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.529 -0.732 . . . . 0.0 110.134 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -57.6 -32.62 67.37 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.31 -0.869 . . . . 0.0 111.66 -178.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.4 m -113.83 -64.69 1.28 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.938 -1.101 . . . . 0.0 111.435 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.5 mm? -65.53 -51.3 60.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.056 -1.028 . . . . 0.0 110.327 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.435 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.59 -38.71 68.24 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.7 tp -58.78 -40.82 85.09 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.396 -1.061 . . . . 0.0 109.167 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.91 -43.02 99.69 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.25 -0.906 . . . . 0.0 108.694 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 35.1 mttt -64.42 -36.9 85.68 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.349 -0.845 . . . . 0.0 109.293 179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 40' ' ' GLY . 57.0 t -60.01 -44.72 95.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.426 -0.796 . . . . 0.0 109.901 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.05 -48.86 86.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.176 -0.952 . . . . 0.0 109.62 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.55 -41.67 98.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.763 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 3.0 t90 -68.96 -39.08 79.7 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.81 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 18.8 tp -61.97 -43.6 98.51 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.254 -0.904 . . . . 0.0 109.903 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.2 tt0 -67.17 -37.22 83.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -59.19 -37.86 78.44 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.966 -1.084 . . . . 0.0 110.124 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.763 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 84.1 mtt180 -86.01 -42.82 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 111.88 -178.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.21 -8.13 19.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.818 -1.176 . . . . 0.0 111.203 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.64 29.96 74.36 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.407 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 91.6 mt -86.93 144.94 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.212 -1.169 . . . . 0.0 110.015 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.47 29.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -0.972 . . . . 0.0 109.324 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.96 -39.09 73.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.279 -0.888 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 51.24 49.97 19.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 108.94 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -72.4 116.27 12.64 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.248 -0.908 . . . . 0.0 109.968 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.34 -178.21 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -86.41 124.29 32.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.946 -1.096 . . . . 0.0 109.714 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.592 HD12 HD21 ' A' ' 41' ' ' LEU . 28.2 mt -113.75 146.6 39.65 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.37 153.93 38.71 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.242 -0.911 . . . . 0.0 109.563 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -62.35 -21.79 73.17 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.716 2.277 . . . . 0.0 112.169 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.04 -32.31 71.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.282 -0.886 . . . . 0.0 109.864 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.405 ' CE1' ' O ' ' A' ' 71' ' ' SER . 84.4 t60 -69.42 -26.3 64.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.374 -0.829 . . . . 0.0 111.275 -179.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -96.6 9.85 40.27 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.804 -1.185 . . . . 0.0 111.019 -178.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 34.2 mmt180 -59.44 -35.93 74.96 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.911 -1.118 . . . . 0.0 110.284 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.0 p -135.17 153.38 51.99 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.095 -1.003 . . . . 0.0 110.11 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.1 mt -62.28 -36.52 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 O-C-N 121.383 -0.823 . . . . 0.0 109.811 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -60.73 -37.61 82.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -0.927 . . . . 0.0 109.927 -179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.405 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 36.8 m -59.63 -40.85 88.97 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.079 -1.013 . . . . 0.0 109.321 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.06 -38.65 81.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.264 -0.898 . . . . 0.0 109.207 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 77' ' ' VAL . 81.9 m-20 -57.82 -37.6 74.08 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.373 -0.829 . . . . 0.0 109.331 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.0 96.04 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.8 t80 -62.21 -46.51 88.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 109.369 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.9 t -64.92 -40.9 90.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.292 -0.88 . . . . 0.0 109.584 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.881 HG22 ' NE2' ' A' ' 2' ' ' GLN . 63.7 t -61.25 -41.22 88.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.315 -0.865 . . . . 0.0 109.645 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.47 -36.47 84.63 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -96.47 -50.04 4.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.976 -1.308 . . . . 0.0 110.222 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 76' ' ' VAL . 49.2 m -130.16 137.82 50.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.405 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.42 ' CB ' ' NE2' ' A' ' 2' ' ' GLN . 1.2 t -130.37 88.09 48.57 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.386 -0.821 . . . . 0.0 109.783 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.454 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.9 Cg_exo -65.34 -175.68 0.44 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.657 2.238 . . . . 0.0 111.836 179.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.463 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 21.7 Cg_exo -62.01 150.67 85.5 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.533 2.156 . . . . 0.0 111.752 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 84' ' ' VAL . 32.7 m -89.96 128.45 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.11 -0.994 . . . . 0.0 109.991 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -141.44 157.63 44.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.498 -0.751 . . . . 0.0 109.08 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -60.2 139.75 57.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.067 -1.02 . . . . 0.0 109.111 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.658 ' HE3' HG21 ' A' ' 26' ' ' VAL . 37.6 tttm -59.57 -38.16 80.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.477 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.9 mt -60.24 -35.16 74.84 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.539 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.485 ' O ' ' O ' ' A' ' 86' ' ' ALA . 63.6 tt0 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' N9 ' ' O4 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.0 mtp . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.655 ' OE1' HG21 ' A' ' 81' ' ' THR . 92.7 mt-30 -94.19 121.69 35.95 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.262 -0.899 . . . . 0.0 108.677 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.8 m80 48.67 35.31 6.06 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.104 -0.997 . . . . 0.0 108.839 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.408 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.79 -35.65 75.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.663 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -59.62 -38.48 81.42 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.161 -0.962 . . . . 0.0 109.755 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG11 ' H ' ' A' ' 84' ' ' VAL . 72.6 t -64.73 -38.71 83.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -0.909 . . . . 0.0 109.584 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.488 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 80.5 mt -59.25 -46.05 92.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.408 -0.807 . . . . 0.0 109.88 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.74 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.17 -46.54 86.65 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.154 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.23 -33.0 72.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.476 -0.765 . . . . 0.0 109.474 179.572 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -59.32 -52.87 63.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.956 . . . . 0.0 110.069 -179.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.6 p -74.94 -41.66 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.219 -0.925 . . . . 0.0 110.048 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.3 t -64.61 -38.04 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.25 -0.906 . . . . 0.0 110.465 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.76 -32.09 63.14 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.489 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.2 tt0 -65.44 -31.58 72.74 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.631 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.579 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.0 p90 -141.32 45.91 1.73 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 109.764 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.815 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.65 131.21 61.61 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.993 -1.067 . . . . 0.0 109.934 -179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.2 Cg_endo -75.59 -152.19 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.0 1.8 . . . . 0.0 110.454 178.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.94 12.29 1.43 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.893 -1.13 . . . . 0.0 108.727 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' PRO . 31.3 t -113.55 136.29 50.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.539 -0.725 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.45 138.77 83.78 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.203 -0.936 . . . . 0.0 108.855 179.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.438 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.6 Cg_exo -48.43 -30.82 16.44 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.851 1.7 . . . . 0.0 112.16 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.7 -24.41 66.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.369 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -99.86 5.55 45.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.393 -0.817 . . . . 0.0 109.237 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.0 t -105.42 137.74 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.557 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.54 95.7 0.23 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.187 -0.945 . . . . 0.0 109.478 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.4 ' H ' HG13 ' A' ' 26' ' ' VAL . 3.8 m -60.85 5.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.557 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -91.58 12.84 19.65 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.207 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.9 tp -85.39 134.14 34.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -0.843 . . . . 0.0 109.685 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -63.72 122.49 16.52 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.39 -0.819 . . . . 0.0 108.817 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.744 HD11 HG12 ' A' ' 69' ' ' ILE . 66.3 mt -62.17 -3.64 1.38 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.272 -0.892 . . . . 0.0 109.552 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -50.54 -42.69 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.103 -0.998 . . . . 0.0 109.211 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -55.86 -41.31 74.16 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.579 ' O ' ' N ' ' A' ' 35' ' ' VAL . 59.9 m-80 -91.53 13.24 18.34 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.439 ' O ' ' N9 ' ' A' ' 101' ' ' PN7 . . . -42.3 -17.78 0.03 OUTLIER Glycine 0 N--CA 1.488 2.142 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.579 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -51.37 -33.6 14.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.881 -1.364 . . . . 0.0 108.354 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.592 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.44 -24.1 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.587 -0.696 . . . . 0.0 110.114 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.5 m-20 -53.0 -36.93 60.97 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.635 -0.665 . . . . 0.0 111.972 -177.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.3 t -115.07 -64.65 1.29 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.907 -1.121 . . . . 0.0 111.803 -178.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.446 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.4 mp -62.83 -52.33 63.58 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.994 -1.066 . . . . 0.0 110.35 -178.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.71 -38.43 66.96 Favored Glycine 0 N--CA 1.485 1.942 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 36' ' ' ILE . 42.2 tp -58.77 -45.69 89.22 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.434 -1.039 . . . . 0.0 109.586 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.55 -42.64 92.83 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.071 -1.018 . . . . 0.0 109.144 -179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 49.8 mttm -64.36 -40.54 96.04 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.479 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.6 t -68.99 -48.03 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -0.857 . . . . 0.0 110.349 -179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.536 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 37.4 mm -64.3 -40.4 88.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.125 -0.984 . . . . 0.0 110.181 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.27 -45.78 91.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.83 -1.169 . . . . 0.0 109.718 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.1 OUTLIER -79.73 -49.04 12.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.043 -1.036 . . . . 0.0 109.354 179.138 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.479 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 22.5 tp -59.07 -41.2 87.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.603 -0.685 . . . . 0.0 110.685 -178.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.59 ' O ' ' N ' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -67.41 -38.17 84.21 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.828 -1.17 . . . . 0.0 109.522 -179.55 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.33 -38.75 92.15 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -0.974 . . . . 0.0 109.15 179.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.6 ttp180 -59.62 -40.4 87.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 110.12 -179.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.4 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 37.4 m-85 -108.11 -1.28 20.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -0.945 . . . . 0.0 110.352 -179.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.02 39.45 84.72 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.7 mt -84.76 144.61 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.125 -1.22 . . . . 0.0 109.254 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.19 122.74 26.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.057 -1.027 . . . . 0.0 109.784 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.9 -19.39 61.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.372 -0.83 . . . . 0.0 109.563 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -51.32 -35.7 39.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.332 -0.855 . . . . 0.0 109.784 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -61.51 135.82 57.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.101 -0.999 . . . . 0.0 109.4 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG22 ' A' ' 59' ' ' VAL . 4.8 p -144.45 30.81 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.865 . . . . 0.0 109.115 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.0 -22.94 67.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.679 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.5 mp -68.79 140.88 55.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.841 -179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -124.26 165.58 23.73 Favored Pre-proline 0 N--CA 1.487 1.386 0 O-C-N 121.592 -0.693 . . . . 0.0 109.17 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -52.39 -31.08 46.11 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.12 1.88 . . . . 0.0 111.424 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.16 -26.22 66.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.473 -0.767 . . . . 0.0 109.274 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.9 t-80 -67.64 -26.32 66.17 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.375 -0.828 . . . . 0.0 109.679 -179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.404 ' CE1' HD13 ' A' ' 41' ' ' LEU . 98.4 m-85 -91.62 11.38 24.51 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.321 -0.862 . . . . 0.0 109.314 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -55.11 -39.11 69.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.468 -0.77 . . . . 0.0 109.944 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -149.47 159.74 44.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.001 -1.062 . . . . 0.0 110.383 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.744 HG12 HD11 ' A' ' 30' ' ' LEU . 89.1 mt -64.05 -36.6 77.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.497 -0.752 . . . . 0.0 110.127 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -60.36 -41.45 93.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.221 -0.924 . . . . 0.0 110.22 -179.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.2 p -63.59 -37.98 89.39 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.046 -1.034 . . . . 0.0 109.567 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.2 mt -68.11 -39.2 80.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.263 -0.898 . . . . 0.0 109.771 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.488 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 57.0 t0 -59.84 -42.33 93.35 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.396 -0.815 . . . . 0.0 110.307 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.53 -44.08 83.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.114 -0.991 . . . . 0.0 110.394 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.628 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 70.3 t80 -61.75 -50.08 73.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.127 -0.983 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 80' ' ' THR . 75.7 t -66.61 -45.28 88.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.134 -0.979 . . . . 0.0 109.555 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.487 HG23 ' OD1' ' A' ' 73' ' ' ASP . 39.4 t -59.11 -40.05 79.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.937 -1.102 . . . . 0.0 109.398 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.89 -32.4 66.18 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.6 -51.28 3.11 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.126 -1.22 . . . . 0.0 110.468 -179.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.691 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.6 t -155.69 150.49 26.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.234 -0.916 . . . . 0.0 109.559 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.655 HG21 ' OE1' ' A' ' 2' ' ' GLN . 1.4 t -129.16 88.84 49.98 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.27 -0.894 . . . . 0.0 109.226 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.4 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -91.18 109.16 0.31 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.239 2.626 . . . . 0.0 112.972 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -82.02 133.84 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.303 2.002 . . . . 0.0 111.97 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG22 ' H ' ' A' ' 86' ' ' ALA . 13.9 p -134.26 141.09 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.25 -0.906 . . . . 0.0 109.498 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.15 -36.34 83.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.965 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.474 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -148.2 155.32 41.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.185 -0.947 . . . . 0.0 109.698 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.8 tttm -58.49 -38.24 77.23 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.299 -0.875 . . . . 0.0 109.402 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.8 tp -58.09 -37.45 74.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.308 -0.87 . . . . 0.0 109.374 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 . . . . . 0 N--CA 1.49 1.525 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.487 -179.985 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.538 ' O4 ' ' C7 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.471 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.0 mtm . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.393 0.616 . . . . 0.0 109.927 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 94.3 mt-30 -107.4 140.02 40.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.673 ' ND1' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.12 27.45 0.2 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.123 -0.986 . . . . 0.0 109.015 -179.795 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -55.11 -38.83 68.66 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.197 -0.939 . . . . 0.0 109.561 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.1 m -61.93 -41.14 97.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.13 -0.981 . . . . 0.0 109.511 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.673 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.9 t -66.13 -38.37 81.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.684 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.92 -44.1 97.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.337 -0.852 . . . . 0.0 109.859 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.5 -51.08 64.8 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.27 -0.894 . . . . 0.0 110.718 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.74 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.12 -38.31 75.55 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.991 -1.068 . . . . 0.0 110.1 -179.523 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.74 ' N ' HE21 ' A' ' 9' ' ' GLN . 71.2 t80 -61.37 -47.11 87.36 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.883 -1.136 . . . . 0.0 111.191 -179.1 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 ' N ' ' A' ' 12' ' ' VAL . 8.1 p -74.08 -50.1 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.032 -1.042 . . . . 0.0 112.264 -178.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.657 HG22 ' O ' ' A' ' 8' ' ' ALA . 14.1 m -66.48 -35.48 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 120.802 -1.187 . . . . 0.0 111.561 -178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.426 ' N ' HG23 ' A' ' 12' ' ' VAL . 93.4 mt-10 -60.32 -32.26 71.06 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.91 -1.118 . . . . 0.0 110.297 -178.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.81 -31.76 72.91 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.997 -1.064 . . . . 0.0 109.122 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -97.96 -56.77 2.4 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 110.28 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -131.51 83.12 59.6 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.213 -0.929 . . . . 0.0 111.233 -178.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -86.88 -4.32 8.05 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 123.018 2.479 . . . . 0.0 112.127 178.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -75.85 -4.65 41.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.142 -0.973 . . . . 0.0 109.089 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.71 140.99 31.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.576 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.26 115.75 16.1 Favored Pre-proline 0 C--N 1.302 -1.465 0 O-C-N 120.693 -1.255 . . . . 0.0 108.334 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -64.85 -34.65 48.33 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 C-N-CA 121.555 1.503 . . . . 0.0 112.008 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.0 -14.51 61.03 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 108.941 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.576 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -93.9 8.68 40.37 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.423 -0.798 . . . . 0.0 109.646 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.0 t -96.96 136.44 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 108.763 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.549 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -66.18 84.75 0.09 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.218 -0.926 . . . . 0.0 109.312 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.436 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 22.1 m -61.41 4.61 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.459 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.549 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -96.17 6.49 48.71 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 108.892 179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.0 tp -97.19 137.34 36.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.482 -0.761 . . . . 0.0 109.516 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.0 m-20 -61.91 121.78 13.79 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.426 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.16 7.84 0.51 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.239 -0.913 . . . . 0.0 110.102 -178.864 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -53.38 -39.49 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.013 -1.054 . . . . 0.0 108.813 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.6 m-20 -58.04 -35.57 71.5 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 63.3 m-80 -84.21 15.87 3.3 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.37 -15.7 0.02 OUTLIER Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.6 t -51.78 -36.96 19.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.963 -1.316 . . . . 0.0 108.398 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.623 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.4 tt -70.42 -24.47 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.595 -0.69 . . . . 0.0 110.22 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 88.5 m-20 -60.06 -31.22 69.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.214 -0.929 . . . . 0.0 111.442 -178.21 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.55 ' N ' ' O2P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -110.87 -64.56 1.26 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.919 -1.113 . . . . 0.0 111.366 -178.634 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.47 52.18 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 0.0 110.572 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.55 -38.75 68.65 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.623 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.3 tt -58.9 -40.53 84.78 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.373 -1.075 . . . . 0.0 109.128 -179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.57 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -62.72 -44.26 96.67 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.269 -0.895 . . . . 0.0 108.619 179.756 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.6 mttm -64.88 -35.14 80.17 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.9 t -60.38 -43.45 93.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.409 -0.807 . . . . 0.0 110.265 -179.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -59.91 -44.51 94.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.157 -0.964 . . . . 0.0 109.946 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.02 -44.23 80.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.221 -0.925 . . . . 0.0 110.216 -179.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.506 ' CZ2' ' CE2' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -73.67 -41.64 62.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.088 -1.007 . . . . 0.0 109.727 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -56.82 -45.62 82.17 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.326 -0.859 . . . . 0.0 109.395 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' N ' ' A' ' 53' ' ' GLY . 83.1 tt0 -66.92 -41.8 86.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.172 -0.955 . . . . 0.0 108.963 179.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -60.46 -37.4 80.89 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.113 -0.992 . . . . 0.0 109.771 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -86.44 -48.53 8.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 111.635 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -101.37 -8.64 21.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.763 -1.21 . . . . 0.0 111.645 -177.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.51 24.46 76.19 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.165 -1.493 . . . . 0.0 109.396 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 97.7 mt -80.6 151.28 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.186 -1.185 . . . . 0.0 110.038 -179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.63 152.93 29.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.313 -0.867 . . . . 0.0 109.716 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.47 -32.9 70.66 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 110.051 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 59' ' ' VAL . 59.6 t0 -149.35 60.73 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.037 -1.039 . . . . 0.0 109.962 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.76 -37.85 80.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -0.947 . . . . 0.0 109.172 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.484 ' O ' ' OD1' ' A' ' 57' ' ' ASP . 22.8 m -130.9 161.7 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.544 -0.722 . . . . 0.0 109.19 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -83.33 136.84 34.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.072 -1.017 . . . . 0.0 109.581 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.7 mt -104.86 143.49 33.07 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.455 -0.778 . . . . 0.0 109.729 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -128.51 162.46 50.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.431 -0.793 . . . . 0.0 109.3 179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -58.11 -28.42 83.59 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.697 2.264 . . . . 0.0 111.959 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.14 -30.03 71.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.357 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.476 ' O ' ' ND1' ' A' ' 65' ' ' HIS . 13.4 t-80 -67.79 -27.05 66.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.455 -0.778 . . . . 0.0 109.927 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.458 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.4 m-85 -105.89 5.26 30.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -56.95 -39.71 75.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.086 -1.009 . . . . 0.0 109.649 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -141.36 154.61 45.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.06 -1.025 . . . . 0.0 109.888 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.7 mt -62.52 -36.39 74.75 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.365 -0.834 . . . . 0.0 109.882 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -60.87 -38.84 87.01 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.233 -0.917 . . . . 0.0 109.895 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.44 -37.36 86.99 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.108 -0.995 . . . . 0.0 109.239 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.434 HG23 ' HE1' ' A' ' 65' ' ' HIS . 74.7 mt -67.64 -38.6 80.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.37 -0.831 . . . . 0.0 109.374 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.799 ' O ' HG23 ' A' ' 77' ' ' VAL . 82.5 m-20 -58.28 -38.81 77.74 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.411 -0.806 . . . . 0.0 109.792 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.82 -42.7 97.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.429 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 67.4 t80 -64.38 -48.78 74.17 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.231 -0.918 . . . . 0.0 109.394 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 55.4 t -64.24 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.403 -0.811 . . . . 0.0 109.597 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.9 t -59.53 -42.96 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.221 -0.924 . . . . 0.0 109.758 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.95 -38.31 95.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -80.0 -50.37 10.49 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.013 -1.287 . . . . 0.0 109.804 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.8 p -134.19 148.46 50.9 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 81' ' ' THR . 1.8 t -140.74 88.03 10.95 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.101 -1.0 . . . . 0.0 109.853 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -86.3 151.36 9.28 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.705 2.27 . . . . 0.0 111.878 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 32.7 Cg_endo -67.44 137.43 43.01 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.444 2.096 . . . . 0.0 112.224 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG22 ' H ' ' A' ' 86' ' ' ALA . 10.6 p -134.23 139.4 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.236 -0.915 . . . . 0.0 109.525 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.679 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 97.1 mt-10 -66.27 -35.83 81.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.158 -0.964 . . . . 0.0 109.344 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 85' ' ' GLU . . . 164.03 153.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.345 -0.847 . . . . 0.0 109.251 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.436 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 12.4 tttm -75.12 133.7 41.46 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.095 -1.003 . . . . 0.0 109.424 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.2 mt -94.28 142.08 27.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.443 179.952 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.59 ' C4 ' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.1 mtm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.49 0.662 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tp60 -101.28 120.4 40.2 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.46 -0.775 . . . . 0.0 109.009 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 52.65 32.75 12.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.213 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.01 -33.06 73.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.654 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.28 -32.88 73.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.21 -0.931 . . . . 0.0 109.949 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.3 t -63.97 -41.97 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.101 -1.0 . . . . 0.0 109.333 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.2 mt -59.77 -44.53 94.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -63.69 -47.48 81.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.241 -0.912 . . . . 0.0 109.421 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.593 HE22 ' H ' ' A' ' 87' ' ' LYS . 1.1 pp0? -69.17 -33.59 73.62 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.384 -0.822 . . . . 0.0 109.773 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.405 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 44.2 t80 -60.1 -52.18 66.43 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.963 -1.086 . . . . 0.0 109.472 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 32.7 m -75.74 -46.11 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.862 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 62.1 t -63.35 -39.74 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.254 -0.903 . . . . 0.0 111.119 -178.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -58.78 -34.64 71.68 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.097 -1.002 . . . . 0.0 109.569 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -66.88 -37.9 85.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.349 -0.844 . . . . 0.0 110.719 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 11' ' ' VAL . 42.0 m-85 -92.37 -57.39 2.71 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.008 -1.058 . . . . 0.0 110.88 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.1 tp -124.89 83.55 59.59 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.365 -0.835 . . . . 0.0 110.131 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -86.46 -18.93 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 123.011 2.474 . . . . 0.0 112.18 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.884 ' OD1' HG23 ' A' ' 19' ' ' VAL . 55.1 p30 -76.77 -3.82 40.23 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.115 -0.991 . . . . 0.0 108.735 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.884 HG23 ' OD1' ' A' ' 18' ' ' ASP . 49.0 t -114.06 142.76 25.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.429 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.04 115.69 15.35 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 120.776 -1.203 . . . . 0.0 108.801 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -63.65 -33.9 65.09 Favored 'Trans proline' 0 N--CA 1.488 1.197 0 C-N-CA 121.59 1.527 . . . . 0.0 111.719 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.08 -15.65 62.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 108.888 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 88.8 m-20 -91.5 3.15 55.67 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.462 -0.774 . . . . 0.0 109.053 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -101.85 136.94 31.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.55 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -59.8 96.97 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.154 -0.966 . . . . 0.0 109.511 -179.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.717 ' O ' HD12 ' A' ' 69' ' ' ILE . 17.1 m -61.34 5.04 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.299 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.55 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -89.83 10.3 24.16 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.5 tp -83.83 133.48 34.75 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.467 -0.771 . . . . 0.0 109.374 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.448 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 90.1 m-20 -65.59 122.27 16.86 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.991 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.564 HD11 HG12 ' A' ' 69' ' ' ILE . 77.4 mt -63.36 -3.81 2.23 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.252 -0.905 . . . . 0.0 109.185 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -50.43 -43.94 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 120.988 -1.07 . . . . 0.0 108.231 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.73 -34.58 67.64 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.097 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -82.46 16.87 1.92 Allowed 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 37' ' ' ASP . . . -41.35 -15.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.9 t -51.18 -40.09 21.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 O-C-N 120.693 -1.475 . . . . 0.0 107.207 178.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.487 ' O ' ' C ' ' A' ' 37' ' ' ASP . 14.5 tt -71.37 -19.08 20.56 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.524 ' CB ' ' O ' ' A' ' 34' ' ' GLY . 11.1 t0 -30.65 -74.32 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 122.011 -0.431 . . . . 0.0 111.535 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 7.5 m -114.53 -37.85 4.19 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.962 -177.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.3 mp -66.93 -54.24 24.02 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.619 -1.301 . . . . 0.0 109.995 -178.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -73.61 -41.03 44.94 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 19.5 tp -57.39 -46.04 83.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.151 -1.206 . . . . 0.0 109.307 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -63.84 -40.39 96.48 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -62.98 -38.95 93.19 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.658 -0.651 . . . . 0.0 109.681 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.2 t -60.74 -45.03 98.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.429 -0.794 . . . . 0.0 110.469 -179.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mm -60.52 -45.25 97.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.089 -1.007 . . . . 0.0 109.901 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.92 -44.27 85.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.824 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -71.28 -39.54 71.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.224 -0.922 . . . . 0.0 109.399 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.472 HD21 HD12 ' A' ' 54' ' ' ILE . 7.6 tp -59.06 -43.28 91.69 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.339 -0.851 . . . . 0.0 109.323 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.4 -42.16 96.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.261 -0.9 . . . . 0.0 109.137 179.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -64.72 -37.88 89.08 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 110.154 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.678 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 59.2 ttt-85 -86.45 -47.45 9.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.304 -0.872 . . . . 0.0 111.833 -178.242 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.678 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.7 m-85 -100.42 -5.8 26.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.761 -1.212 . . . . 0.0 111.544 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.5 25.73 75.23 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.205 -1.474 . . . . 0.0 109.574 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 48' ' ' LEU . 89.0 mt -89.16 139.74 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.092 -1.24 . . . . 0.0 109.742 -179.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.52 157.11 17.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.854 . . . . 0.0 109.818 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.29 -37.6 70.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.394 -0.816 . . . . 0.0 109.773 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 52.71 51.9 15.09 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.045 -1.034 . . . . 0.0 108.91 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -64.35 108.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.883 -179.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.419 HG13 HD21 ' A' ' 61' ' ' LEU . 13.1 p -136.32 146.9 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -81.25 126.81 31.99 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.993 -1.067 . . . . 0.0 109.913 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.419 HD21 HG13 ' A' ' 59' ' ' VAL . 39.4 mt -115.96 141.2 48.43 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.643 -0.661 . . . . 0.0 109.565 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.35 152.73 67.96 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.931 . . . . 0.0 109.427 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -62.29 -22.48 74.19 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.652 2.234 . . . . 0.0 112.239 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.14 -30.9 70.66 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.27 -0.894 . . . . 0.0 109.631 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.414 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 86.5 t60 -69.98 -26.19 63.97 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 111.304 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.459 ' CB ' ' N9 ' ' A' ' 101' ' ' PN7 . 75.0 m-85 -97.68 5.28 49.53 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.85 -1.156 . . . . 0.0 111.234 -178.175 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.448 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 36.2 mmt180 -60.28 -25.94 66.1 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.925 -1.109 . . . . 0.0 110.254 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.3 p -140.78 153.5 45.87 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.033 -1.042 . . . . 0.0 110.459 -179.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 26' ' ' VAL . 84.5 mt -66.23 -36.96 78.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.805 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -60.63 -39.74 89.35 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.26 -0.9 . . . . 0.0 110.382 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 m -59.23 -44.59 92.33 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.996 -1.065 . . . . 0.0 109.754 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.14 -38.84 83.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.159 -0.963 . . . . 0.0 109.692 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.509 ' OD1' HG23 ' A' ' 77' ' ' VAL . 49.9 t0 -57.33 -38.38 73.98 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.841 . . . . 0.0 109.91 -179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.1 -43.64 86.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.269 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 72.8 t80 -62.12 -49.9 74.05 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.995 -1.065 . . . . 0.0 109.522 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 80' ' ' THR . 61.1 t -66.09 -44.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.3 -0.875 . . . . 0.0 109.754 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.509 HG23 ' OD1' ' A' ' 73' ' ' ASP . 50.5 t -63.17 -39.23 84.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.122 -0.987 . . . . 0.0 109.758 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.67 -32.91 66.03 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -1.167 . . . . 0.0 110.468 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 76' ' ' VAL . 32.9 m -154.72 137.68 15.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.822 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t -119.03 88.19 36.04 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.402 -0.811 . . . . 0.0 108.983 179.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.415 ' HB2' ' CE1' ' A' ' 52' ' ' PHE . 96.3 Cg_endo -91.56 113.19 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 123.229 2.619 . . . . 0.0 113.186 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -80.17 130.66 8.36 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 122.037 1.825 . . . . 0.0 111.496 178.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.415 HG12 ' O ' ' A' ' 86' ' ' ALA . 25.0 t -128.95 133.42 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 109.751 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.43 -36.35 83.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.848 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.415 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -147.52 157.67 43.67 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.124 -0.985 . . . . 0.0 109.739 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.593 ' H ' HE22 ' A' ' 9' ' ' GLN . 20.6 tttm -57.06 -37.84 72.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.228 -0.92 . . . . 0.0 109.419 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 36.8 tp -100.84 131.39 46.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.504 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.487 ' O3 ' ' OD1' ' A' ' 37' ' ' ASP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.511 ' SD ' ' CG ' ' A' ' 73' ' ' ASP . 55.5 mtt . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 -97.31 128.01 43.77 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.276 -0.89 . . . . 0.0 108.713 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.7 m80 51.68 33.24 10.57 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.09 -1.006 . . . . 0.0 108.858 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.58 -33.71 73.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.416 -0.802 . . . . 0.0 109.677 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.89 -33.73 74.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.15 -0.969 . . . . 0.0 109.833 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.437 HG11 ' H ' ' A' ' 84' ' ' VAL . 55.1 t -65.18 -39.67 86.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -0.952 . . . . 0.0 109.59 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.506 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 83.4 mt -59.36 -49.81 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.588 -179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.72 96.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -0.94 . . . . 0.0 108.711 179.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -64.78 -38.3 90.53 Favored 'General case' 0 N--CA 1.489 1.499 0 CA-C-O 121.669 0.747 . . . . 0.0 109.031 179.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -58.89 -46.52 87.67 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.545 -0.722 . . . . 0.0 109.616 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.7 t -73.68 -49.44 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.385 -0.822 . . . . 0.0 110.773 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.0 t -64.1 -38.54 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.201 -0.937 . . . . 0.0 110.279 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -57.69 -31.88 66.81 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.53 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.39 -28.9 68.99 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.938 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -119.02 -51.17 2.35 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.129 -0.982 . . . . 0.0 111.786 -178.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.9 mt -125.96 82.88 63.98 Favored Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 120.977 -1.077 . . . . 0.0 111.371 -178.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -87.89 -12.89 4.09 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 123.231 2.621 . . . . 0.0 112.082 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.46 -4.77 44.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.2 p -115.2 145.87 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 23' ' ' ASP . . . -61.74 115.84 17.54 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 120.85 -1.156 . . . . 0.0 108.619 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -64.2 -33.34 60.75 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 121.538 1.492 . . . . 0.0 111.76 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.35 -16.68 61.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.374 -0.829 . . . . 0.0 108.886 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 88.9 m-20 -91.22 3.04 55.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.503 -0.748 . . . . 0.0 109.02 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -100.98 138.74 24.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.1 t0 -65.52 94.82 0.2 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 109.351 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.5 m -61.16 4.77 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.33 -0.856 . . . . 0.0 109.427 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 60.6 t0 -90.36 10.24 25.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.253 -0.904 . . . . 0.0 108.976 179.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 13.0 tp -86.98 131.57 34.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.438 -0.789 . . . . 0.0 109.341 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -68.94 121.48 16.68 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.44 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -70.47 7.56 1.03 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.243 -0.911 . . . . 0.0 109.219 -179.582 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.8 p -51.52 -40.6 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.221 -0.924 . . . . 0.0 108.964 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.475 ' N ' HG13 ' A' ' 31' ' ' VAL . 55.8 t0 -58.49 -38.16 77.06 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.7 m-20 -88.75 15.5 8.19 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.67 0.01 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.1 p -50.94 -34.13 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.978 -1.307 . . . . 0.0 108.622 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.564 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -71.56 -24.25 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.495 -0.753 . . . . 0.0 110.23 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.424 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.9 m-20 -54.17 -35.72 62.6 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.608 -0.683 . . . . 0.0 111.797 -177.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.451 ' OG ' ' N9 ' ' A' ' 101' ' ' PN7 . 56.0 m -114.98 -64.73 1.27 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.996 -1.065 . . . . 0.0 111.533 -178.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.91 -52.16 65.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.991 -1.068 . . . . 0.0 110.198 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.94 -39.41 64.09 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 61' ' ' LEU . 15.5 tp -60.73 -41.77 96.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.325 -1.103 . . . . 0.0 110.032 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -62.43 -45.09 94.66 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.203 -0.935 . . . . 0.0 109.849 -179.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -66.14 -42.22 89.39 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.86 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 83.2 t -69.32 -44.31 80.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.338 -0.851 . . . . 0.0 110.442 -179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.24 -50.19 80.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.132 -0.98 . . . . 0.0 109.592 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.433 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -64.54 -44.25 91.41 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.161 -0.962 . . . . 0.0 110.762 -179.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.41 ' HE1' ' HD3' ' A' ' 51' ' ' ARG . 2.9 t90 -77.59 -47.7 18.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.135 -0.978 . . . . 0.0 110.754 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.904 HD12 HH21 ' A' ' 51' ' ' ARG . 8.7 tp -62.88 -46.44 87.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 110.806 -178.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.564 ' O ' ' N ' ' A' ' 53' ' ' GLY . 97.0 mt-10 -67.81 -34.79 77.45 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.052 -1.03 . . . . 0.0 110.344 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -59.28 -39.89 84.37 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.068 -1.02 . . . . 0.0 109.431 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.904 HH21 HD12 ' A' ' 48' ' ' LEU . 73.0 mtm180 -64.62 -38.89 92.57 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.27 -0.894 . . . . 0.0 110.551 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -100.04 -4.52 29.75 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.059 -1.026 . . . . 0.0 110.181 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.13 33.5 87.18 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 88.8 mt -86.65 140.37 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.078 -1.248 . . . . 0.0 109.822 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.56 132.52 43.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.029 -1.044 . . . . 0.0 109.301 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.47 70.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.43 0.6 51.77 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.8 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.6 -37.42 68.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.159 -0.963 . . . . 0.0 109.573 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.75 145.53 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.398 -0.814 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -79.32 138.97 37.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.107 -0.996 . . . . 0.0 109.427 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -102.19 138.71 38.77 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.338 -0.851 . . . . 0.0 109.808 -179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.18 156.38 57.92 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.291 -0.881 . . . . 0.0 109.171 179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.07 -31.89 83.6 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.571 2.181 . . . . 0.0 111.995 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.24 -32.15 73.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.452 -0.78 . . . . 0.0 109.807 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -68.6 -26.49 65.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.345 -0.847 . . . . 0.0 110.936 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.503 ' CE1' HD13 ' A' ' 41' ' ' LEU . 92.9 m-85 -94.87 8.5 42.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.921 -1.112 . . . . 0.0 110.574 -178.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -59.61 -38.14 80.48 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.91 -1.118 . . . . 0.0 110.4 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.1 p -137.72 150.94 47.71 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.077 -1.015 . . . . 0.0 110.475 -179.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.94 -36.54 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.579 -0.7 . . . . 0.0 109.966 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.2 ttm180 -60.43 -41.52 94.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 0.0 110.427 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -57.61 -42.51 83.42 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.181 -0.949 . . . . 0.0 109.759 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.17 -38.91 80.41 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.163 -0.961 . . . . 0.0 109.688 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.511 ' CG ' ' SD ' ' A' ' 1' ' ' MET . 58.0 t0 -59.24 -40.78 87.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.325 -0.859 . . . . 0.0 110.435 -179.412 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.18 -44.5 83.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.1 -1.0 . . . . 0.0 110.135 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -63.96 -45.38 89.38 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.153 -0.967 . . . . 0.0 109.631 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 80' ' ' THR . 64.1 t -67.38 -44.8 86.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.186 -0.947 . . . . 0.0 109.748 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.506 HG23 ' OD1' ' A' ' 73' ' ' ASP . 48.7 t -62.76 -40.49 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.095 -1.003 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.14 67.82 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.54 -50.7 3.25 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -1.222 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 76' ' ' VAL . 50.0 m -153.75 136.49 15.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 109.996 -179.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 81' ' ' THR . 1.3 t -118.97 88.28 36.0 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.361 -0.837 . . . . 0.0 108.872 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -89.25 113.97 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.085 2.524 . . . . 0.0 112.99 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -80.3 132.71 9.34 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.094 1.862 . . . . 0.0 111.697 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.437 ' H ' HG11 ' A' ' 6' ' ' VAL . 34.3 t -125.25 132.15 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.395 -0.815 . . . . 0.0 109.621 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.87 -35.69 81.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.489 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.406 ' O ' HG12 ' A' ' 84' ' ' VAL . . . -151.75 153.48 34.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.238 -0.914 . . . . 0.0 109.608 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 15.4 tttm -59.19 -34.85 72.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.542 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.9 mt -57.02 -35.65 69.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.556 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.468 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.616 ' CE1' ' N5 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.496 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 89.6 mmm . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.628 ' HG2' HG12 ' A' ' 84' ' ' VAL . 92.3 mt-30 -111.25 138.7 47.38 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.445 -0.784 . . . . 0.0 109.152 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.453 ' C ' ' O ' ' A' ' 2' ' ' GLN . 0.1 OUTLIER 41.33 25.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.825 . . . . 0.0 109.31 -179.937 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.24 -37.47 80.47 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.29 -0.881 . . . . 0.0 109.893 -179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.581 ' CB ' ' NE2' ' A' ' 89' ' ' GLN . 86.3 p -63.67 -36.33 83.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.98 . . . . 0.0 109.705 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.428 HG21 ' CE1' ' A' ' 3' ' ' HIS . 68.3 t -66.67 -39.48 83.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.134 -0.978 . . . . 0.0 109.078 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.0 mt -61.48 -50.9 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.763 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.45 -47.25 79.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.056 179.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.36 -44.19 95.52 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.554 -0.716 . . . . 0.0 109.351 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -65.34 -48.58 72.51 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.572 -0.705 . . . . 0.0 109.509 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 7' ' ' ILE . 93.7 t -67.7 -44.94 85.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.427 -0.796 . . . . 0.0 109.443 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.763 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.8 t -64.29 -35.13 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.488 -0.757 . . . . 0.0 109.464 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.11 -30.92 60.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.266 -0.897 . . . . 0.0 109.726 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.76 -30.84 71.56 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.206 -0.934 . . . . 0.0 109.602 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.4 p90 -142.94 44.99 1.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.124 -0.985 . . . . 0.0 109.784 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.821 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.6 131.05 62.24 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.016 -1.052 . . . . 0.0 110.084 -179.873 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -76.44 -152.01 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.005 1.804 . . . . 0.0 110.412 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -77.31 12.65 1.42 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.891 -1.131 . . . . 0.0 108.741 179.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.5 t -113.54 136.7 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.57 -0.706 . . . . 0.0 109.905 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.92 139.31 85.45 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.253 -0.904 . . . . 0.0 108.833 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.429 ' O ' HG12 ' A' ' 24' ' ' VAL . 53.5 Cg_exo -48.35 -32.19 19.37 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.797 1.665 . . . . 0.0 111.922 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.73 -23.99 65.32 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.285 -0.885 . . . . 0.0 109.35 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -103.68 8.64 37.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.351 -0.843 . . . . 0.0 109.4 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.4 OUTLIER -94.18 143.18 12.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.257 -0.902 . . . . 0.0 108.912 179.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -70.34 87.94 0.63 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.158 -0.964 . . . . 0.0 109.573 -179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 26' ' ' VAL . 5.7 p -59.57 4.7 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.211 -0.931 . . . . 0.0 109.553 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.9 m-20 -95.97 9.87 39.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 108.714 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -88.58 136.35 33.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.471 -0.768 . . . . 0.0 109.49 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.598 ' CG ' HH12 ' A' ' 67' ' ' ARG . 84.7 m-20 -65.2 121.38 14.65 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.33 10.29 4.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.177 -0.952 . . . . 0.0 109.773 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 65.0 t -56.26 -40.98 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.174 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.37 -37.75 70.5 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.595 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.4 m-80 -86.75 12.47 10.74 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.21 -15.89 0.03 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.595 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.4 p -51.37 -30.61 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.267 . . . . 0.0 108.949 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.583 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.1 tt -70.76 -22.13 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.696 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.7 m-20 -54.92 -35.59 64.35 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.676 -0.64 . . . . 0.0 111.79 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.8 m -115.32 -64.8 1.26 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.883 -1.136 . . . . 0.0 111.538 -178.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.13 -52.15 65.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.09 -1.006 . . . . 0.0 110.161 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.429 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -39.22 65.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.583 ' N ' ' O ' ' A' ' 36' ' ' ILE . 29.4 tp -58.86 -40.39 84.2 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.367 -1.078 . . . . 0.0 109.636 -179.48 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -64.31 -44.55 91.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.364 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -64.07 -38.63 91.76 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.318 -0.864 . . . . 0.0 109.531 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.5 t -63.92 -45.38 97.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.35 -0.844 . . . . 0.0 109.876 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.97 -44.25 98.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.122 -0.986 . . . . 0.0 109.552 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.37 -44.25 95.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 109.773 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -73.21 -39.01 65.88 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.212 -0.93 . . . . 0.0 109.439 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -57.73 -40.79 80.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.395 -0.816 . . . . 0.0 109.464 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.24 -42.59 99.46 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 108.95 179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -67.48 -40.28 85.27 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.283 -0.886 . . . . 0.0 110.019 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 21.8 tpt180 -61.74 -45.32 94.42 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.379 -0.825 . . . . 0.0 110.845 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -110.4 -4.61 15.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.018 -1.051 . . . . 0.0 110.874 -178.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.13 33.66 64.97 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 66.4 mt -104.76 145.24 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -1.118 . . . . 0.0 109.742 -179.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 150.87 33.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.248 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.57 -36.41 71.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.295 -0.878 . . . . 0.0 109.932 -179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 52.42 50.8 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 108.94 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -70.55 117.22 11.8 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.969 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.5 m -130.2 163.0 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -60.64 126.13 26.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.963 -1.085 . . . . 0.0 109.284 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.6 mp -116.73 143.57 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.496 -0.753 . . . . 0.0 109.51 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.93 155.74 36.19 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.898 . . . . 0.0 109.398 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.23 -24.82 76.41 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.754 2.303 . . . . 0.0 112.189 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.99 -32.03 72.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.661 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.8 t60 -68.04 -26.72 66.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.754 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.407 ' CE1' HD13 ' A' ' 41' ' ' LEU . 93.4 m-85 -98.68 6.88 46.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.598 HH12 ' CG ' ' A' ' 29' ' ' ASP . 26.8 tpt85 -56.39 -38.16 71.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 109.902 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.3 p -137.43 155.05 49.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.084 -1.01 . . . . 0.0 109.931 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.535 HD12 HG23 ' A' ' 26' ' ' VAL . 92.5 mt -62.48 -36.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 O-C-N 121.287 -0.883 . . . . 0.0 109.948 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -61.01 -37.06 81.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 110.088 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.2 m -59.01 -41.67 88.29 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.028 -1.045 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -62.48 -38.97 82.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.246 -0.909 . . . . 0.0 109.153 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.489 ' HA ' HD13 ' A' ' 7' ' ' ILE . 55.4 t0 -58.28 -36.88 73.95 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.345 -0.847 . . . . 0.0 109.343 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.37 -40.16 89.82 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.241 -0.912 . . . . 0.0 109.086 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -61.71 -45.73 92.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.329 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.494 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.8 t -64.05 -42.59 96.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.352 -0.842 . . . . 0.0 109.638 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.42 -41.16 88.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.349 -0.844 . . . . 0.0 109.656 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.19 -30.88 77.12 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.54 -50.3 3.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.911 -1.347 . . . . 0.0 110.394 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.494 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.3 p -127.02 154.55 44.5 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.04 87.97 12.09 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.0 . . . . 0.0 110.0 -179.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.48 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.5 Cg_exo -63.43 -173.58 0.18 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.81 2.34 . . . . 0.0 111.594 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.48 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.4 Cg_exo -61.73 150.78 84.34 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.389 2.06 . . . . 0.0 111.438 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 2' ' ' GLN . 4.1 m -89.53 127.31 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.075 -1.016 . . . . 0.0 110.092 -179.117 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.25 156.68 48.0 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.477 -0.764 . . . . 0.0 108.985 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -73.28 126.17 29.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.054 -1.029 . . . . 0.0 109.347 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.549 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 59.0 tttm -59.92 -38.34 82.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 66.8 mt -60.56 -34.97 74.94 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.515 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.581 ' NE2' ' CB ' ' A' ' 5' ' ' SER . 95.3 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.432 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.594 ' O3 ' ' N9 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.528 ' HB3' ' HB3' ' A' ' 4' ' ' ALA . 62.8 mtm . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.433 0.635 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.415 ' C ' ' N ' ' A' ' 4' ' ' ALA . 63.6 tt0 -97.34 118.16 33.19 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.544 ' CE1' ' OG1' ' A' ' 81' ' ' THR . 19.6 m170 55.77 10.29 0.53 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.147 -0.971 . . . . 0.0 108.843 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.646 ' HB2' ' OD2' ' A' ' 73' ' ' ASP . . . -64.28 -32.69 74.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.827 . . . . 0.0 109.693 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.7 p -61.29 -31.5 71.33 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 110.161 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.0 t -62.63 -42.12 94.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.029 -1.044 . . . . 0.0 109.323 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.417 ' O ' HG12 ' A' ' 11' ' ' VAL . 85.3 mt -61.48 -41.62 90.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.406 -0.808 . . . . 0.0 109.787 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.56 -49.86 71.78 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.165 -0.96 . . . . 0.0 109.48 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.417 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.4 pp0? -69.41 -34.03 73.88 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.155 -0.966 . . . . 0.0 109.266 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 60.5 t80 -72.14 -51.29 22.04 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.296 -0.878 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -67.86 -41.68 85.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.346 -0.847 . . . . 0.0 110.037 -179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.5 t -64.68 -35.73 75.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 109.579 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.45 -32.0 62.39 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.209 -0.932 . . . . 0.0 109.804 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -65.87 -31.01 71.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.161 -0.962 . . . . 0.0 109.718 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.682 ' CZ ' ' ND2' ' A' ' 33' ' ' ASN . 31.9 p90 -141.45 44.98 1.74 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 109.721 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.56 130.9 62.95 Favored Pre-proline 0 N--CA 1.488 1.46 0 O-C-N 120.978 -1.076 . . . . 0.0 110.108 -179.826 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -76.62 -150.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.03 1.82 . . . . 0.0 110.287 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.539 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -78.83 13.04 1.84 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 120.835 -1.166 . . . . 0.0 108.73 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.539 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.2 t -113.59 136.6 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.488 -0.757 . . . . 0.0 109.874 -179.624 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.68 139.06 80.36 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.23 -0.919 . . . . 0.0 108.854 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.465 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 50.9 Cg_exo -48.57 -30.73 16.82 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.804 1.669 . . . . 0.0 112.052 179.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.63 -22.19 66.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.371 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -97.38 4.01 50.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -0.809 . . . . 0.0 109.086 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -105.72 137.16 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.554 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -64.91 97.95 0.26 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.138 -0.976 . . . . 0.0 109.456 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -60.35 4.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.291 -0.881 . . . . 0.0 109.545 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.554 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.68 10.12 31.98 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.234 -0.916 . . . . 0.0 108.791 179.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -89.4 134.56 34.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.545 -0.722 . . . . 0.0 109.53 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -64.75 121.46 14.59 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.21 6.58 4.2 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.146 -0.971 . . . . 0.0 109.563 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.36 -38.8 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.185 -0.947 . . . . 0.0 109.147 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.441 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.3 m-20 -56.27 -36.6 68.78 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.682 ' ND2' ' CZ ' ' A' ' 15' ' ' PHE . 77.6 m-20 -84.93 16.03 3.64 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.36 -14.41 0.01 OUTLIER Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -51.52 -38.94 21.73 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.945 -1.326 . . . . 0.0 108.402 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -71.4 -24.63 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.557 -0.714 . . . . 0.0 110.303 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -58.39 -29.61 66.18 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.244 -0.91 . . . . 0.0 111.105 -178.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.416 ' OG ' ' S12' ' A' ' 101' ' ' PN7 . 58.3 m -112.12 -64.75 1.25 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.007 -1.058 . . . . 0.0 111.346 -178.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.473 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.48 -50.08 55.05 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.017 -1.052 . . . . 0.0 110.408 -178.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.2 -38.0 72.1 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.9 tp -59.66 -41.7 91.17 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.447 -1.031 . . . . 0.0 109.503 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.36 -44.19 95.81 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.176 -0.953 . . . . 0.0 108.505 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -67.6 -35.13 78.38 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.443 -0.786 . . . . 0.0 109.518 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 62.0 t -61.57 -44.66 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.414 -0.804 . . . . 0.0 110.368 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -60.84 -44.7 98.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.148 -0.97 . . . . 0.0 109.638 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.22 -44.17 89.13 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.28 -0.887 . . . . 0.0 109.97 -179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.445 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 1.3 t90 -72.67 -39.48 67.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.651 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.0 tp -58.76 -42.22 88.4 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.296 -0.878 . . . . 0.0 109.476 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' ' N ' ' A' ' 53' ' ' GLY . 73.8 tt0 -63.78 -40.37 96.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.216 -0.928 . . . . 0.0 109.532 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -67.61 -47.42 69.69 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.152 -0.968 . . . . 0.0 110.508 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.681 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 63.7 ttt-85 -69.48 -43.11 73.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.33 -0.857 . . . . 0.0 111.843 -178.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.681 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 98.3 m-85 -101.67 -7.76 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.801 -1.187 . . . . 0.0 111.17 -178.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.69 25.98 74.94 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -100.69 130.47 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.246 -1.15 . . . . 0.0 109.471 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.25 148.86 39.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.101 -0.999 . . . . 0.0 109.794 -179.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.567 ' C ' ' H ' ' A' ' 58' ' ' ASP . . . -58.53 -22.31 55.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.521 -0.737 . . . . 0.0 109.204 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 58.24 -4.61 0.06 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.607 -0.683 . . . . 0.0 110.19 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 56' ' ' ALA . 87.1 m-20 52.3 48.81 21.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.052 -1.03 . . . . 0.0 109.807 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.4 m -104.17 138.08 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.526 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.4 tt0 -107.28 136.0 47.83 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.387 -0.821 . . . . 0.0 109.669 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.886 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.7 mm? -104.82 139.85 38.98 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.317 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.09 161.92 58.69 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 109.987 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.99 -29.6 74.43 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.927 2.418 . . . . 0.0 112.064 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.5 mm-40 -64.01 -29.73 70.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.339 -0.851 . . . . 0.0 109.682 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -67.67 -26.72 66.34 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.3 -0.875 . . . . 0.0 109.879 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -96.99 7.13 47.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.15 -0.969 . . . . 0.0 109.599 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.3 tpt180 -55.95 -38.77 70.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.081 -1.012 . . . . 0.0 109.777 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t -144.18 149.3 36.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.956 -1.09 . . . . 0.0 109.972 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -59.45 -37.03 67.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.362 -0.836 . . . . 0.0 109.926 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -61.2 -37.4 82.85 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.938 . . . . 0.0 110.15 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -59.14 -40.78 86.59 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.045 -1.034 . . . . 0.0 109.472 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.2 mt -64.76 -38.7 83.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.267 -0.895 . . . . 0.0 109.445 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.708 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.6 t0 -57.29 -39.2 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.373 -0.829 . . . . 0.0 109.844 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.25 -44.79 90.72 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.094 -1.004 . . . . 0.0 109.482 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -65.74 -47.34 75.59 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.222 -0.924 . . . . 0.0 109.221 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 80' ' ' THR . 57.1 t -65.47 -41.05 90.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.416 -0.802 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.708 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.7 t -61.41 -41.48 90.09 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 O-C-N 121.127 -0.983 . . . . 0.0 109.803 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.94 -35.98 78.49 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -92.14 -49.79 6.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.146 -1.208 . . . . 0.0 110.14 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 76' ' ' VAL . 13.0 t -148.24 150.53 33.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.22 -0.925 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.619 HG23 ' O ' ' A' ' 81' ' ' THR . 4.3 t -140.66 89.27 10.36 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.298 -0.876 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -83.8 129.6 4.83 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.598 2.199 . . . . 0.0 112.371 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.54 149.14 34.14 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.22 1.946 . . . . 0.0 112.223 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.5 p -131.87 138.25 53.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 109.491 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.35 -39.39 92.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -0.932 . . . . 0.0 109.517 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -159.81 153.66 23.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.253 -0.904 . . . . 0.0 109.511 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.485 ' HE3' ' HB3' ' A' ' 8' ' ' ALA . 32.0 tttt -59.11 -37.97 78.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.5 tp -101.67 132.02 47.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.287 -0.883 . . . . 0.0 109.494 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.438 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.562 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.532 ' O4 ' ' S12' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.316 0.579 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.571 ' O ' HG21 ' A' ' 84' ' ' VAL . 93.1 mt-30 -59.63 -38.5 81.53 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.351 -0.843 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 55.9 m80 -124.04 9.28 8.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.515 -0.741 . . . . 0.0 109.698 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.588 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.78 -32.98 71.11 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.3 m -62.0 -46.38 89.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.139 -0.975 . . . . 0.0 110.525 -179.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 3' ' ' HIS . 3.5 p -67.73 -35.55 72.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.068 -1.02 . . . . 0.0 109.296 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.588 HD12 ' HA ' ' A' ' 4' ' ' ALA . 96.6 mt -58.95 -50.18 80.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.211 -0.931 . . . . 0.0 109.492 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.568 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . . . -63.33 -47.57 81.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.204 -0.935 . . . . 0.0 108.791 179.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.42 -39.23 92.62 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.582 -0.699 . . . . 0.0 109.541 179.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.42 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 63.8 t80 -65.19 -51.43 61.07 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 110.612 -179.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' N ' ' A' ' 12' ' ' VAL . 18.3 m -74.07 -44.7 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 110.785 -179.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.571 ' N ' HG23 ' A' ' 11' ' ' VAL . 78.6 t -61.14 -35.64 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.136 -0.978 . . . . 0.0 110.273 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -57.41 -37.41 72.7 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.167 -0.958 . . . . 0.0 109.161 -179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -68.17 -37.49 81.04 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' O ' HD12 ' A' ' 16' ' ' LEU . 57.4 m-85 -91.22 -57.57 2.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.077 -1.014 . . . . 0.0 110.778 -178.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.547 HD12 ' O ' ' A' ' 15' ' ' PHE . 1.3 mp -129.02 83.6 65.65 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.296 -0.877 . . . . 0.0 110.658 -178.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -88.37 -21.11 1.58 Allowed 'Trans proline' 0 C--N 1.305 -1.74 0 C-N-CA 123.058 2.505 . . . . 0.0 112.159 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.31 -4.75 43.79 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.158 -0.964 . . . . 0.0 108.624 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.8 t -113.75 143.44 23.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 107.734 -1.209 . . . . 0.0 107.734 178.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.501 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -61.0 115.92 16.33 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.695 -1.253 . . . . 0.0 108.671 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -63.4 -23.69 71.44 Favored 'Trans proline' 0 C--N 1.316 -1.162 0 C-N-CA 121.492 1.461 . . . . 0.0 111.511 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.541 ' HB2' ' HG2' ' A' ' 87' ' ' LYS . . . -73.16 -15.0 61.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -0.793 . . . . 0.0 109.92 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.1 p30 -90.09 10.27 24.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.107 -0.996 . . . . 0.0 109.589 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.434 ' O ' ' N ' ' A' ' 26' ' ' VAL . 47.6 t -94.7 136.21 26.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.544 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -63.85 82.82 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.169 -0.957 . . . . 0.0 109.317 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 24' ' ' VAL . 18.2 m -61.66 4.21 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.272 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.544 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -98.89 5.8 47.14 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.899 . . . . 0.0 108.7 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -97.44 137.5 36.32 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.545 -0.722 . . . . 0.0 109.415 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -61.24 121.6 12.96 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.19 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.445 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.35 8.16 0.36 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.258 -0.901 . . . . 0.0 109.722 -179.025 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.2 p -52.91 -38.38 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.084 -1.01 . . . . 0.0 108.931 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.588 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 31.1 p-10 -61.32 -33.97 74.47 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -86.6 16.59 4.53 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.03 -14.49 0.01 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.18 -37.58 17.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.028 -1.277 . . . . 0.0 108.375 179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -70.79 -24.78 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -57.76 -30.76 65.87 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 111.038 -178.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -111.75 -64.49 1.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.001 -1.062 . . . . 0.0 111.139 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.9 -50.52 55.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.071 -1.018 . . . . 0.0 110.539 -178.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.16 -37.54 72.26 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.681 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.74 -41.49 86.6 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.38 -1.071 . . . . 0.0 109.54 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.8 tp -63.11 -44.17 96.41 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.236 -0.915 . . . . 0.0 108.722 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -68.38 -36.49 79.25 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.415 -0.803 . . . . 0.0 109.754 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.1 t -62.17 -45.95 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.351 -0.843 . . . . 0.0 110.214 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -61.13 -46.76 96.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.372 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.37 93.72 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.369 -0.832 . . . . 0.0 109.694 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.42 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.5 t90 -74.31 -41.3 61.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.357 -0.839 . . . . 0.0 109.941 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 24.3 tp -58.17 -46.43 85.76 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.197 -0.939 . . . . 0.0 109.515 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.591 ' O ' ' N ' ' A' ' 53' ' ' GLY . 56.2 tt0 -66.89 -39.41 87.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.01 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -65.41 -42.28 92.69 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.346 -0.846 . . . . 0.0 110.366 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.7 ttt180 -63.77 -44.51 93.2 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.284 -0.885 . . . . 0.0 111.382 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.402 ' CE1' HG21 ' A' ' 80' ' ' THR . 96.5 m-85 -105.94 -9.08 17.28 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.876 -1.14 . . . . 0.0 110.55 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.35 27.04 73.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.2 pt -116.07 152.11 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.287 -1.125 . . . . 0.0 109.841 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 155.26 23.33 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.25 -0.906 . . . . 0.0 109.513 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.24 -28.31 40.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.291 -0.881 . . . . 0.0 109.249 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 58' ' ' ASP . 84.8 m-20 55.83 45.84 23.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.452 -0.78 . . . . 0.0 109.975 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 57' ' ' ASP . 87.2 m-20 -134.68 102.45 5.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.269 -0.894 . . . . 0.0 109.107 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.597 HG12 ' HG3' ' A' ' 60' ' ' GLU . 61.1 t -62.19 -44.73 99.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.869 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.597 ' HG3' HG12 ' A' ' 59' ' ' VAL . 97.5 mt-10 -141.35 143.35 33.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.098 -1.002 . . . . 0.0 109.922 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.509 HD23 ' C ' ' A' ' 60' ' ' GLU . 1.7 mt -109.11 133.65 52.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.51 -0.744 . . . . 0.0 109.045 -179.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -135.66 154.12 77.92 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.67 -26.39 75.47 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.733 2.289 . . . . 0.0 112.045 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.04 -32.36 69.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.34 -0.85 . . . . 0.0 109.914 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -70.43 -26.53 63.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.314 -0.866 . . . . 0.0 111.195 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -100.14 7.35 44.64 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.932 -1.105 . . . . 0.0 111.415 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -59.75 -36.13 76.0 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.681 -1.262 . . . . 0.0 110.054 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.1 p -138.16 151.47 47.77 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.054 -1.029 . . . . 0.0 110.225 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 90.8 mt -65.77 -35.96 76.41 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.466 -0.771 . . . . 0.0 109.944 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 94.4 mtm-85 -60.38 -36.83 79.0 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -0.895 . . . . 0.0 110.314 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 t -58.64 -46.17 87.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.976 -1.077 . . . . 0.0 109.57 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.1 mt -68.25 -40.72 83.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.231 -0.918 . . . . 0.0 109.998 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.486 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.5 t0 -59.53 -39.9 85.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 110.311 -179.307 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.47 -44.54 86.83 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.103 -0.998 . . . . 0.0 110.028 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.0 t80 -62.8 -45.5 92.34 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.661 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -64.6 -43.31 96.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.234 -0.916 . . . . 0.0 109.896 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.559 HG22 ' ND1' ' A' ' 3' ' ' HIS . 52.6 t -61.16 -41.39 89.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 O-C-N 121.145 -0.972 . . . . 0.0 109.842 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.13 -32.85 72.36 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.17 -49.9 3.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.142 -1.211 . . . . 0.0 110.678 -179.084 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 44.8 m -128.14 138.02 52.33 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.382 -0.824 . . . . 0.0 109.939 -179.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.92 88.39 51.89 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 121.379 -0.826 . . . . 0.0 109.175 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 64.8 Cg_endo -81.89 161.26 18.57 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.69 2.26 . . . . 0.0 112.506 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -63.4 150.57 88.2 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.703 2.269 . . . . 0.0 111.761 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.571 HG21 ' O ' ' A' ' 2' ' ' GLN . 47.0 t -105.94 130.44 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.219 -0.926 . . . . 0.0 109.691 -179.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -145.77 12.82 1.31 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.346 -0.846 . . . . 0.0 109.114 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.88 151.5 23.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.317 -0.864 . . . . 0.0 109.632 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.568 ' HE2' ' HB3' ' A' ' 8' ' ' ALA . 15.1 mttm 58.85 45.14 15.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.526 -0.734 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' O ' ' O ' ' A' ' 89' ' ' GLN . 71.0 mt -59.31 -35.1 73.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.377 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.413 ' O ' ' O ' ' A' ' 88' ' ' LEU . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.462 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.5 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 67.6 mtm . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.435 0.636 . . . . 0.0 109.967 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.711 ' HG2' HG22 ' A' ' 84' ' ' VAL . 92.9 mt-30 -107.73 139.72 41.86 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.436 ' C ' ' O ' ' A' ' 2' ' ' GLN . 5.6 m170 43.83 30.85 0.42 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.17 -0.956 . . . . 0.0 108.982 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.14 -37.83 81.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.355 -0.841 . . . . 0.0 109.659 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 20.1 m -60.35 -39.24 86.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.207 -0.933 . . . . 0.0 109.686 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.3 t -65.43 -40.23 87.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.222 -0.924 . . . . 0.0 109.1 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.735 ' O ' HG22 ' A' ' 11' ' ' VAL . 82.7 mt -59.55 -47.03 92.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.433 -0.792 . . . . 0.0 109.785 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.759 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -49.06 74.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 0.0 109.816 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.421 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.6 pp0? -69.3 -33.8 73.74 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.171 -0.956 . . . . 0.0 109.93 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.434 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.0 t80 -65.05 -51.33 62.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.016 -1.053 . . . . 0.0 110.288 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.735 HG22 ' O ' ' A' ' 7' ' ' ILE . 34.8 m -73.49 -40.47 55.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 110.207 -179.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.3 t -64.74 -36.41 77.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.143 -0.973 . . . . 0.0 109.863 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -55.03 -35.72 64.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.234 -0.916 . . . . 0.0 109.938 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 77.2 mm-40 -66.41 -31.61 72.48 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.185 -0.947 . . . . 0.0 109.729 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -135.2 42.36 2.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.174 -0.954 . . . . 0.0 110.028 -179.815 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.818 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.32 131.12 63.03 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 120.836 -1.165 . . . . 0.0 109.991 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.01 -150.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.019 1.812 . . . . 0.0 110.37 178.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.583 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.2 p30 -77.77 11.66 2.05 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.815 -1.178 . . . . 0.0 108.622 179.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.583 HG23 ' OD1' ' A' ' 18' ' ' ASP . 33.1 t -113.74 136.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.623 -0.673 . . . . 0.0 109.85 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.46 139.61 84.16 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.214 -0.929 . . . . 0.0 108.752 179.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.511 ' O ' HG12 ' A' ' 24' ' ' VAL . 51.8 Cg_exo -48.78 -29.82 15.66 Favored 'Trans proline' 0 N--CA 1.492 1.41 0 C-N-CA 121.673 1.582 . . . . 0.0 111.829 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.33 -14.91 61.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.863 . . . . 0.0 109.409 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -105.01 11.24 33.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 110.06 -179.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 21' ' ' PRO . 2.3 p -104.65 141.85 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.164 -0.96 . . . . 0.0 108.996 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.9 m-20 -71.9 86.53 0.99 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.45 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 19.0 m -62.35 4.74 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.297 -0.877 . . . . 0.0 109.311 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.8 4.88 53.01 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 108.912 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.87 138.89 32.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.516 -0.74 . . . . 0.0 109.494 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.459 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -60.67 121.75 13.01 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.337 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.3 pp -66.63 7.85 0.31 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.25 -0.906 . . . . 0.0 109.972 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -51.33 -38.08 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.103 -0.998 . . . . 0.0 109.098 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 33' ' ' ASN . 32.6 p-10 -60.62 -33.84 73.36 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.23 16.15 5.52 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.28 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -56.06 -36.0 43.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.139 -1.212 . . . . 0.0 108.439 179.119 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -70.34 -24.46 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.586 -0.696 . . . . 0.0 110.209 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.419 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.0 m-20 -57.67 -32.6 67.49 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.31 -0.869 . . . . 0.0 111.531 -177.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -113.42 -64.51 1.3 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.969 -1.082 . . . . 0.0 111.574 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 39' ' ' LEU . 4.5 mp -66.35 -51.53 56.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.063 -1.023 . . . . 0.0 110.446 -178.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -38.55 68.89 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.6 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.1 tp -58.89 -41.82 88.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.397 -1.061 . . . . 0.0 109.098 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.21 -42.96 92.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 79.9 mttt -66.28 -37.86 86.44 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.353 -0.842 . . . . 0.0 109.358 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.48 -48.66 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.839 . . . . 0.0 110.439 -179.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.0 mm -61.4 -41.38 89.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.974 -1.079 . . . . 0.0 109.813 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.18 -44.33 88.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.046 -1.034 . . . . 0.0 109.546 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.434 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.0 OUTLIER -72.12 -39.92 68.51 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.689 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -58.66 -40.96 84.98 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.399 -0.813 . . . . 0.0 109.487 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 67.8 tt0 -61.98 -37.75 85.98 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.233 -0.917 . . . . 0.0 109.67 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.42 -38.4 83.95 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.991 -1.068 . . . . 0.0 109.955 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -75.73 -44.83 39.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 112.003 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -105.46 -7.15 18.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.88 -1.138 . . . . 0.0 110.985 -178.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.69 31.67 76.59 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.6 mt -95.61 138.0 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.176 -1.191 . . . . 0.0 109.659 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.565 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -60.75 142.22 56.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.035 -1.041 . . . . 0.0 109.422 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.43 -34.72 77.32 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.422 -0.799 . . . . 0.0 109.936 -179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -93.18 4.47 53.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.918 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.5 t0 -56.7 -39.95 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -129.58 135.38 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.429 -0.794 . . . . 0.0 109.534 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -103.95 132.34 50.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.267 -0.896 . . . . 0.0 109.726 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.57 143.59 44.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.614 -0.679 . . . . 0.0 109.568 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.39 162.03 24.9 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.195 -0.94 . . . . 0.0 109.582 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.62 -32.22 87.19 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.883 2.389 . . . . 0.0 111.922 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.89 -29.09 69.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.425 -0.797 . . . . 0.0 109.534 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.696 ' NE2' ' CD1' ' A' ' 75' ' ' PHE . 13.2 t-80 -68.74 -26.18 65.11 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.488 -0.757 . . . . 0.0 110.937 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -91.2 7.99 38.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.003 -1.061 . . . . 0.0 110.685 -178.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -59.69 -38.51 81.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.027 -1.046 . . . . 0.0 110.025 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.6 m -127.2 144.98 50.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.322 -0.861 . . . . 0.0 110.002 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.2 mt -64.67 -36.87 78.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.34 -0.85 . . . . 0.0 109.774 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -61.23 -36.89 81.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.899 . . . . 0.0 110.122 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -58.11 -39.08 77.74 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.095 -1.003 . . . . 0.0 109.404 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.48 -38.91 82.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.344 -0.847 . . . . 0.0 109.395 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.786 ' O ' HG23 ' A' ' 77' ' ' VAL . 87.0 m-20 -59.18 -37.6 77.77 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.393 -0.817 . . . . 0.0 109.672 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.89 -45.54 88.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.773 -179.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.696 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 29.0 m-85 -66.09 -43.67 86.62 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.192 -0.942 . . . . 0.0 109.452 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.0 t -65.14 -40.55 89.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.227 -0.921 . . . . 0.0 109.229 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.3 t -60.52 -42.44 91.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.358 -0.839 . . . . 0.0 109.657 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.64 90.46 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 120.352 -0.927 . . . . 0.0 110.838 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -89.98 -50.33 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.973 -1.31 . . . . 0.0 110.094 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.8 p -128.16 153.37 46.95 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.436 ' HG1' ' CD ' ' A' ' 2' ' ' GLN . 1.2 t -140.29 88.01 11.68 Favored Pre-proline 0 C--N 1.302 -1.48 0 O-C-N 121.101 -1.0 . . . . 0.0 110.092 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 19.0 Cg_exo -63.71 -173.95 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 122.782 2.321 . . . . 0.0 111.741 179.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.473 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.2 Cg_exo -61.9 151.15 82.92 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.479 2.119 . . . . 0.0 111.481 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 2' ' ' GLN . 39.5 t -92.12 128.42 43.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.092 -1.005 . . . . 0.0 110.016 -179.119 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -141.32 156.12 45.89 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.37 134.31 52.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.06 -1.025 . . . . 0.0 109.357 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.45 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 16.5 tttm -60.41 -36.27 77.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 109.354 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 87' ' ' LYS . 36.7 tp 43.92 76.85 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.493 179.926 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.451 ' O3 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.6 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.298 0.57 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.734 ' HG2' HG22 ' A' ' 84' ' ' VAL . 93.7 mt-30 -91.11 129.03 37.15 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 108.776 179.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.529 ' CD2' HG21 ' A' ' 6' ' ' VAL . 1.0 OUTLIER 44.97 33.33 1.0 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.138 -0.976 . . . . 0.0 108.724 -179.486 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.23 -37.5 77.66 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.644 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.9 p -63.11 -32.65 74.08 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.152 -0.967 . . . . 0.0 109.491 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.529 HG21 ' CD2' ' A' ' 3' ' ' HIS . 74.7 t -66.64 -38.56 81.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.509 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' HG23 ' A' ' 11' ' ' VAL . 87.2 mt -59.81 -50.85 78.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.163 -0.96 . . . . 0.0 109.309 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.78 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.62 -46.67 81.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.348 -0.845 . . . . 0.0 109.38 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -44.31 92.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.492 -0.755 . . . . 0.0 109.495 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.54 -47.63 85.32 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.496 -0.753 . . . . 0.0 109.457 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG13 HD12 ' A' ' 36' ' ' ILE . 57.8 t -70.26 -46.28 72.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.499 -0.75 . . . . 0.0 109.394 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 8' ' ' ALA . 65.0 t -64.66 -34.79 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 110.042 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -55.07 -33.92 63.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.213 -0.929 . . . . 0.0 110.193 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.02 -31.19 71.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.109 -0.995 . . . . 0.0 109.851 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -138.37 43.63 2.15 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.098 -1.001 . . . . 0.0 109.865 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.811 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.16 130.58 65.53 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.831 -1.168 . . . . 0.0 109.964 -179.81 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.1 Cg_endo -76.92 -151.86 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 122.025 1.817 . . . . 0.0 110.401 178.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -76.59 12.23 1.36 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.878 -1.139 . . . . 0.0 108.698 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 17' ' ' PRO . 34.8 t -113.71 136.53 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.519 -0.738 . . . . 0.0 109.802 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.38 139.61 81.61 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.164 -0.96 . . . . 0.0 108.905 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -48.34 -31.04 16.51 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.864 1.71 . . . . 0.0 112.023 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.14 -22.63 66.39 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.189 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -99.6 7.51 45.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.417 -0.802 . . . . 0.0 109.126 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -98.89 137.89 25.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.574 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.86 91.67 0.15 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 -179.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.7 HG11 ' HZ1' ' A' ' 87' ' ' LYS . 22.7 m -60.39 4.9 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.354 -0.841 . . . . 0.0 109.439 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.574 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.4 m-20 -86.03 4.39 38.15 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.895 . . . . 0.0 108.737 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 31.3 tp -90.41 134.07 34.59 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.506 -0.746 . . . . 0.0 109.213 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.94 121.99 14.9 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.242 -0.912 . . . . 0.0 108.76 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.977 ' H ' HD12 ' A' ' 30' ' ' LEU . 1.4 mp -57.01 -7.07 0.42 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.305 -0.872 . . . . 0.0 109.31 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.438 ' H ' ' C ' ' A' ' 29' ' ' ASP . 46.2 t -50.41 -40.51 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.228 -0.92 . . . . 0.0 109.147 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.56 -36.85 67.26 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.93 15.96 4.53 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 178.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.3 -14.78 0.01 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.1 t -52.1 -37.86 22.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.922 -1.34 . . . . 0.0 108.456 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.93 -24.7 24.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.475 -0.766 . . . . 0.0 110.04 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.16 -29.21 68.52 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.206 -0.934 . . . . 0.0 110.954 -178.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 m -113.02 -64.87 1.25 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.059 -1.026 . . . . 0.0 111.402 -178.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -68.37 -51.34 45.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.933 -1.105 . . . . 0.0 110.477 -178.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.587 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.34 -36.16 69.89 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 10.6 tp -57.98 -41.53 83.17 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -1.184 . . . . 0.0 109.417 -178.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.4 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.5 mt -64.64 -44.14 91.44 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.127 -0.983 . . . . 0.0 108.867 179.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -68.41 -38.13 80.98 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.349 -0.844 . . . . 0.0 109.697 179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.7 t -64.69 -44.93 96.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.397 -0.814 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.478 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -61.92 -42.94 96.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.115 -0.99 . . . . 0.0 109.555 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.8 -40.71 95.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.301 -0.874 . . . . 0.0 110.055 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -78.8 -47.03 17.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 110.124 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.5 tp -60.24 -43.34 96.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 110.711 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.552 ' O ' ' N ' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -65.72 -39.46 91.18 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.918 -1.114 . . . . 0.0 108.827 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -69.13 -42.4 76.08 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.48 -0.762 . . . . 0.0 109.77 179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.688 ' NH1' ' CZ ' ' A' ' 52' ' ' PHE . 61.8 ttt-85 -60.8 -42.19 97.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.539 -0.726 . . . . 0.0 110.722 -179.015 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CZ ' ' NH1' ' A' ' 51' ' ' ARG . 97.2 m-85 -105.2 -6.29 19.92 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.073 -1.017 . . . . 0.0 109.874 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.81 35.72 90.08 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.1 mt -100.95 127.46 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.19 -1.182 . . . . 0.0 109.577 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.76 141.16 57.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.206 -0.934 . . . . 0.0 109.541 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 59' ' ' VAL . . . -64.02 -30.06 71.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.253 -0.904 . . . . 0.0 109.295 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 55.28 40.48 31.58 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.474 -0.766 . . . . 0.0 109.905 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 t0 44.36 55.14 5.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.217 -0.927 . . . . 0.0 109.995 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 56' ' ' ALA . 49.9 t -103.94 131.66 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.185 -0.947 . . . . 0.0 109.568 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.479 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.1 tt0 -118.88 138.78 52.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.523 -0.736 . . . . 0.0 109.423 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.913 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.6 mm? -103.79 138.23 40.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.306 -0.871 . . . . 0.0 109.397 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.26 162.26 37.77 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.453 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.41 -31.02 88.04 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.69 2.26 . . . . 0.0 111.811 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.41 -28.07 68.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.39 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.406 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.7 t60 -67.61 -26.6 66.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.351 -0.843 . . . . 0.0 109.755 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -93.77 10.47 32.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.427 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.408 ' HA ' HG23 ' A' ' 31' ' ' VAL . 20.1 tpt180 -56.4 -35.75 68.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.39 -0.819 . . . . 0.0 109.927 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.441 ' C ' HD11 ' A' ' 30' ' ' LEU . 83.7 p -145.82 160.39 41.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.98 -1.075 . . . . 0.0 110.261 -179.467 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.802 HG22 HD21 ' A' ' 30' ' ' LEU . 5.2 pt -64.54 -36.22 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.359 -0.838 . . . . 0.0 110.013 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.2 mtm180 -60.85 -37.39 81.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 110.082 -179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.8 t -60.18 -43.06 96.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.111 -0.993 . . . . 0.0 109.75 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -62.5 -39.68 85.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.198 -0.939 . . . . 0.0 109.598 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.642 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.8 t0 -57.03 -37.06 71.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.89 -44.38 96.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.225 -0.922 . . . . 0.0 109.557 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.406 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.5 t80 -64.19 -46.85 82.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.175 -0.953 . . . . 0.0 109.255 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -62.96 -42.56 97.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.399 -0.813 . . . . 0.0 109.535 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.3 t -60.42 -40.07 83.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.171 -0.956 . . . . 0.0 109.599 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.92 -34.14 70.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.07 -50.16 3.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.12 -1.224 . . . . 0.0 110.266 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.5 m -126.24 136.24 52.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.406 -0.809 . . . . 0.0 109.378 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.8 88.64 53.53 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.299 -0.876 . . . . 0.0 109.762 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.477 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 20.1 Cg_exo -61.49 -174.55 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.615 2.21 . . . . 0.0 111.829 179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.3 Cg_exo -62.36 151.11 84.56 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.593 2.195 . . . . 0.0 111.595 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.734 HG22 ' HG2' ' A' ' 2' ' ' GLN . 22.4 t -93.34 125.33 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.079 -1.013 . . . . 0.0 109.705 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -147.98 154.89 40.9 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.387 -0.821 . . . . 0.0 109.079 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.76 136.14 55.02 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.061 -1.024 . . . . 0.0 109.187 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.7 ' HZ1' HG11 ' A' ' 26' ' ' VAL . 33.6 tttm -60.05 -38.79 83.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.143 -0.973 . . . . 0.0 109.455 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.455 ' O ' ' O ' ' A' ' 89' ' ' GLN . 53.7 mt -98.89 141.51 31.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.294 -0.879 . . . . 0.0 109.427 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' A' ' 88' ' ' LEU . 7.2 tt0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.468 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.486 ' N9 ' ' O1P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.405 0.622 . . . . 0.0 109.635 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.819 ' NE2' HG21 ' A' ' 81' ' ' THR . 62.7 tt0 -55.89 -39.78 72.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 109.207 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.604 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 31.1 m80 -166.25 25.33 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.16 -32.8 72.52 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.442 -0.786 . . . . 0.0 110.156 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.3 p -60.69 -42.39 97.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.982 -1.074 . . . . 0.0 109.832 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.452 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.7 t -68.43 -39.62 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.086 -1.009 . . . . 0.0 108.606 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.507 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.65 -49.35 84.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.568 -0.707 . . . . 0.0 109.7 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.786 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.31 -44.98 93.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.104 -0.997 . . . . 0.0 108.483 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -37.76 88.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.114 179.057 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' N ' ' O ' ' A' ' 6' ' ' VAL . 55.7 t80 -63.89 -51.81 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.498 -0.751 . . . . 0.0 110.036 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.9 p -73.79 -41.51 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 110.25 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 8' ' ' ALA . 59.3 t -64.52 -37.9 81.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.115 -0.991 . . . . 0.0 110.112 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -55.57 -32.49 63.07 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.11 -0.994 . . . . 0.0 109.528 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.479 ' OE1' ' CD1' ' A' ' 36' ' ' ILE . 84.9 tt0 -65.97 -31.94 73.14 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.634 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.578 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 34.2 p90 -139.58 44.89 1.95 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.128 -0.982 . . . . 0.0 109.784 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.64 131.6 60.51 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.996 -1.065 . . . . 0.0 110.13 -179.82 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 63.0 Cg_endo -75.35 -151.85 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.955 1.77 . . . . 0.0 110.335 178.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -76.91 11.49 1.73 Allowed 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.888 -1.132 . . . . 0.0 108.694 179.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 23.4 t -113.63 136.66 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.567 -0.708 . . . . 0.0 109.832 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.01 139.98 82.91 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.154 -0.966 . . . . 0.0 108.932 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.414 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.4 Cg_exo -48.16 -29.76 13.25 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 121.908 1.738 . . . . 0.0 112.208 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.72 -22.63 66.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 109.276 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -105.04 6.67 33.52 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.442 -0.786 . . . . 0.0 109.157 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.06 139.95 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -66.73 97.1 0.44 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.12 -0.988 . . . . 0.0 109.256 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.8 p -59.08 4.73 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.419 -0.8 . . . . 0.0 109.531 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.23 13.01 28.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.042 -1.037 . . . . 0.0 108.9 179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.9 tp -84.22 133.17 34.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.675 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.51 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 39.2 p30 -67.78 121.71 16.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.639 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -62.88 -7.69 5.61 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.9 t -50.27 -43.4 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.058 -1.027 . . . . 0.0 109.184 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.92 -36.52 67.81 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 65.9 m-80 -85.84 16.69 3.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.68 -16.68 0.02 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.1 t -53.87 -38.85 37.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.001 -1.293 . . . . 0.0 108.059 178.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.612 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.0 tt -71.23 -24.81 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.563 -0.711 . . . . 0.0 110.317 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -60.68 -30.72 70.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.213 -0.929 . . . . 0.0 111.278 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.68 -64.72 1.25 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.09 -1.006 . . . . 0.0 111.306 -178.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -67.95 -50.96 52.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.076 -1.015 . . . . 0.0 110.61 -178.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.453 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -39.7 69.81 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.612 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.5 tt -58.81 -40.83 85.27 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.323 -1.104 . . . . 0.0 109.363 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 13.0 tp -61.1 -44.28 97.6 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 108.626 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -69.29 -39.78 78.12 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.337 -0.852 . . . . 0.0 109.781 179.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 40' ' ' GLY . 71.0 t -65.53 -45.89 91.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.317 -0.865 . . . . 0.0 110.237 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -63.03 -42.73 97.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.079 -1.013 . . . . 0.0 109.426 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.82 -42.98 89.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.316 -0.865 . . . . 0.0 109.928 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.44 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.7 OUTLIER -76.84 -45.28 29.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.928 -179.768 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.44 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.7 tp -57.44 -43.21 83.69 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.351 -0.843 . . . . 0.0 109.763 -179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.582 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.7 tm-20 -64.38 -41.19 96.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.138 -0.977 . . . . 0.0 109.15 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -67.38 -46.6 72.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.362 -0.836 . . . . 0.0 110.472 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -62.98 -42.65 99.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.357 -0.839 . . . . 0.0 111.047 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.44 -4.84 22.27 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.991 -1.068 . . . . 0.0 110.527 -178.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.3 30.19 75.15 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.55 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 62.5 mt -103.94 132.1 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.277 -1.131 . . . . 0.0 109.619 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.34 151.27 37.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.279 -0.888 . . . . 0.0 109.364 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.07 -31.34 65.12 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.246 -0.909 . . . . 0.0 109.204 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 54.5 46.34 25.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 109.717 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.516 ' OD1' HD13 ' A' ' 61' ' ' LEU . 60.4 t0 -82.77 116.59 22.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.227 -0.92 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -126.27 -44.18 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.506 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.42 ' C ' HD12 ' A' ' 61' ' ' LEU . 84.4 tt0 -173.61 84.21 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.859 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.6 mp -96.86 143.59 27.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.412 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.42 162.58 49.93 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.434 -0.791 . . . . 0.0 109.53 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.37 -23.38 74.49 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.76 2.307 . . . . 0.0 111.951 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.43 -30.23 71.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.328 -0.858 . . . . 0.0 109.765 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.64 -26.84 66.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 109.696 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -97.11 6.69 48.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.182 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 14.1 tpt180 -55.2 -35.11 64.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.386 -0.821 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -145.91 152.52 39.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.159 -0.963 . . . . 0.0 110.039 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.639 HG12 HD11 ' A' ' 30' ' ' LEU . 89.2 mt -66.01 -36.08 76.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.378 -0.827 . . . . 0.0 109.946 179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.23 -39.16 85.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 110.382 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.24 -44.61 88.38 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 120.965 -1.085 . . . . 0.0 109.45 -179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -68.03 -38.52 79.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.287 -0.883 . . . . 0.0 109.418 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.495 ' OD1' HG23 ' A' ' 77' ' ' VAL . 64.4 t0 -57.08 -39.95 75.97 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.48 -0.762 . . . . 0.0 110.182 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.52 -41.04 93.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.103 -0.998 . . . . 0.0 109.984 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -62.31 -49.22 76.48 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.095 -1.003 . . . . 0.0 109.511 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.5 -46.7 85.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.157 -0.964 . . . . 0.0 109.873 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.603 HG13 ' OE1' ' A' ' 2' ' ' GLN . 38.8 t -61.68 -38.66 80.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.028 -1.045 . . . . 0.0 109.489 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.68 -32.54 65.51 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.35 -51.24 3.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.183 -1.187 . . . . 0.0 110.36 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.524 ' O ' HG12 ' A' ' 76' ' ' VAL . 9.8 t -160.12 149.29 17.53 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.165 -0.96 . . . . 0.0 109.829 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.819 HG21 ' NE2' ' A' ' 2' ' ' GLN . 1.7 t -131.08 88.33 45.58 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.188 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -92.32 111.64 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.259 2.64 . . . . 0.0 112.91 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -79.42 137.03 12.89 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 122.111 1.874 . . . . 0.0 111.845 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.486 HG22 ' H ' ' A' ' 86' ' ' ALA . 12.6 p -134.19 141.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.205 -0.934 . . . . 0.0 109.523 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.39 -34.69 78.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 110.02 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.486 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -142.23 155.28 45.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.136 -0.977 . . . . 0.0 109.705 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 18.3 tttm -58.65 -37.34 75.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.274 -0.891 . . . . 0.0 109.533 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 53.7 mt -94.07 142.13 27.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.494 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.456 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_